<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Environ Chem Lett</journal-id><journal-id journal-id-type="iso-abbrev">Environ Chem Lett</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Environmental Chemistry Letters</journal-title></journal-title-group><issn pub-type="ppub">1610-3653</issn><issn pub-type="epub">1610-3661</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8479502</article-id><article-id pub-id-type="pmcid-ver">PMC8479502.1</article-id><article-id pub-id-type="pmcaid">8479502</article-id><article-id pub-id-type="pmcaiid">8479502</article-id><article-id pub-id-type="pmid">34602924</article-id><article-id pub-id-type="doi">10.1007/s10311-021-01274-z</article-id><article-id pub-id-type="publisher-id">1274</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The impact of human vaccines on bacterial antimicrobial resistance. A review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jansen</surname><given-names initials="KU">Kathrin U.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gruber</surname><given-names initials="WC">William C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Simon</surname><given-names initials="R">Raphael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wassil</surname><given-names initials="J">James</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6413-1718</contrib-id><name name-style="western"><surname>Anderson</surname><given-names initials="AS">Annaliesa S.</given-names></name><address><email>annaliesa.anderson@pfizer.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Pfizer Vaccine Research and Development, Pearl River, NY USA </aff><aff id="Aff2"><label>2</label>Pfizer Patient and Health Impact, Collegeville, PA USA </aff><aff id="Aff3"><label>3</label>Present Address: Vaxcyte, 353 Hatch Drive, Foster City, CA 94404 USA </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>9</month><year>2021</year></pub-date><pub-date pub-type="ppub"><year>2021</year></pub-date><volume>19</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">390918</issue-id><fpage>4031</fpage><lpage>4062</lpage><history><date date-type="received"><day>25</day><month>6</month><year>2021</year></date><date date-type="accepted"><day>9</day><month>7</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>29</day><month>09</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-29 03:25:40.600"><day>29</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10311_2021_Article_1274.pdf"/><abstract id="Abs1"><p id="Par1">At present, the dramatic rise in antimicrobial resistance (AMR) among important human bacterial pathogens is reaching a state of global crisis threatening a return to the pre-antibiotic era. AMR, already a significant burden on public health and economies, is anticipated to grow even more severe in the coming decades. Several licensed vaccines, targeting both bacterial (<italic toggle="yes">Haemophilus influenzae</italic> type b, <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Salmonella enterica</italic> serovar Typhi) and viral (influenza virus, rotavirus) human pathogens, have already proven their anti-AMR benefits by reducing unwarranted antibiotic consumption and antibiotic-resistant bacterial strains and by promoting herd immunity. A number of new investigational vaccines, with a potential to reduce the spread of multidrug-resistant bacterial pathogens, are also in various stages of clinical development. Nevertheless, vaccines as a tool to combat AMR remain underappreciated and unfortunately underutilized. Global mobilization of public health and industry resources is key to maximizing the use of licensed vaccines, and the development of new prophylactic vaccines could have a profound impact on reducing AMR.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Bacterial vaccine</kwd><kwd>Viral vaccine</kwd><kwd>Human vaccination</kwd><kwd>Herd immunity</kwd><kwd>Antibiotic resistance</kwd><kwd>Multidrug resistance</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004319</institution-id><institution>pfizer</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Switzerland AG 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par20">The development of effective vaccines and the discovery of antibiotics, along with improvements in effective sanitation and hygiene practices and nutrition, led to the unprecedented increases in life expectancy seen today (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR39">2017</xref>). However, antimicrobial resistance (AMR) among important human bacterial pathogens is on the rise, representing an alarming global crisis with threats to return to the pre-antibiotic era and to have a significant adverse effect on public health in the coming decades. Vaccines are effective in preventing infections by induction of a typically broad polyclonal antibody and/or cellular immune responses specifically targeted to the pathogen of concern. Unlike current antibiotics, vaccines cannot cause &#8220;bystander&#8221; microbial resistance or induce resistance in the pathogens targeted. The present article reviews the evidence, rationale, and opportunity for vaccines to reduce and prevent AMR and combat the rise of multidrug-resistant bacterial pathogens. This article is an abridged version of the book chapter published by Jansen et al. (Jansen et al. <xref ref-type="bibr" rid="CR106">2021</xref>).</p></sec><sec id="Sec2"><title>Antimicrobial resistance is an urgent public health threat</title><p id="Par21">Antimicrobial resistance predates the age of humans, as bacteria and the eukaryotic fungi and molds from which many antibiotics have been derived have been engaged in a chemical arms race for millennia as they compete for ecological niches. The introduction of antibiotics in the 1940 and 1950s placed evolutionary pressure on microorganisms to adapt developing AMR. Indeed, introduction of each new antibiotic class since has been reliably met with the expansion of resistance. Moreover, this trend has accelerated over time, with recognition of the shortening of the intervals from introduction of a new antibiotic to first documented cases of resistance (Pray <xref ref-type="bibr" rid="CR194">2008</xref>). Molecular mechanisms of resistance to different classes of antibiotics associated with major bacterial pathogens and survival strategies have been reviewed (Walsh <xref ref-type="bibr" rid="CR245">2000</xref>) and are schematically shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Molecular mechanisms of action for antibiotics compared to vaccines. <bold>a</bold> Antibiotics either kill bacteria (bactericidal) or stop them from growing (bacteriostatic) by four main mechanisms: preventing DNA/RNA synthesis; preventing folate synthesis, which prevents nucleic acid synthesis; destroying the cell wall/membrane; and targeting ribosomes to prevent protein synthesis. Antibiotic resistance mechanisms neutralize the mechanism of action for the antibiotic. Resistance mechanisms can be acquired through horizontal transfer from plasmids and other genetic elements donated by bacteria that are co-localized with the pathogen. Alternatively, resistance can occur through vertical transmission via chromosomal mutations. These resistance mechanisms include the expression of enzymes such as the &#946;-lactamases which inactivate the antibiotics (&#946;-lactams); the expression or overexpression of efflux pumps which remove the antibiotic from the bacteria; the modification of the target so that it is no longer susceptible to the antibiotic; and using bypass mechanisms to circumvent antibiotic toxicity, including modification of the cell surface to prevent antibiotic entry or direct modification of antibiotics to prevent target engagement (Kohanski et al. <xref ref-type="bibr" rid="CR118">2010</xref>; Levy and Marshall <xref ref-type="bibr" rid="CR136">2004</xref>). <bold>b</bold> In contrast to antibiotics, vaccines exert their action via immune pathways, eliciting antigen specific polyclonal antibodies that can either neutralize bacterial virulence factors such as toxins or adhesins, or engage effector arms to kill the bacteria through mechanisms including the complement cascade or opsonophagocytic uptake into phagocytes (Forthal <xref ref-type="bibr" rid="CR69">2014</xref>). ROS, reactive oxygen species. Copyright [Kathrin U. Jansen, William C. Gruber, Raphael Simon, James Wassil, and Annaliesa S. Anderson] 2021</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="10311_2021_1274_Fig1_HTML.jpg"/></fig></p><p id="Par22">AMR spread has been further exacerbated due to globalization that served as a vehicle for rapid transmission of emerging antibiotic-resistant microbial strains and associated resistance plasmids across continents. This phenomenon is illustrated well by the spread of fluoroquinolone-resistant <italic toggle="yes">Clostridioides</italic> (previously known as <italic toggle="yes">Clostridium) difficile</italic> 027 epidemic lineages (He et al. <xref ref-type="bibr" rid="CR91">2013</xref>; Peng et al. <xref ref-type="bibr" rid="CR183">2017</xref>), as well as methicillin- and fluoroquinolone-resistant <italic toggle="yes">Staphylococcus aureus</italic> strains detected in clinical trial isolates (Holden et al. <xref ref-type="bibr" rid="CR99">2013</xref>). The excessive and irresponsible use of antimicrobials in healthcare, agriculture, and the food industry has fueled the dramatic rise of AMR globally (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.combatamr.org/amr-review-antimicrobial-resistance">https://www.combatamr.org/amr-review-antimicrobial-resistance</ext-link>). Worldwide, AMR is a significant and growing cause of mortality. It is estimated that at least 700,000 people die of infections with AMR pathogens every year, with up to 50,000 deaths occurring in the U.S. and Europe alone (O&#8217;Neill <xref ref-type="bibr" rid="CR171">2014</xref>). The mortality rates due to AMR are greater than those due to tetanus, cholera, and measles combined, and not much lower than those caused by common afflictions such as diarrheal disease or diabetes (O&#8217;Neill <xref ref-type="bibr" rid="CR172">2016a</xref>). With rates of resistance continuing at their current pace, it is estimated that annually, 10 million people worldwide will succumb to an AMR infection by 2050, exceeding the number of deaths from cancer (O&#8217;Neill <xref ref-type="bibr" rid="CR172">2016a</xref>). AMR also represents a major economic burden on healthcare systems, with an associated cost of over 20 billion U.S. dollars each year in the U.S. alone (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR36">2013a</xref>; Tufts University <xref ref-type="bibr" rid="CR231">2010</xref>). If no action is taken against AMR, the cost in terms of lost global production until 2050 is estimated to be 100 trillion U.S. dollars. AMR is thus an immense global problem with serious implications for public health, healthcare systems, and economies.</p><p id="Par23">In 2013, the United States (U.S.) Centers for Disease Control and Prevention (CDC) published a list of antibiotic-resistant pathogens in the U.S. (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR36">2013a</xref>), which were stratified into urgent, serious, and concerning threat tiers based on the threat they pose to human health and urgency of the need for new and effective modalities for their treatment and prevention. This list was updated in 2019 (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>) (Table <xref rid="Tab1" ref-type="table">1</xref>). A global priority list of antibiotic-resistant pathogens was also established by the World Health Organization (WHO) in 2017, stratified them into three priority tiers: critical, high, and medium (Table <xref rid="Tab1" ref-type="table">1</xref>) (World Health Organization <xref ref-type="bibr" rid="CR253">2017a</xref>). Global antibiotic resistance levels associated with major bacterial pathogens are shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> (Jansen et al. <xref ref-type="bibr" rid="CR105">2018a</xref>). Pathogens of the highest priority on both lists include <italic toggle="yes">Acinetobacter baumannii</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, and members of the <italic toggle="yes">Enterobacteriaceae</italic> family (primarily <italic toggle="yes">Klebsiella</italic> spp<italic toggle="yes">.</italic> and <italic toggle="yes">Escherichia coli</italic>) (Table <xref rid="Tab1" ref-type="table">1</xref>). These ominous public health threats are important causes of hospital based, or nosocomial infections and have demonstrated resistance to a large number of antibiotics, including carbapenems and third-generation cephalosporins (World Health Organization <xref ref-type="bibr" rid="CR253">2017a</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/en/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed">https://www.who.int/en/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed</ext-link>). These highlighted pathogens cause a wide range of diseases, including pneumonia, urinary tract infection, bacteremia, and wound infections (Gaynes et al. <xref ref-type="bibr" rid="CR75">2005</xref>). Other pathogens of concern identified by the CDC and WHO include those responsible for diarrheal and enteric illness (<italic toggle="yes">C. difficile</italic>, <italic toggle="yes">Helicobacter pylori</italic>, <italic toggle="yes">Campylobacter</italic>, <italic toggle="yes">Salmonella</italic> spp., <italic toggle="yes">Shigella</italic> spp.) or sexually transmitted disease (<italic toggle="yes">Neisseria gonorrhoeae</italic>) (Table <xref rid="Tab1" ref-type="table">1</xref>). Other notable AMR bacterial pathogens recognized by the CDC and WHO are also listed in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Stratification of antibiotic-resistant microbial pathogens according to the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidelines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1">CDC</th><th align="left" colspan="2" rowspan="1">WHO</th></tr></thead><tbody><tr><td align="left" rowspan="5" colspan="1">Urgent threats</td><td align="left" colspan="1" rowspan="1">Carbapenem-resistant <italic toggle="yes">Acinetobacter</italic></td><td align="left" rowspan="5" colspan="1">Critical priority</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Acinetobacter baumannii</italic>, carbapenem resistant</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Candida auris</italic></td><td align="left" rowspan="2" colspan="1"><italic toggle="yes">Pseudomonas aeruginosa</italic>, carbapenem resistant</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Clostridioides difficile</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Carbapenem-resistant <italic toggle="yes">Enterobacteriaceae</italic></td><td align="left" rowspan="2" colspan="1"><italic toggle="yes">Enterobacteriaceae</italic>*, carbapenem resistant, 3<sup>rd</sup>-generation cephalosporin resistant</td></tr><tr><td align="left" colspan="1" rowspan="1">Drug-resistant <italic toggle="yes">Neisseria gonorrhoeae</italic></td></tr><tr><td align="left" rowspan="11" colspan="1">Serious threats</td><td align="left" colspan="1" rowspan="1">Drug-resistant <italic toggle="yes">Campylobacter</italic></td><td align="left" rowspan="11" colspan="1">High priority</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Enterococcus faecium</italic>, vancomycin resistant</td></tr><tr><td align="left" colspan="1" rowspan="1">Drug-resistant <italic toggle="yes">Candida</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Staphylococcus aureus</italic>, methicillin resistant, vancomycin intermediate and resistant</td></tr><tr><td align="left" colspan="1" rowspan="1">Extended spectrum &#946;-lactamase producing <italic toggle="yes">Enterobacteriaceae</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Helicobacter pylori</italic>, clarithromycin resistant</td></tr><tr><td align="left" colspan="1" rowspan="1">Vancomycin-resistant <italic toggle="yes">Enterococcus</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Campylobacter</italic>, fluoroquinolone resistant</td></tr><tr><td align="left" colspan="1" rowspan="1">Multidrug-resistant <italic toggle="yes">Pseudomonas aeruginosa</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Salmonella</italic> spp., fluoroquinolone resistant</td></tr><tr><td align="left" colspan="1" rowspan="1">Drug-resistant non-typhoidal <italic toggle="yes">Salmonella</italic></td><td align="left" rowspan="6" colspan="1"><italic toggle="yes">Neisseria gonorrhoeae</italic>, 3rd-generation cephalosporin resistant, fluoroquinolone resistant</td></tr><tr><td align="left" colspan="1" rowspan="1">Drug-resistant <italic toggle="yes">Salmonella</italic> serotype Typhi</td></tr><tr><td align="left" colspan="1" rowspan="1">Drug-resistant <italic toggle="yes">Shigella</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Drug-resistant <italic toggle="yes">Streptococcus pneumoniae</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Drug-resistant <italic toggle="yes">Mycobacterium tuberculosis</italic></td></tr><tr><td align="left" rowspan="3" colspan="1">Concerning threats</td><td align="left" colspan="1" rowspan="1">Erythromycin-resistant Group A <italic toggle="yes">Streptococcus</italic></td><td align="left" rowspan="3" colspan="1">Medium priority</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Streptococcus pneumoniae</italic>, penicillin nonsusceptible</td></tr><tr><td align="left" rowspan="2" colspan="1">Clindamycin-resistant Group B <italic toggle="yes">Streptococcus</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Haemophilus influenzae</italic>, ampicillin resistant</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Shigella</italic> spp., fluoroquinolone resistant</td></tr><tr><td align="left" rowspan="3" colspan="1">Watch list</td><td align="left" colspan="1" rowspan="1">Azole-resistant <italic toggle="yes">Aspergillus fumigatus</italic></td><td align="left" rowspan="3" colspan="1"/><td align="left" rowspan="3" colspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Drug-resistant <italic toggle="yes">Mycoplasma genitalium</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Drug-resistant <italic toggle="yes">Bordetella pertussis</italic></td></tr></tbody></table><table-wrap-foot><p>*<italic toggle="yes">Enterobacteriaceae</italic> include: <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Enterobacter</italic> spp., <italic toggle="yes">Serratia</italic> spp., <italic toggle="yes">Proteus</italic> spp., <italic toggle="yes">Providencia</italic> spp, and <italic toggle="yes">Morganella</italic> spp</p><p>CDC, Centers for Disease Control and Prevention; WHO, World Health Organization</p><p>Adapted from (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>; World Health Organization <xref ref-type="bibr" rid="CR253">2017a</xref>)</p></table-wrap-foot></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Antibiotic resistance levels associated with major bacterial pathogens across the globe. Data shown are from 2000 to 2014 and represent the percentage of isolates (the range) tested that are resistant to each antibiotic class used for each pathogen (pathogen specific), not taking into account the proportion of strains that are resistant to more than one antibiotic class. ROS: reactive oxygen species.&#160;For all pathogens except <italic toggle="yes">M. tuberculosis</italic> and <italic toggle="yes">N. gonorrhoeae</italic>, data were obtained from the Center for Disease Dynamics, Economics &amp; Policy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://resistancemap.cddep.org">https://resistancemap.cddep.org</ext-link>). For <italic toggle="yes">M. tuberculosis</italic>, data were obtained from WHO Drug Resistant TB Surveillance &amp; Response&#8212;Supplement: Global Tuberculosis Report 2014 (World Health Organization <xref ref-type="bibr" rid="CR250">2014a</xref>). For <italic toggle="yes">N. gonorrhoeae</italic>, data were obtained from the World Health Organization Global Gonococcal Antimicrobial Surveillance Program which covers strains analyzed between 2011 and 2014 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/reproductivehealth/topics/rtis/gonococcal_resistance/en/">http://www.who.int/reproductivehealth/topics/rtis/gonococcal_resistance/en/</ext-link>). ND, no data provided. Copyright [Kathrin U. Jansen, William C. Gruber, Raphael Simon, James Wassil, and Annaliesa S. Anderson] 2021</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="10311_2021_1274_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec3"><title>Vaccines are an underutilized tool to address the antimicrobial resistance problem</title><p id="Par24">To address the AMR crisis, a number of international organizations, including the WHO, the United Nations General Assembly, the World Bank, the G7, the G20, and the EU, as well as the U.S. and United Kingdom (UK) governments have been urgently developing strategic action plans to address the rising AMR issues (G<xref ref-type="bibr" rid="CR72">7</xref> Summit <xref ref-type="bibr" rid="CR72">2015</xref>; Tagliabue and Rappuoli <xref ref-type="bibr" rid="CR218">2018</xref>). Among the proposed measures against AMR, these organizations emphasize the importance of prudent use of existing antimicrobials, and development of new effective antimicrobial medicines and vaccines for human and animals (World Health Organization <xref ref-type="bibr" rid="CR252">2015</xref>; Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR37">2015</xref>; National Vaccine Advisory Committee <xref ref-type="bibr" rid="CR165">2016</xref>; O&#8217;Neill <xref ref-type="bibr" rid="CR172">2016a</xref>; Chatham House <xref ref-type="bibr" rid="CR41">2017</xref>; Clift and Salisbury <xref ref-type="bibr" rid="CR43">2017</xref>). Despite concerted efforts, no new classes of antibiotics have been introduced over the past 15&#160;years and there are few candidates in the pipeline (O&#8217;Neill <xref ref-type="bibr" rid="CR172">2016a</xref>). Additionally, new antimicrobials are placed on the WHO reserve list, limiting their use. These factors make the development of new antimicrobials commercially unattractive for pharmaceutical companies. On the other hand, the research and development pipelines for prophylactic infectious disease vaccines are on the rise (Shen and Cooke <xref ref-type="bibr" rid="CR213">2019</xref>; World Health Organization <xref ref-type="bibr" rid="CR255">2019a</xref>), providing valuable opportunities to prevent disease caused by AMR pathogens.</p><p id="Par25">The mechanisms of action of vaccines and antibiotics are fundamentally different (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Antibiotics classically treat established infections and disease, whereas vaccines classically prevent infections from happening in the first place. The mode of action for antibiotics centers on interference with a pathogen&#8217;s physiology, addressing usually a single biological target (Kohanski et al. <xref ref-type="bibr" rid="CR118">2010</xref>). The broad spectrum action of antibiotics is beneficial when the etiology of the infection is not or cannot be identified; however, antibiotics also kill bystander bacteria and microbial flora, making the patient vulnerable to dysbiosis and outgrowth of resistant disease causing pathogens, as well as promote selection for bacteria to develop AMR. In contrast to antibiotics, prophylactic vaccines are species specific and prevent the infection or disease, thus reducing both antibiotic use and spread of resistant bacterial strains and do not induce antibiotic resistance. Vaccines act through immune pathways, inducing protective immune responses that are pathogen specific and target one or more bacterial virulence factors such as toxins or adhesins, either neutralizing them or engaging the effector arms of the immune system to kill the bacterial pathogen through complement and/or opsonophagocytosis (Forthal <xref ref-type="bibr" rid="CR69">2014</xref>). The polyclonal nature of vaccine induced immune responses limits escape mutants. Although vaccine immunity may fade over time due to waning of the specific host immune response (Kennedy and Read <xref ref-type="bibr" rid="CR113">2017</xref>), functional immunity can be restored following re-immunization with a booster dose and that can be done repeatedly over one&#8217;s lifetime.</p><p id="Par26">Vaccination can affect AMR both directly and indirectly. Bacterial vaccines directly reduce antibiotic use through prevention of bacterial infections, and thus selection for AMR strains. Viral vaccines also diminish antibiotic use through avoidance of unwarranted antibiotic prescriptions as well as through prevention of secondary bacterial infections. Additionally, bacterial vaccines decrease circulation of resistant strains in vaccinated populations in regions with adequate vaccine coverage. In such settings, vaccines are known to induce herd immunity, an indirect vaccine phenomenon that leads to protection of even unvaccinated individuals in a vaccinated population. In the following sections of this article, we will discuss examples of proven anti-AMR benefits of licensed vaccines, review the status of new vaccine candidates with potential against AMR, and outline challenges and prospects related to the use of vaccines as a tool to reduce prevent AMR.</p></sec><sec id="Sec4"><title>Vaccines have reduced incidence and evolution of antimicrobial-resistant bacterial pathogens</title><p id="Par27">There are several well-documented and epidemiologically supported examples whereby both bacterial and viral vaccines have impacted AMR. Additionally, vaccine strategies have been purposefully used to combat the rise of an AMR pathogen.</p><sec id="Sec5"><title>Vaccines reduce circulating antibiotic-resistant strains and antibiotic use</title><sec id="Sec6"><title><italic toggle="yes">Haemophilus influenzae</italic> type b vaccine</title><p id="Par28"><italic toggle="yes">H. influenzae</italic> is an invasive bacterial pathogen that can cause severe infection characterized by pneumonia, septicemia, and meningitis, where mortality occurs in up to 5% of infected individuals (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/hi-disease/about/index.html">https://www.cdc.gov/hi-disease/about/index.html</ext-link>). Prior to the introduction of Hib conjugate vaccines into the routine infant immunization schedule in 1987, first in the U.S. and then globally, Hib was a devastating pathogen in infants and young children. At that time, incidence rates of Hib disease (including bacterial meningitis and other invasive diseases) in children younger than 5&#160;years ranged from 49 to 601 per 100,000 in some populations (Peltola et al. <xref ref-type="bibr" rid="CR181">1990</xref>; Ward et al. <xref ref-type="bibr" rid="CR247">1986</xref>). In addition, a steady increase in &#946;-lactam resistance among invasive Hib isolates had been observed starting in the early 1970s (Tristram et al. <xref ref-type="bibr" rid="CR228">2007</xref>).</p><p id="Par29">The development and deployment of Hib capsular polysaccharide conjugate vaccines (PCV) as part of routine childhood immunizations rapidly reduced the incidence of Hib disease (Adam et al. <xref ref-type="bibr" rid="CR1">2010</xref>; Centers for Disease Control and Prevention (CDC) <xref ref-type="bibr" rid="CR35">2002</xref>; Peltola et al. <xref ref-type="bibr" rid="CR182">1999</xref>). According to the CDC reported Active Bacterial Core Surveillance data from 2014, the invasive Hib disease incidence was 0.19 per 100,000 for children younger than 5&#160;years, the value below the Healthy People 2020 objective of 0.27 per 100,000 (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR38">2016</xref>), indicating a dramatic reduction in the disease rates due to Hib vaccination. Comparable successes were observed globally (Hargreaves et al. <xref ref-type="bibr" rid="CR89">1996</xref>). Moreover, global use of the Hib vaccine turned the tide against growing Hib antibiotic resistance (Heilmann et al. <xref ref-type="bibr" rid="CR93">2005</xref>). The impact of Hib conjugate vaccines on AMR strains was also confirmed in studies that have shown a correlation between Hib vaccine use and a reduction in resistance to one or more antibiotics. For example, in a 10-year Italian study, after universal introduction of Hib vaccine in 1999, a 50% decrease in resistance to ampicillin and related antibiotics among clinical isolates across all ages was observed (Giufre et al. <xref ref-type="bibr" rid="CR82">2011</xref>).</p></sec><sec id="Sec7"><title>Pneumococcal conjugate vaccines</title><p id="Par30"><italic toggle="yes">S. pneumoniae</italic> continues to be a leading global cause of serious illness among unvaccinated children and adults. In 2005, the WHO estimated that 1.6 million deaths were caused by this pathogen annually (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/ith/diseases/pneumococcal/en/">http://www.who.int/ith/diseases/pneumococcal/en/</ext-link>). In the 1990s, before the introduction of the 7-valent pneumococcal capsular polysaccharide conjugate vaccine (PCV7, Prevnar&#174;) into the childhood immunization program,&#8201;~&#8201;63,000 cases of invasive pneumococcal disease occurred each year in the U.S. (Feldman and Anderson <xref ref-type="bibr" rid="CR66">2016</xref>). Importantly, at this time resistance to penicillin and other classes of antibiotics also emerged among <italic toggle="yes">S. pneumoniae</italic> isolates in the U.S. (Breiman et al. <xref ref-type="bibr" rid="CR26">1994</xref>; Butler et al. <xref ref-type="bibr" rid="CR28">1996</xref>).</p><p id="Par31">Introduction of PCVs, initially covering 7 (PCV7; Wyeth, 2000) and subsequently 13 (PCV13, Prevnar&#160;13&#174;; Pfizer, 2010) pneumococcal serotypes, had a tremendous success in the U.S. with more than 90% efficacy against invasive pneumococcal disease observed in the primary target population of children younger than 5&#160;years (Cohen et al. <xref ref-type="bibr" rid="CR45">2017</xref>). Importantly, PCVs protected against both antibiotic-susceptible and antibiotic-resistant isolates. Several studies in the U.S. have analyzed the laboratory confirmed data from the population based Active Bacterial Core Surveillance system to evaluate changes in invasive pneumococcal disease rates following introduction of PCVs. One of those analyses, performed on the data from 1996 to 2004, found that after introduction of PCV7 in the U.S., rates of penicillin nonsusceptible infections with serotypes included in the vaccine fell by 87% (5.0&#8211;0.7 cases per 100,000) for any ages, 98% (61.5&#8211;1.2 cases per 100,000) for children younger than 2&#160;years, and 79% (12.3&#8211;2.6 cases per 100,000) for adults 65&#160;years of age and older. Additionally, the rate of infection with strains of <italic toggle="yes">S. pneumoniae</italic> showing reduced susceptibility to multiple antibiotics dropped by 59% for people of all ages (Kyaw et al. <xref ref-type="bibr" rid="CR123">2006</xref>). Prevention of invasive pneumococcal disease caused by the seven serotypes covered by PCV7 (including antibiotic-resistant strains) in children younger than 5&#160;years as well as adults 65&#160;years of age and older was also confirmed in other studies (Pilishvili et al. <xref ref-type="bibr" rid="CR188">2010</xref>; Hampton et al. <xref ref-type="bibr" rid="CR87">2012</xref>).</p><p id="Par32">A subsequent study on the impact of PCV13 on antibiotic nonsusceptible invasive pneumococcal disease in the U.S. also demonstrated decreased rates of antibiotic nonsusceptible invasive pneumococcal disease caused by serotypes included in PCV13 but not in PCV7 between 2009 (immediately before PCV13 was introduced) and 2013: from 6.7 to 2.2 per 100,000 for all ages, from 6.5 to 0.5 per 100,000 in children younger than 5&#160;years, and from 4.4 to 1.4 per 100,000 in adults 65&#160;years of age and older (Tomczyk et al. <xref ref-type="bibr" rid="CR224">2016</xref>) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Marked decreases were also observed for rates of multidrug nonsusceptible invasive pneumococcal disease. Furthermore, following the introduction of PCV13, the annual incidence of antibiotic nonsusceptible invasive pneumococcal disease in children younger than 5&#160;years in the U.S. was reduced from 2010 through 2013 by a range of 63&#8211;83% for strains resistant to macrolides, cephalosporins, tetracyclines, and penicillins, indicating direct impact on circulating AMR strains (Tomczyk et al. <xref ref-type="bibr" rid="CR224">2016</xref>). Surveillance studies in other countries have also shown a considerable impact of PCVs on invasive pneumococcal disease rates (von Gottberg et al. <xref ref-type="bibr" rid="CR240">2014</xref>; von Gottberg et al. <xref ref-type="bibr" rid="CR241">2016</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Reduction of antimicrobial resistance after broad rollout of PCV13. Data presented show average annual rates of antibiotic nonsusceptible invasive pneumococcal disease (IPD) of the vaccine- and non-vaccine type, with standard deviations in (<bold>a</bold>) vaccinated (children younger than 5&#160;years) and (<bold>b</bold>) non-vaccinated (adults 65&#160;years of age and older) populations, prior to (2005&#8211;2009) and following (2011&#8211;2013) introduction of PCV13 vaccine. Adapted from (Tomczyk et al. <xref ref-type="bibr" rid="CR224">2016</xref>). Copyright [Kathrin U. Jansen, William C. Gruber, Raphael Simon, James Wassil, and Annaliesa S. Anderson] 2021</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="10311_2021_1274_Fig3_HTML.jpg"/></fig></p><p id="Par33">Studies in different countries demonstrate that vaccination with PCV also decreases antibiotic use and reduces pneumonia cases misattributed to respiratory viral infection. For example, with introduction of PCV7 in 2000 in the U.S., antibiotic prescription for acute otitis media in children younger than 2&#160;years fell by 42% from 1997&#8211;1999 to 2004 (Zhou et al. <xref ref-type="bibr" rid="CR259">2008</xref>). An international group of experts estimated that overall, universal coverage with PCV could avert up to 11.4 million days of antibiotic therapy for pneumonia caused by <italic toggle="yes">S. pneumoniae</italic> annually in children younger than 5&#160;years, a 47% reduction in the 75 countries included in the analysis (Laxminarayan et al. <xref ref-type="bibr" rid="CR130">2016</xref>). In a large randomized, placebo-controlled study in South Africa, a 9-valent PCV prevented 31% (95% confidence interval, 15&#8211;43%) of pneumonias attributed to influenza A and parainfluenza viruses and respiratory syncytial virus (RSV) in fully immunized infants, with the effect presumed due to otherwise undiagnosed contemporaneous pneumococcal infection (Madhi et al. <xref ref-type="bibr" rid="CR141">2004</xref>).</p></sec><sec id="Sec8"><title>Typhoid conjugate vaccine</title><p id="Par34">Typhoid vaccines also provide a contemporary example of how a vaccine can be used to prevent dissemination of an AMR pathogen. In 2000, <italic toggle="yes">S.</italic> Typhi caused approximately 21.7 million illnesses and 216,000 deaths worldwide (Crump et al. <xref ref-type="bibr" rid="CR48">2004</xref>). Typhoid fever remains a common infectious disease in low- and middle-income countries, causing approximately 11.9 million cases and 129,000 deaths in 2010 according to the International Vaccine Institute (Mogasale et al. <xref ref-type="bibr" rid="CR158">2014</xref>), although the true disease burden is likely underestimated. The CDC has categorized <italic toggle="yes">S</italic>. Typhi as being of serious concern as an antibiotic resistance threat, as 74% of <italic toggle="yes">S.</italic> Typhi infections had partial or full resistance to ciprofloxacin in 2017, and resistance to other antibiotics was also observed (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>).</p><p id="Par35">The discovery in 2016, in the Sindh province of Pakistan, of an extensively drug-resistant haplotype 58 clone of <italic toggle="yes">S.</italic> Typhi, resistant to first- and second-line antibiotics as well as third-generation cephalosporins, thus evoked particular alarm (Andrews et al. <xref ref-type="bibr" rid="CR9">2018</xref>). Since recognition of its emergence, the ongoing major typhoid outbreak with this clone has affected more than 5,200 people within the Sindh region (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/csr/don/27-december-2018-typhoid-pakistan/en/">https://www.who.int/csr/don/27-december-2018-typhoid-pakistan/en/</ext-link>) (Qamar et al. <xref ref-type="bibr" rid="CR196">2018</xref>), and extensively drug-resistant H58 <italic toggle="yes">S</italic>. Typhi has the capacity to cause a global public health crisis (Klemm et al. <xref ref-type="bibr" rid="CR116">2018</xref>; Levine and Simon <xref ref-type="bibr" rid="CR135">2018</xref>). In response to the outbreak, and due to the limited treatment options and risk for rapid spread of this extensively drug-resistant typhoid clone, Pakistani authorities launched an emergency typhoid vaccination campaign in the most affected areas, using the WHO prequalified Vi capsular conjugate vaccine Typbar-TCV&#8482; manufactured by Bharat Biotech (India) and approved for use in children and infants younger than 2&#160;years (Sahastrabuddhe and Saluja <xref ref-type="bibr" rid="CR206">2019</xref>; Bhatti <xref ref-type="bibr" rid="CR22">2019</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/csr/don/27-december-2018-typhoid-pakistan/en/">https://www.who.int/csr/don/27-december-2018-typhoid-pakistan/en/</ext-link>). Another Vi-conjugate vaccine intervention effort to control a typhoid outbreak was undertaken in Zimbabwe, Africa, where <italic toggle="yes">S.</italic> Typhi isolates manifested high levels of multidrug resistance and reduced fluoroquinolone susceptibility (N&#8217;Cho et al. <xref ref-type="bibr" rid="CR163">2019</xref>). In February&#8211;March 2019, surveillance for febrile cases with suspected typhoid in the worst affected communities, performed three months after initiation of the vaccination effort, revealed a complete absence of typhoid cases among 24 children 6&#160;months&#8211;15&#160;years of age who provided blood cultures, compared with 23 of 109 (21%) positive blood cultures seen in a study directly preceding the start of the campaign. This was the first attempt to control a typhoid outbreak in Africa through vaccination and the first use of the typhoid Vi-conjugate vaccine in the continent (Olaru et al. <xref ref-type="bibr" rid="CR175">2019</xref>).</p><p id="Par36">These examples of the purposeful use of a vaccine to control an outbreak with an AMR pathogen thus represent a new paradigm in public health that may be extended to other pathogens in the future.</p></sec></sec><sec id="Sec9"><title>Vaccines mediate herd immunity</title><p id="Par37">Herd immunity is the protection conferred through broad vaccine coverage at the population level, to members of the community who are not vaccinated, cannot be vaccinated, or do not mount effective immune responses following vaccination. High vaccination rates at the population level are needed to achieve herd immunity and can both reduce transmission of AMR pathogens and limit antibiotic use by non-vaccinated individuals. Significant herd immunity has been achieved by both Hib and pneumococcal conjugate vaccines, driven in part by the reduction of nasopharyngeal colonization with pathogens expressing vaccine serotypes. Infant immunization with Hib vaccines led to a rapid fall in the rates of invasive Hib infections worldwide, in both vaccinated and unvaccinated children, an effect attributed to decreased carriage and transmission among young children (Steinhoff and Goldblatt <xref ref-type="bibr" rid="CR217">2003</xref>).</p><p id="Par38">The introduction of PCV7 and PCV13 in pediatric vaccination programs has had significant impact on reduction of vaccine type invasive pneumococcal disease in both unvaccinated pediatric and adult populations, particularly elderly (65&#160;years of age and older), due to the herd effect. This has been attributed to both the reduction in bacterial carriage and a substantial decrease in the incidence of invasive pneumococcal disease (Cohen et al. <xref ref-type="bibr" rid="CR45">2017</xref>). As described in Sect.&#160;<xref rid="Sec5" ref-type="sec">4.1</xref>, analyses of invasive pneumococcal disease cases identified through the U.S. Active Bacterial Core Surveillance system demonstrated significant reductions in the rates of penicillin nonsusceptible infections for the all-ages population as well as adults 65&#160;years of age and older, which were associated with serotypes included in PCV7 (between late 1990 and middle-to-late 2000s) (Hampton et al. <xref ref-type="bibr" rid="CR87">2012</xref>; Kyaw et al. <xref ref-type="bibr" rid="CR123">2006</xref>; Pilishvili et al. <xref ref-type="bibr" rid="CR188">2010</xref>) and PCV13 (between middle 2000 and early 2010s) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>b) (Tomczyk et al. <xref ref-type="bibr" rid="CR224">2016</xref>). In other countries, the invasive pneumococcal disease and pneumonia disease rates also declined after PCV introduction through herd immunity (Ingels et al. <xref ref-type="bibr" rid="CR103">2012</xref>; Lai et al. <xref ref-type="bibr" rid="CR126">2014</xref>; Tsaban and Ben-Shimol <xref ref-type="bibr" rid="CR230">2017</xref>; von Gottberg et al. <xref ref-type="bibr" rid="CR240">2014</xref>; von Gottberg et al. <xref ref-type="bibr" rid="CR241">2016</xref>). With the recent licensure of a PCV20 vaccine in adults (Pfizer <xref ref-type="bibr" rid="CR187">2021</xref>), the prospect of an even greater reduction in pneumococcal disease is possible.</p></sec><sec id="Sec10"><title>Preventing antimicrobial resistance using viral vaccines</title><p id="Par39">Although they do not directly generate antibacterial immunity, viral vaccines are an important tool for containment of AMR. First, they help prevent viral disease and thus avoid the inappropriate use of antibiotics. Additionally, bacterial infections are common secondary complications following some viral diseases and may even cause concurrent viral-bacterial superinfections that can be reduced by vaccination against a bacterial pathogen (Madhi et al. <xref ref-type="bibr" rid="CR141">2004</xref>). Vaccination against viral pathogens thus prevents secondary bacterial infections that may be antibiotic resistant. Influenza virus and rotavirus vaccines represent prominent examples of approved vaccines with these anti AMR benefits.</p><sec id="Sec11"><title>Influenza virus vaccine</title><p id="Par40">An estimated 3&#8211;5 million cases of influenza occur each year worldwide, causing 290,000&#8211;650,000 respiratory deaths (Iuliano et al. <xref ref-type="bibr" rid="CR104">2018</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal">https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal</ext-link>)). The elderly population, people with chronic pulmonary or cardiovascular conditions, and immunocompromised individuals are at greatest risk for severe influenza disease and disease complications (Mertz et al. <xref ref-type="bibr" rid="CR153">2013</xref>). Live-attenuated, inactivated, and recombinant influenza vaccines, targeting influenza A and B, are produced annually to match changes in the hemagglutinin proteins contained in the strains expected to circulate in the following influenza season (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal">https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal</ext-link>)). Globally, the influenza season represents the period of greatest antibiotic use, in part due to the frequent inappropriate prescription of antibiotics for respiratory tract infections caused by viral pathogens. In the U.S., nearly half of all antibiotic prescriptions are written for respiratory illnesses associated with pathogens such as influenza that are not susceptible to antibiotics (Fleming-Dutra et al. <xref ref-type="bibr" rid="CR68">2016</xref>). Reduction in influenza infection through vaccination thus reduces antibiotic use. In Ontario, Canada, universal influenza vaccination resulted in approximately 64% reduction in influenza-associated antibiotic prescriptions (Kwong et al. <xref ref-type="bibr" rid="CR122">2009</xref>). In the UK, children 2&#8211;4&#160;years of age who were vaccinated with a live-attenuated influenza vaccine had 14.5% fewer amoxicillin prescriptions during the period of influenza vaccine immunity compared with other winter seasons (Hardelid et al. <xref ref-type="bibr" rid="CR88">2018</xref>).</p><p id="Par41">Recovery from influenza infection is accompanied by an overt risk for secondary bacterial respiratory infections (Prasso and Deng <xref ref-type="bibr" rid="CR193">2017</xref>), thus further amplifying the morbidity and mortality due to influenza (Kash and Taubenberger <xref ref-type="bibr" rid="CR111">2015</xref>). <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">H. influenzae</italic>, and <italic toggle="yes">S. aureus</italic> are reported as the most common causes of secondary bacterial infections associated with influenza (Joseph et al. <xref ref-type="bibr" rid="CR109">2013</xref>; Morris et al. <xref ref-type="bibr" rid="CR160">2017</xref>). Vaccination against influenza thus indirectly protects against these bacterial pneumonias that may be antibiotic resistant. Acute otitis media is another common secondary bacterial infection associated with influenza (Kash and Taubenberger <xref ref-type="bibr" rid="CR111">2015</xref>). Several studies worldwide provided evidence that influenza vaccination in young children decreases the incidence of this infection (approximately 50% reduction, Turkey (Ozgur et al. <xref ref-type="bibr" rid="CR177">2006</xref>); 54.8% reduction [<italic toggle="yes">p</italic>&#8201;=&#8201;0.03], Italy (Marchisio et al. <xref ref-type="bibr" rid="CR145">2009</xref>); 85% [95% confidence interval, 78.3&#8211;89.8%] and 54% [95% confidence interval, 27.0&#8211;71.7%] efficacy, live-attenuated and trivalent inactivated influenza vaccines, respectively, U.S., Europe, and Asia (Block et al. <xref ref-type="bibr" rid="CR23">2011</xref>)), as well as reduce influenza-associated antibiotic use (13.2% [<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001], Italy (Marchisio et al. <xref ref-type="bibr" rid="CR145">2009</xref>); 71, 36, and 59%, Europe, Asia Pacific, and Central America, respectively (Dbaibo et al. <xref ref-type="bibr" rid="CR52">2020</xref>)). Implementation of national universal influenza vaccination programs, improvement of existing vaccines towards increased breadth of efficacy to an extended repertoire of viral strains, higher efficacy in older adults and young children, and development of universal influenza vaccines would provide further impact in the fight against AMR.</p></sec><sec id="Sec12"><title>Rotavirus vaccine</title><p id="Par42">Diarrheal disease is a second leading cause of mortality and morbidity among children younger than 5&#160;years, and children in low-income countries are particularly affected (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/en/news-room/fact-sheets/detail/diarrhoeal-disease">https://www.who.int/en/news-room/fact-sheets/detail/diarrhoeal-disease</ext-link>). Rotavirus is a leading cause of severe diarrheal disease in infants and young children (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/immunization/diseases/rotavirus/en/">https://www.who.int/immunization/diseases/rotavirus/en/</ext-link>). Two oral rotavirus vaccines are currently licensed for infants in the U.S.: RotaTeq&#174; and Rotarix&#174; (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/rotavirus/vaccination.html">https://www.cdc.gov/rotavirus/vaccination.html</ext-link>), and two more are approved internationally and are WHO prequalified (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/immunization/diseases/rotavirus/en/">https://www.who.int/immunization/diseases/rotavirus/en/</ext-link>). Rotavirus vaccines have had a significant public health impact through their efficacy (Giaquinto et al. <xref ref-type="bibr" rid="CR81">2011</xref>; Linhares et al. <xref ref-type="bibr" rid="CR137">2008</xref>; Vesikari et al. <xref ref-type="bibr" rid="CR237">2007</xref>) as well as herd protection (Patel et al. <xref ref-type="bibr" rid="CR179">2011</xref>; Pollard et al. <xref ref-type="bibr" rid="CR190">2015</xref>). As infection with rotavirus can lead to inappropriate antibiotic use if a misdiagnosis of bacterial infection is given (e.g., enterotoxigenic <italic toggle="yes">E. coli</italic> or <italic toggle="yes">Vibrio cholerae</italic>) or if treatment is sought based on symptoms, implementation of national rotavirus vaccination programs worldwide would benefit containment of AMR by reducing inappropriate antibiotic prescriptions in countries endemic for these bacterial pathogens.</p></sec></sec></sec><sec id="Sec13"><title>Vaccines under development with potential to reduce antimicrobial resistance</title><p id="Par43">Given the proven success of licensed vaccines in combating AMR, sustained efforts are being directed towards the development of new and improved vaccines targeting pathogens that exhibit increased antibiotic resistance, are associated with high antibiotic use, and are considered priority organisms by the WHO and the CDC (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>; World Health Organization <xref ref-type="bibr" rid="CR253">2017a</xref>). In the following sections, we will discuss select examples of vaccines under development that target pathogens with demonstrated propensity to acquire antibiotic resistance, and thus hold promise in further reducing AMR (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Examples of vaccine candidates in active clinical development with the potential to reduce antimicrobial resistance</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Vaccine name</th><th align="left" colspan="1" rowspan="1">Organization</th><th align="left" colspan="1" rowspan="1">Vaccine type</th><th align="left" colspan="1" rowspan="1">Vaccine composition</th><th align="left" colspan="1" rowspan="1">Stage</th><th align="left" colspan="1" rowspan="1">NCT</th><th align="left" colspan="1" rowspan="1">Status</th><th align="left" colspan="1" rowspan="1">Study population</th><th align="left" colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Clostridioides difficile</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">PF-06425090</td><td align="left" colspan="1" rowspan="1">Pfizer</td><td align="left" colspan="1" rowspan="1">Toxoid</td><td align="left" colspan="1" rowspan="1">Genetically-/chemically-inactivated toxins A and B</td><td align="left" colspan="1" rowspan="1">Phase 3</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03090191">NCT03090191</ext-link></td><td align="left" colspan="1" rowspan="1">Ongoing</td><td align="left" colspan="1" rowspan="1">Adults at risk of developing <italic toggle="yes">C. difficile</italic> infection,&#8201;&#8805;&#8201;50&#160;years</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">VLA84</td><td align="left" colspan="1" rowspan="1">Valneva</td><td align="left" colspan="1" rowspan="1">Toxoid</td><td align="left" colspan="1" rowspan="1">Recombinant fusion protein consisting of truncated toxins A and B</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02316470">NCT02316470</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults,&#8201;&#8805;&#8201;50&#160;years</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">GSK2904545A</td><td align="left" colspan="1" rowspan="1">GSK</td><td align="left" colspan="1" rowspan="1">Toxoid</td><td align="left" colspan="1" rowspan="1">Recombinant F2 antigen</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04026009">NCT04026009</ext-link></td><td align="left" colspan="1" rowspan="1">Ongoing</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;45 and 50&#8211;70&#160;years</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Streptococcus pneumoniae</italic></td></tr><tr><td align="left" rowspan="3" colspan="1">V114</td><td align="left" rowspan="3" colspan="1">Merck</td><td align="left" rowspan="3" colspan="1">Conjugate (15-valent)</td><td align="left" rowspan="3" colspan="1">Capsular polysaccharides of <italic toggle="yes">S. pneumoniae</italic> conjugated to CRM<sub>197</sub></td><td align="left" rowspan="3" colspan="1">Phase 3</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03480763">NCT03480763</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults,&#8201;&#8805;&#8201;50&#160;years</td><td align="left" rowspan="3" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03480802">NCT03480802</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults,&#8201;&#8805;&#8201;18&#160;years</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03692871">NCT03692871</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy infants</td></tr><tr><td align="left" rowspan="2" colspan="1">20vPnC</td><td align="left" rowspan="2" colspan="1">Pfizer</td><td align="left" rowspan="2" colspan="1">Conjugate (20-valent)</td><td align="left" rowspan="2" colspan="1">Capsular polysaccharides of <italic toggle="yes">S. pneumoniae</italic> conjugated to CRM<sub>197</sub></td><td align="left" rowspan="2" colspan="1">Phase 3</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04382326">NCT04382326</ext-link></td><td align="left" rowspan="2" colspan="1">Ongoing</td><td align="left" rowspan="2" colspan="1">Healthy infants</td><td align="left" rowspan="2" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04379713">NCT04379713</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Pneumosil</td><td align="left" colspan="1" rowspan="1">Serum Institute of India</td><td align="left" colspan="1" rowspan="1">Conjugate (10-valent)</td><td align="left" colspan="1" rowspan="1">Capsular polysaccharides of <italic toggle="yes">S. pneumoniae</italic> conjugated to CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">Phase 3</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03896477">NCT03896477</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy infants, 42&#8211;56&#160;days</td><td align="left" colspan="1" rowspan="1">(Moffitt and Malley <xref ref-type="bibr" rid="CR157">2016</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">GSK2830929A, GSK2830930A</td><td align="left" colspan="1" rowspan="1">GSK</td><td align="left" colspan="1" rowspan="1">Conjugate (11- and 12-valent)</td><td align="left" colspan="1" rowspan="1">Capsular polysaccharides of <italic toggle="yes">S. pneumoniae</italic> conjugated to non-typeable <italic toggle="yes">H. influenzae</italic> protein D (PHiD-CV)</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01616459">NCT01616459</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy infants, 6&#8211;12&#160;weeks</td><td align="left" colspan="1" rowspan="1">(Carmona Martinez et al. <xref ref-type="bibr" rid="CR32">2019</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">GSK2189242A</td><td align="left" colspan="1" rowspan="1">GSK</td><td align="left" colspan="1" rowspan="1">Conjugate/subunit (bivalent)</td><td align="left" colspan="1" rowspan="1">Recombinant PhtD and PlyD1 of <italic toggle="yes">S. pneumoniae</italic> plus PHiD-CV</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01204658">NCT01204658</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy infants, 6&#8211;14&#160;weeks</td><td align="left" colspan="1" rowspan="1">(Prymula et al. <xref ref-type="bibr" rid="CR195">2017</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">ASP3772</td><td align="left" colspan="1" rowspan="1">Affinivax</td><td align="left" colspan="1" rowspan="1">Complex (MAPS)</td><td align="left" colspan="1" rowspan="1">Capsular polysaccharides and proteins of <italic toggle="yes">S. pneumoniae</italic></td><td align="left" colspan="1" rowspan="1">Phase 1/2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03803202">NCT03803202</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;85&#160;years</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://affinivax.com/vaccine-pipeline/">http://affinivax.com/vaccine-pipeline/</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Unspecified</td><td align="left" colspan="1" rowspan="1">Sanofi</td><td align="left" colspan="1" rowspan="1">Subunit (trivalent)</td><td align="left" colspan="1" rowspan="1">Recombinant PhtD, PcpA, and PlyD1 of <italic toggle="yes">S. pneumoniae</italic></td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01444352">NCT01444352</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;50&#160;years</td><td align="left" colspan="1" rowspan="1">(Kamtchoua et al. <xref ref-type="bibr" rid="CR110">2013</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">PATH-wSP</td><td align="left" colspan="1" rowspan="1">PATH/Boston Children&#8217;s Hospital</td><td align="left" colspan="1" rowspan="1">Inactivated whole cell</td><td align="left" colspan="1" rowspan="1">Mutation inactivated whole cell <italic toggle="yes">S. pneumoniae</italic></td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02097472">NCT02097472</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy toddlers and adults, 12&#160;months to 45&#160;years</td><td align="left" colspan="1" rowspan="1">(Moffitt and Malley <xref ref-type="bibr" rid="CR157">2016</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Group B streptococcus</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">GBSIII-TT</td><td align="left" colspan="1" rowspan="1">NIAID</td><td align="left" colspan="1" rowspan="1">Conjugate (monovalent)</td><td align="left" colspan="1" rowspan="1">Capsular polysaccharide of GBS serotype III conjugated to TT</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00128219">NCT00128219</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy non-pregnant women, 18&#8211;40&#160;years</td><td align="left" colspan="1" rowspan="1">(Hillier et al. <xref ref-type="bibr" rid="CR95">2019</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">GBSII-TT/III-TT</td><td align="left" colspan="1" rowspan="1">Baylor College of Medicine</td><td align="left" colspan="1" rowspan="1">Conjugate (bivalent)</td><td align="left" colspan="1" rowspan="1">Capsular polysaccharide of GBS serotypes II and III conjugated to TT</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;45&#160;years</td><td align="left" colspan="1" rowspan="1">(Baker et al. <xref ref-type="bibr" rid="CR14">2003</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">GBS-NN</td><td align="left" rowspan="2" colspan="1">Minervax ApS</td><td align="left" rowspan="2" colspan="1">Subunit (bivalent)</td><td align="left" rowspan="2" colspan="1">Recombinant fusion of N-terminal domains of GBS Rib and Alpha C surface proteins</td><td align="left" rowspan="2" colspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02459262">NCT02459262</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" rowspan="2" colspan="1">Healthy non-pregnant women, 18&#8211;40&#160;years</td><td align="left" rowspan="2" colspan="1">(Rose et al. <xref ref-type="bibr" rid="CR204">2018</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03807245">NCT03807245</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td></tr><tr><td align="left" rowspan="2" colspan="1">GBS trivalent vaccine</td><td align="left" rowspan="2" colspan="1">GSK</td><td align="left" rowspan="2" colspan="1">Conjugate (trivalent)</td><td align="left" rowspan="2" colspan="1">Capsular epitopes of GBS serotypes Ia, Ib, and III conjugated to CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02270944">NCT02270944</ext-link></td><td align="left" rowspan="2" colspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy non-pregnant women, 18&#8211;40&#160;years</td><td align="left" rowspan="2" colspan="1">(Leroux-Roels et al. <xref ref-type="bibr" rid="CR133">2019</xref>, <xref ref-type="bibr" rid="CR132">2016</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02690181">NCT02690181</ext-link></td><td align="left" colspan="1" rowspan="1">Healthy non-pregnant women, 22&#8211;46&#160;years</td></tr><tr><td align="left" colspan="1" rowspan="1">GBS6</td><td align="left" colspan="1" rowspan="1">Pfizer</td><td align="left" colspan="1" rowspan="1">Conjugate (hexavalent)</td><td align="left" colspan="1" rowspan="1">Capsular epitopes of GBS serotypes Ia, Ib, II, III, IV, and V conjugated to CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03765073">NCT03765073</ext-link></td><td align="left" colspan="1" rowspan="1">Ongoing</td><td align="left" colspan="1" rowspan="1">Healthy non-pregnant and pregnant women, 18&#8211;40&#160;years</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Escherichia coli</italic></td></tr><tr><td align="left" rowspan="2" colspan="1">ExPEC4V/EcoXyn-4&#160;V or JNJ-63871860</td><td align="left" rowspan="2" colspan="1">LimmaTech (formerly GlycoVaxyn) and Janssen</td><td align="left" rowspan="2" colspan="1">Conjugate (tetravalent)</td><td align="left" rowspan="2" colspan="1">O-antigens of <italic toggle="yes">E. coli</italic> serotypes O1A, O2, O6A, and O25B individually bioconjugated to rEPA</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02289794">NCT02289794</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy women with a history of recurrent UTIs, 18&#8211;70&#160;years</td><td align="left" rowspan="2" colspan="1">(Frenck et al. <xref ref-type="bibr" rid="CR71">2019</xref>; Huttner et al. <xref ref-type="bibr" rid="CR102">2017</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02546960">NCT02546960</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults,&#8201;&#8805;&#8201;18&#160;years</td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Mycobacterium tuberculosis</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple vaccines</td><td align="left" colspan="1" rowspan="1">Multiple</td><td align="left" colspan="2" rowspan="1">Genetically modified BCG, whole cell inactivated, subunit, recombinant vector</td><td align="left" colspan="1" rowspan="1">Phase 1&#8211;3</td><td align="left" colspan="1" rowspan="1">Multiple</td><td align="left" colspan="1" rowspan="1">Various</td><td align="left" colspan="1" rowspan="1">Various</td><td align="left" colspan="1" rowspan="1">(Andersen and Scriba <xref ref-type="bibr" rid="CR8">2019</xref>; Khoshnood et al. <xref ref-type="bibr" rid="CR114">2018</xref>; World Health Organization <xref ref-type="bibr" rid="CR254">2018</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Shigella</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">CVD 1208S</td><td align="left" colspan="1" rowspan="1">University of Maryland</td><td align="left" colspan="1" rowspan="1">Live attenuated</td><td align="left" colspan="1" rowspan="1">Live attenuated <italic toggle="yes">S. flexneri</italic> 2a strain</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;45&#160;years</td><td align="left" colspan="1" rowspan="1">(Kotloff et al. <xref ref-type="bibr" rid="CR119">2007</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">WRSS1</td><td align="left" colspan="1" rowspan="1">WRAIR</td><td align="left" colspan="1" rowspan="1">Live attenuated</td><td align="left" colspan="1" rowspan="1">Live attenuated <italic toggle="yes">S. sonnei</italic></td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy men, 18&#8211;22&#160;years</td><td align="left" colspan="1" rowspan="1">(Orr et al. <xref ref-type="bibr" rid="CR176">2005</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">SsWC</td><td align="left" colspan="1" rowspan="1">WRAIR</td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Whole-cell formalin-inactivated trivalent <italic toggle="yes">S. sonnei</italic></td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;50&#160;years</td><td align="left" colspan="1" rowspan="1">(McKenzie et al. <xref ref-type="bibr" rid="CR150">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">S. sonnei</italic>-rEPA</td><td align="left" colspan="1" rowspan="1">WRAIR</td><td align="left" colspan="1" rowspan="1">Conjugate</td><td align="left" colspan="1" rowspan="1">O-antigen of <italic toggle="yes">S. sonnei</italic> conjugated to rEPA</td><td align="left" colspan="1" rowspan="1">Phase 3</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy men, 18&#8211;22&#160;years</td><td align="left" colspan="1" rowspan="1">(Cohen et al. <xref ref-type="bibr" rid="CR44">1997</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">SF2a-TT15</td><td align="left" colspan="1" rowspan="1">Institut Pasteur</td><td align="left" colspan="1" rowspan="1">Conjugate</td><td align="left" colspan="1" rowspan="1">Synthetic repeats of <italic toggle="yes">S. flexneri</italic> type 2a O-antigen conjugated to TT</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02797236">NCT02797236</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;45&#160;years</td><td align="left" colspan="1" rowspan="1">(Barel and Mulard <xref ref-type="bibr" rid="CR17">2019</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">GVXNS D133</td><td align="left" colspan="1" rowspan="1">LimmaTech</td><td align="left" colspan="1" rowspan="1">Conjugate</td><td align="left" colspan="1" rowspan="1">Bioconjugate of <italic toggle="yes">S. dysenteriae</italic> type 1 O-antigen and rEPA</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01069471">NCT01069471</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;50&#160;years</td><td align="left" colspan="1" rowspan="1">(Hatz et al. <xref ref-type="bibr" rid="CR90">2015</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Flexyn2a</td><td align="left" rowspan="2" colspan="1">LimmaTech</td><td align="left" rowspan="2" colspan="1">Conjugate</td><td align="left" rowspan="2" colspan="1">Bioconjugate of <italic toggle="yes">S. flexneri</italic> type 2a O-antigen and rEPA</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02388009">NCT02388009</ext-link></td><td align="left" rowspan="2" colspan="1">Completed</td><td align="left" rowspan="2" colspan="1">Healthy adults, 18&#8211;50&#160;years</td><td align="left" rowspan="2" colspan="1">(Riddle et al. <xref ref-type="bibr" rid="CR203">2016</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Phase 2b</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02646371">NCT02646371</ext-link></td></tr><tr><td align="left" rowspan="2" colspan="1">1790GAHB</td><td align="left" rowspan="2" colspan="1">GSK</td><td align="left" rowspan="2" colspan="1">Subunit (GMMA)</td><td align="left" rowspan="2" colspan="1">OMV vaccine for <italic toggle="yes">S. sonnei</italic></td><td align="left" rowspan="2" colspan="1">Phase 2a</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02676895">NCT02676895</ext-link></td><td align="left" rowspan="2" colspan="1">Completed</td><td align="left" rowspan="2" colspan="1">Healthy adults, 18&#8211;45&#160;years</td><td align="left" rowspan="2" colspan="1">(Obiero et al. <xref ref-type="bibr" rid="CR174">2017</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03089879">NCT03089879</ext-link></td></tr><tr><td align="left" rowspan="2" colspan="1">Invaplex 50</td><td align="left" rowspan="2" colspan="1">Naval Medical Research Center/WRAIR</td><td align="left" rowspan="2" colspan="1">Subunit</td><td align="left" rowspan="2" colspan="1">Complex of IpaB/C/D with <italic toggle="yes">S. flexneri</italic> 2a LPS</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00082069">NCT00082069</ext-link></td><td align="left" rowspan="2" colspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;40&#160;years</td><td align="left" rowspan="2" colspan="1">(Riddle et al. <xref ref-type="bibr" rid="CR202">2011</xref>; Tribble et al. <xref ref-type="bibr" rid="CR227">2010</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;45&#160;years</td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Non-typhoidal Salmonella</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">CVD 1000</td><td align="left" colspan="1" rowspan="1">University of Maryland</td><td align="left" colspan="1" rowspan="1">Conjugate</td><td align="left" colspan="1" rowspan="1">Conjugates of O-antigen and flagellin from <italic toggle="yes">S.</italic> Typhimurium and <italic toggle="yes">S.</italic> Enteritidis, formulated with Typbar-TCV&#8482;</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03981952">NCT03981952</ext-link></td><td align="left" colspan="1" rowspan="1">Ongoing</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;45&#160;years</td><td align="left" colspan="1" rowspan="1">(Baliban et al. <xref ref-type="bibr" rid="CR15">2018</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Paratyphoid Salmonella</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">CVD 1902</td><td align="left" colspan="1" rowspan="1">University of Maryland</td><td align="left" colspan="1" rowspan="1">Live attenuated</td><td align="left" colspan="1" rowspan="1">Live attenuated <italic toggle="yes">S.</italic> Paratyphi A strain 9150</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01129453">NCT01129453</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;45&#160;years</td><td align="left" colspan="1" rowspan="1">(Wahid et al. <xref ref-type="bibr" rid="CR244">2019</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Staphylococcus aureus</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">4C-Staph</td><td align="left" colspan="1" rowspan="1">GSK</td><td align="left" colspan="1" rowspan="1">Subunit</td><td align="left" colspan="1" rowspan="1">Csa1A (Sur2), FhuD2, EsxA/EsxB, HlAH35L</td><td align="left" rowspan="2" colspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01160172">NCT01160172</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;40&#160;years</td><td align="left" colspan="1" rowspan="1">(Mancini et al. <xref ref-type="bibr" rid="CR143">2016</xref>);<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">NDV-3</td><td align="left" colspan="1" rowspan="1">NovaDigm</td><td align="left" colspan="1" rowspan="1">Subunit</td><td align="left" colspan="1" rowspan="1">Recombinant N-terminal portion of Als3p of <italic toggle="yes">Candida albicans</italic></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03455309">NCT03455309</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Men at increased risk for <italic toggle="yes">S. aureus</italic> colonization and disease, 17&#8211;35&#160;years</td><td align="left" colspan="1" rowspan="1">(Schmidt et al. <xref ref-type="bibr" rid="CR209">2012</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Respiratory syncytial virus</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">ResVax</td><td align="left" colspan="1" rowspan="1">Novavax</td><td align="left" colspan="1" rowspan="1">Nanoparticle</td><td align="left" colspan="1" rowspan="1">Recombinant RSV-F protein in nanoparticles</td><td align="left" colspan="1" rowspan="1">Phase 3</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02624947">NCT02624947</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy third-trimester pregnant women, 18&#8211;40&#160;years</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" rowspan="5" colspan="1">RSV vaccine</td><td align="left" rowspan="5" colspan="1">Pfizer</td><td align="left" rowspan="5" colspan="1">Subunit</td><td align="left" rowspan="5" colspan="1">Engineered soluble pre-fusion site &#216;&#8211;stabilized RSV F trimers</td><td align="left" colspan="1" rowspan="1">Phase 3</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04424316">NCT04424316</ext-link></td><td align="left" colspan="1" rowspan="1">Ongoing</td><td align="left" colspan="1" rowspan="1">Healthy third-trimester pregnant women, 18&#8211;49&#160;years</td><td align="left" rowspan="5" colspan="1">(Schmoele-Thoma et al. <xref ref-type="bibr" rid="CR210">2019</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" rowspan="4" colspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03529773">NCT03529773</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;49 and 50&#8211;85&#160;years</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03572062">NCT03572062</ext-link></td><td align="left" colspan="1" rowspan="1">Terminated</td><td align="left" colspan="1" rowspan="1">Healthy older adults, 65&#8211;85&#160;years</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04071158">NCT04071158</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy non-pregnant women, 18&#8211;49&#160;years</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04032093">NCT04032093</ext-link></td><td align="left" colspan="1" rowspan="1">Ongoing</td><td align="left" colspan="1" rowspan="1">Healthy third-trimester pregnant women, 18&#8211;49&#160;years</td></tr><tr><td align="left" rowspan="2" colspan="1">GSK3003891A</td><td align="left" rowspan="2" colspan="1">GSK</td><td align="left" rowspan="2" colspan="1">Subunit</td><td align="left" rowspan="2" colspan="1">Engineered soluble pre-fusion site &#216;&#8211;stabilized RSV F trimers</td><td align="left" rowspan="2" colspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02360475">NCT02360475</ext-link></td><td align="left" rowspan="2" colspan="1">Completed</td><td align="left" rowspan="2" colspan="1">Healthy non-pregnant women, 18&#8211;45&#160;years</td><td align="left" rowspan="2" colspan="1">(Beran et al. <xref ref-type="bibr" rid="CR20">2018</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02753413">NCT02753413</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">VRC-RSVRGP084-00VP (DS-Cav1)</td><td align="left" colspan="1" rowspan="1">NIAID</td><td align="left" colspan="1" rowspan="1">Subunit</td><td align="left" colspan="1" rowspan="1">Engineered soluble pre-fusion site &#216;&#8211;stabilized RSV F trimers</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03049488">NCT03049488</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;50&#160;years</td><td align="left" colspan="1" rowspan="1">(Crank et al. <xref ref-type="bibr" rid="CR46">2019</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple vaccines</td><td align="left" colspan="1" rowspan="1">Multiple</td><td align="left" colspan="2" rowspan="1">Subunit, recombinant vector, live-attenuated</td><td align="left" colspan="1" rowspan="1">Phase 1&#8211;2</td><td align="left" colspan="1" rowspan="1">Multiple</td><td align="left" colspan="1" rowspan="1">Various</td><td align="left" colspan="1" rowspan="1">Healthy children and adults</td><td align="left" colspan="1" rowspan="1">(Jares Baglivo and Polack <xref ref-type="bibr" rid="CR107">2019</xref>; PATH <xref ref-type="bibr" rid="CR180">2019</xref>)</td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Human immunodeficiency virus</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple vaccines</td><td align="left" colspan="1" rowspan="1">Multiple</td><td align="left" colspan="2" rowspan="1">Subunit, recombinant vectors</td><td align="left" colspan="1" rowspan="1">Phase 1&#8211;3</td><td align="left" colspan="1" rowspan="1">Multiple</td><td align="left" colspan="1" rowspan="1">Various</td><td align="left" colspan="1" rowspan="1">Various</td><td align="left" colspan="1" rowspan="1">(Hsu and O&#8217;Connell <xref ref-type="bibr" rid="CR100">2017</xref>; Trovato et al. <xref ref-type="bibr" rid="CR229">2018</xref>)</td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Influenza virus</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">M-001 (universal flu vaccine)</td><td align="left" colspan="1" rowspan="1">BiondVax</td><td align="left" colspan="1" rowspan="1">Subunit</td><td align="left" colspan="1" rowspan="1">Recombinant protein containing 9 B-cell and T-cell conserved epitopes from influenza A and B HA, NP, and M1</td><td align="left" colspan="1" rowspan="1">Phase 3</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03450915">NCT03450915</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults,&#8201;&#8805;&#8201;50&#160;years</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">VTP-100</td><td align="left" colspan="1" rowspan="1">Vaccitech</td><td align="left" colspan="1" rowspan="1">Recombinant vector</td><td align="left" colspan="1" rowspan="1">Recombinant influenza A NP and M1 in MVA vector</td><td align="left" colspan="1" rowspan="1">Phase 2b</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03880474">NCT03880474</ext-link></td><td align="left" colspan="1" rowspan="1">Terminated</td><td align="left" colspan="1" rowspan="1">Healthy adults,&#8201;&#8805;&#8201;18&#160;years</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">VAL-506440</td><td align="left" colspan="1" rowspan="1">Moderna</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">mRNA of H10N8 HA in lipid nanoparticles</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03076385">NCT03076385</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;64&#160;years</td><td align="left" rowspan="2" colspan="1">(Bahl et al. <xref ref-type="bibr" rid="CR13">2017</xref>; Feldman et al. <xref ref-type="bibr" rid="CR67">2019</xref>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">VAL-339851</td><td align="left" colspan="1" rowspan="1">Moderna</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">mRNA of H7N9 HA in lipid nanoparticles</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03345043">NCT03345043</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">Healthy adults, 18&#8211;49&#160;years</td></tr></tbody></table><table-wrap-foot><p>20vPnC, 20-valent pneumococcal conjugate vaccine; Als3p, agglutinin like sequence 3 protein</p><p>BCG, Bacillus Calmette Gu&#233;rin; CRM<sub>197</sub>, Cross reactive material 197; GBS, Group B streptococcus; GMMA, Generalized modules for membrane antigens vaccine delivery system; GSK, GlaxoSmithKline; HA, Hemagglutinin; LPS, Lipopolysaccharide; M1, Matrix protein; MAPS, Multiple antigen presenting system; mRNA, messenger ribonucleic acid; MVA, Modified vaccinia virus Ankara; N/A, Not available; NCT, ClinicalTrials.gov identifier; NIAID, National institute of allergy and infectious diseases; NP, Nucleoprotein; OMV, Outer membrane vesicle; PATH, Program for appropriate technology in health; PcpA, Pneumococcal choline binding protein A; PHiD-CV, Pneumococcal polysaccharide protein D-conjugate vaccine; PhtD, Pneumococcal histidine triad protein D; PlyD1, Pneumolysoid; rEPA, recombinant <italic toggle="yes">Pseudomonas aeruginosa</italic> exotoxin A; RSV, Respiratory syncytial virus; TT, Tetanus toxoid; UTI, Urinary tract infection; WRAIR, Walter reed army institute of research</p></table-wrap-foot></table-wrap></p><sec id="Sec14"><title>Bacterial vaccines in late-stage clinical development</title><sec id="Sec15"><title><italic toggle="yes">Clostridioides difficile</italic> vaccines</title><p id="Par44"><italic toggle="yes">C. difficile</italic>, a Gram positive anaerobic, spore forming bacillus, is the main cause of nosocomial infectious diarrhea in industrialized countries that frequently occurs consequent to antibiotic use (Guerrant et al. <xref ref-type="bibr" rid="CR84">1990</xref>; Kelly et al. <xref ref-type="bibr" rid="CR112">1994</xref>; Kyne and Kelly <xref ref-type="bibr" rid="CR124">1998</xref>; Magill et al. <xref ref-type="bibr" rid="CR142">2014</xref>; McFarland <xref ref-type="bibr" rid="CR148">1995</xref>). According to the CDC, there were 223,900 cases of <italic toggle="yes">C. difficile</italic> infection related to antibiotic use and antibiotic resistance in 2017 in the U.S., along with 12,800 associated deaths (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>). Older adults (65&#160;years of age and older) are at increased risk for <italic toggle="yes">C. difficile</italic> infection, particularly when exposed to healthcare settings (Bartlett and Gerding <xref ref-type="bibr" rid="CR18">2008</xref>; Bauer et al. <xref ref-type="bibr" rid="CR19">2011</xref>; Leffler and Lamont <xref ref-type="bibr" rid="CR131">2015</xref>; Pepin et al. <xref ref-type="bibr" rid="CR185">2005</xref>; Simor <xref ref-type="bibr" rid="CR215">2010</xref>). Although most patients experiencing a first episode of <italic toggle="yes">C. difficile</italic> infection respond well to standard antibiotic treatment (McDonald et al. <xref ref-type="bibr" rid="CR147">2018</xref>), approximately 15&#8211;35% of patients suffer from at least one recurrence (Gerding et al. <xref ref-type="bibr" rid="CR79">2008</xref>; Leffler and Lamont <xref ref-type="bibr" rid="CR131">2015</xref>; Louie et al. <xref ref-type="bibr" rid="CR138">2011</xref>), often leading to a vicious cycle requiring additional antibiotic use. Emergence of hypervirulent pathogenic strains such as BI/NAP1/027, an increased use of antibiotics that disrupt the intestinal microflora, improved detection methods, and an increased exposure to spores in healthcare facilities all contribute to the observed <italic toggle="yes">C. difficile</italic> infection escalation in the U.S. and Europe (Donskey <xref ref-type="bibr" rid="CR54">2017</xref>; Gerding <xref ref-type="bibr" rid="CR78">2004</xref>; Lessa et al. <xref ref-type="bibr" rid="CR134">2015</xref>; Polage et al. <xref ref-type="bibr" rid="CR189">2015</xref>). The current treatment recommendations for <italic toggle="yes">C. difficile</italic> infection include vancomycin, fidaxomicin, and/or metronidazole (McDonald et al. <xref ref-type="bibr" rid="CR147">2018</xref>), which can cause development of AMR (Adler et al. <xref ref-type="bibr" rid="CR2">2015</xref>; Freeman et al. <xref ref-type="bibr" rid="CR70">2015</xref>; Moura et al. <xref ref-type="bibr" rid="CR161">2013</xref>; Saha et al. <xref ref-type="bibr" rid="CR205">2019</xref>). Given this burden of <italic toggle="yes">C. difficile</italic> infection and the rapid global spread of epidemic and antibiotic-resistant strains, the CDC has classified <italic toggle="yes">C. difficile</italic> as an urgent antibiotic resistance threat (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>). A vaccine against <italic toggle="yes">C. difficile</italic> would both protect against disease and, importantly, limit the need for antibiotic use to treat the infection, thus also limiting antibiotic resistance.</p><p id="Par45"><italic toggle="yes">C. difficile</italic> pathogenesis is mediated primarily by two large clostridial glucosylating toxins, toxin A (TcdA) and toxin B (TcdB) (Kuehne et al. <xref ref-type="bibr" rid="CR121">2010</xref>), which modify intracellular signaling pathways in intestinal epithelial cells, causing cytotoxicity, inflammation, and diarrhea (Voth and Ballard <xref ref-type="bibr" rid="CR243">2005</xref>). Vaccines to protect against <italic toggle="yes">C. difficile</italic> infection have focused on the development of neutralizing antibody responses against TcdA and TcdB (Giannasca et al. <xref ref-type="bibr" rid="CR80">1999</xref>; Kyne et al. <xref ref-type="bibr" rid="CR125">2001</xref>; Lowy et al. <xref ref-type="bibr" rid="CR139">2010</xref>; Wilcox et al. <xref ref-type="bibr" rid="CR249">2017</xref>). Four investigational vaccines have progressed to clinical development (Table <xref rid="Tab2" ref-type="table">2</xref>). Currently, the most advanced vaccine candidate is PF-06425090, developed by Pfizer, which is in a Phase 3 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03090191">https://clinicaltrials.gov/ct2/show/NCT03090191</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pfizer.com/science/find-a-trial/nct03090191">https://www.pfizer.com/science/find-a-trial/nct03090191</ext-link>). It is comprised of a bivalent toxoid formulation of <italic toggle="yes">C. difficile</italic> toxins A and B that are each genetically and chemically inactivated (Vidunas et al. <xref ref-type="bibr" rid="CR238">2016</xref>). If licensed and universally recommended, a <italic toggle="yes">C. difficile</italic> vaccine would provide an important tool for preventing AMR, as vaccinated individuals would be protected from <italic toggle="yes">C. difficile</italic> infection, thus reducing the associated antibiotic use and selection of multidrug-resistant bacterial species.</p></sec><sec id="Sec16"><title><italic toggle="yes">Streptococcus pneumoniae</italic> vaccines</title><p id="Par46">Following introduction of PCV13, as a result of the significant effectiveness on both carriage and invasive disease, serotypes not included in the vaccine have become responsible for the majority of invasive pneumococcal disease cases in Europe and North America (Balsells et al. <xref ref-type="bibr" rid="CR16">2017</xref>; Kyaw et al. <xref ref-type="bibr" rid="CR123">2006</xref>). To help address this major unmet medical need, several pneumococcal conjugate vaccines with higher valencies are being developed for children, including 15-valent (Merck; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03692871">NCT03692871</ext-link>) and 20-valent (Pfizer; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04382326">NCT04382326</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04379713">NCT04379713</ext-link>) polysaccharide conjugate formulations (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>). If successful, these vaccines have the potential to further reduce the burden of pneumococcal diseases globally. An alternative approach to increase protection against <italic toggle="yes">S. pneumoniae</italic> is the use of conserved epitopes of pneumococcal surface proteins such as proteins A and C, adhesin A, pneumolysin, histidine triad proteins, and choline binding protein A in pneumococcal conjugate and subunit vaccines (Table <xref rid="Tab2" ref-type="table">2</xref>) (Alderson <xref ref-type="bibr" rid="CR4">2016</xref>; Moffitt and Malley <xref ref-type="bibr" rid="CR157">2016</xref>). Another pneumococcal vaccine candidate comprises a macromolecular complex where pneumococcal proteins are used as the carrier for pneumococcal capsular polysaccharides (Zhang et al. <xref ref-type="bibr" rid="CR257">2013</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://affinivax.com/vaccine-pipeline/">http://affinivax.com/vaccine-pipeline/</ext-link>). This vaccine has reached Phase 1/2 evaluation in young as well as elderly adults (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03803202">NCT03803202</ext-link>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>).</p></sec><sec id="Sec17"><title>Group B streptococcus vaccines</title><p id="Par47"><italic toggle="yes">Streptococcus agalactiae</italic>, also known as Group B streptococcus (GBS), is an encapsulated Gram positive bacterium common in the intestinal tract that also asymptomatically colonizes the vaginal mucosa (women) and rectum (women and men) of approximately 25% of the population. GBS can cause invasive infections, including pneumonia, meningitis, bacteremia, and sepsis across all age groups. According to the CDC&#8217;s national estimate, in 2016 there were 31,000 cases of invasive GBS disease, causing 1700 deaths (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>). Pregnant women and their infants are particularly vulnerable to GBS infection (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/groupbstrep/about/fast-facts.html">https://www.cdc.gov/groupbstrep/about/fast-facts.html</ext-link>). Intrapartum antibiotic prophylaxis, frequently applied in the U.S. and some other high income countries, effectively prevents most early onset GBS disease in newborns (Braye et al. <xref ref-type="bibr" rid="CR25">2018</xref>). However, the treatment does not impact acquisition of late onset GBS disease (occurring more than 7&#160;days after birth) and compromises the establishment of the normal microbiota in neonates. Intrapartum antibiotic prophylaxis also has the capacity to induce AMR among constituents of the vaginal microflora. Additionally, GBS resistance to antibiotics, including macrolides, is on the rise (Lu et al. <xref ref-type="bibr" rid="CR140">2014</xref>; Schrag et al. <xref ref-type="bibr" rid="CR211">2002</xref>). The CDC recognizes GBS as a concerning AMR threat. In 2016, 58% of GBS isolates tested were erythromycin resistant and 42% were clindamycin resistant, and clindamycin-resistant GBS was estimated to be associated with 13,000 illnesses and 720 deaths (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>). An effective maternal GBS vaccine administered to the mother would thus not only protect against maternal and infant GBS infections, but also reduce AMR.</p><p id="Par48">Investigational GBS vaccines based on the capsular polysaccharide are thus being pursued that may be used as maternal vaccines to be administered to pregnant women, inducing functional antibodies that would be transferred across the placenta during the third trimester of pregnancy and protect neonates from GBS disease. Several Phase 2 studies have been conducted with GBS capsular polysaccharide conjugate vaccines (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00128219">NCT00128219</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02459262">NCT02459262</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02270944">NCT02270944</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02690181">NCT02690181</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03170609">NCT03170609</ext-link>; Table <xref rid="Tab2" ref-type="table">2</xref>). These include mono- and bivalent vaccines (Baker et al. <xref ref-type="bibr" rid="CR14">2003</xref>; Hillier et al. <xref ref-type="bibr" rid="CR95">2019</xref>; Rose et al. <xref ref-type="bibr" rid="CR204">2018</xref>), a trivalent vaccine (Leroux-Roels et al. <xref ref-type="bibr" rid="CR133">2019</xref>, <xref ref-type="bibr" rid="CR132">2016</xref>), and a hexavalent vaccine (Buurman et al. <xref ref-type="bibr" rid="CR29">2019</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>). The hexavalent GBS vaccine being developed by Pfizer is comprised of serotypes Ia, Ib, II, III, IV, and V,&#160;representing the dominant serotypes associated with GBS disease worldwide, conjugated to cross-reactive material 197 (CRM<sub>197</sub>) used as a carrier protein (Buurman et al. <xref ref-type="bibr" rid="CR29">2019</xref>), and is currently being evaluated in a Phase 2 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03765073">NCT03765073</ext-link>) in healthy non-pregnant and pregnant women (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>). An alternative vaccine candidate, a GBS-NN bivalent subunit vaccine (Minervax ApS), comprising a fusion of recombinant N-terminal domains of the GBS Rib and Alpha C surface proteins, has been evaluated in two Phase 1 trials in healthy non-pregnant women (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02459262">NCT02459262</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03807245">NCT03807245</ext-link>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>).</p></sec></sec><sec id="Sec18"><title>Bacterial vaccines in early stage clinical or pre-clinical development</title><sec id="Sec19"><title><italic toggle="yes">Enterobacteriaceae</italic> vaccines</title><p id="Par49"><italic toggle="yes">Enterobacteriaceae</italic> are a large family of Gram negative microbes that include both normal components of the gut flora and pathogens, with substantial AMR in some prominent family members. <italic toggle="yes">E. coli</italic> is the most frequent cause of urinary tract infections and bloodstream infections at all ages. <italic toggle="yes">E. coli</italic> may also be associated with intra-abdominal infections such as peritonitis as well sepsis and meningitis in neonates. Certain pathotypes of <italic toggle="yes">E. coli</italic> are also leading causative agents of foodborne infections worldwide. <italic toggle="yes">Klebsiella pneumoniae</italic> poses a similar problem; however, it tends to infect more vulnerable individuals including pre-term infants and patients with impaired immune systems, diabetes, or suffering from alcohol abuse, and those receiving advanced medical care.</p><p id="Par50"><italic toggle="yes">E. coli</italic> and <italic toggle="yes">K. pneumoniae</italic> pose the greatest concerns because they have high levels of resistance to third generation cephalosporins and extended spectrum &#946;-lactam antibiotics. <italic toggle="yes">E. coli</italic> infections are also associated with high levels of fluoroquinolone resistance, and <italic toggle="yes">K. pneumoniae</italic> isolates highly resistant to carbapenems have caused frequent nosocomial outbreaks. Carbapenem-resistant <italic toggle="yes">Enterobacteriaceae</italic> are given critical priority by the WHO (World Health Organization <xref ref-type="bibr" rid="CR253">2017a</xref>) and are considered an urgent threat by the CDC (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>). Multidrug-resistant <italic toggle="yes">Enterobacteriaceae</italic> have recently achieved greater attention due to the rapid global spread of NDM-1 producing strains (Walsh et al. <xref ref-type="bibr" rid="CR246">2011</xref>; Yong et al. <xref ref-type="bibr" rid="CR256">2009</xref>), with associated spread of this gene to other Gram negative species (Nordmann et al. <xref ref-type="bibr" rid="CR170">2011</xref>). With the recent discovery of <italic toggle="yes">E. coli</italic> strains harboring the MCR-1 plasmid-1 conferring resistance to the last line antibacterial colistin (McGann et al. <xref ref-type="bibr" rid="CR149">2016</xref>), there is concern that strains containing both MCR-1 and NDM-1 may emerge, resulting in untreatable infections.</p><p id="Par51">Vaccine approaches for <italic toggle="yes">E. coli</italic> have focused on lipopolysaccharides (or O-antigens) (Huttner et al. <xref ref-type="bibr" rid="CR102">2017</xref>; Poolman and Wacker <xref ref-type="bibr" rid="CR192">2016</xref>). Phase 1 clinical studies conducted in the 1990s confirmed that measurable antibody levels and rises in functional activity were induced against all 12 O-antigen types included in the vaccine developed by the Swiss Serum and Vaccine Institute and the Walter Reed Army Institute of Research (O-antigen linked to recombinant <italic toggle="yes">P. aeruginosa</italic> exoprotein A as a carrier) (Cross et al. <xref ref-type="bibr" rid="CR47">1994</xref>). A vaccine targeting extraintestinal pathogenic <italic toggle="yes">E. coli</italic>, containing 4 O-antigen bioconjugates (ExPEC4V/EcoXyn-4&#160;V or JNJ-63871860), is being developed by LimmaTech (formerly GlycoVaxyn) and Janssen (van den Dobbelsteen et al. <xref ref-type="bibr" rid="CR233">2016</xref>) and has been evaluated in Phase 1 and 2 trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02289794">NCT02289794</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02546960">NCT02546960</ext-link>), including healthy women between 18 and 70&#160;years of age with a history of recurrent urinary tract infections (Table <xref rid="Tab2" ref-type="table">2</xref>) (Frenck et al. <xref ref-type="bibr" rid="CR71">2019</xref>; Huttner et al. <xref ref-type="bibr" rid="CR102">2017</xref>). Sequoia Pharmaceuticals is developing a vaccine candidate based on the <italic toggle="yes">E. coli</italic> type I fimbrial adhesin protein (FimH) (Langermann et al. <xref ref-type="bibr" rid="CR128">2000</xref>) that has been assessed in a Phase 1 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://sequoiasciences.com/uti-vaccine-program">https://sequoiasciences.com/uti-vaccine-program</ext-link>). Phase 1 clinical evaluation of the Swiss Serum and Vaccine Institute&#8217;s <italic toggle="yes">Klebsiella</italic> capsule polysaccharide vaccine found it to be safe and well tolerated, with measurable induction of anti-capsular IgG (Cryz et al. <xref ref-type="bibr" rid="CR49">1986</xref>; Edelman et al. <xref ref-type="bibr" rid="CR58">1994</xref>). While this vaccine was not pursued in efficacy studies with active immunization, it was used in combination with a <italic toggle="yes">Pseudomonas</italic> vaccine component (discussed in <italic toggle="yes">Pseudomonas</italic> vaccines later in this section) to generate a hyperimmune intravenous immunoglobulin formulation that was assessed among intensive care patients (Donta et al. <xref ref-type="bibr" rid="CR55">1996</xref>) where a possible trend towards efficacy against <italic toggle="yes">Klebsiella</italic> infection was noted, although this was not statistically significant. Vaccines containing inactivated strains of bacteria have also been explored. Clinical efficacy has been reported with commercially available Uromune&#174; (a mixture of <italic toggle="yes">E. coli</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">Enterococcus faecalis</italic>, and <italic toggle="yes">Proteus vulgaris</italic>) and SolcoUrovac&#174; (6 <italic toggle="yes">E. coli</italic> strains mixed with <italic toggle="yes">Proteus mirabilis</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">Morganella morganii</italic>, and <italic toggle="yes">E. faecalis</italic>) when tested against recurrent urinary tract infections (Nesta and Pizza <xref ref-type="bibr" rid="CR168">2018</xref>).</p></sec><sec id="Sec20"><title>Other Gram negative bacterial vaccines</title><p id="Par52"><italic toggle="yes">P. aeruginosa</italic> and <italic toggle="yes">A. baumannii</italic> infections are both associated with exposure to healthcare settings and though they do not cause high rates of infection, they are characterized by high levels of antibiotic resistance and associated morbidity. Both pathogens cause pneumonia and bloodstream infections in hospital settings, especially in critically ill patients (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>; Jones <xref ref-type="bibr" rid="CR108">2010</xref>). Risk factors for <italic toggle="yes">P. aeruginosa</italic> infections include severe burns, cystic fibrosis, mechanical ventilation, catheterization, and immunocompromise (Gellatly and Hancock <xref ref-type="bibr" rid="CR77">2013</xref>). Gram negative carbapenem-resistant <italic toggle="yes">A. baumannii</italic> and <italic toggle="yes">P. aeruginosa</italic> are listed by the WHO as critical priority pathogens (World Health Organization <xref ref-type="bibr" rid="CR253">2017a</xref>). There were 8500 infections and 700 deaths associated with carbapenem-resistant <italic toggle="yes">A. baumannii</italic> and 32,600 infections and 2700 deaths associated with multidrug-resistant <italic toggle="yes">P. aeruginosa</italic> in 2017 in the U.S. (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>). Some strains of carbapenem-resistant <italic toggle="yes">A. baumannii</italic> and multidrug-resistant <italic toggle="yes">P. aeruginosa</italic> are resistant to nearly all antibiotics (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>).</p><p id="Par53">Vaccines targeting <italic toggle="yes">Acinetobacter</italic> are in early pre-clinical development (Gagneux-Brunon et al. <xref ref-type="bibr" rid="CR73">2018</xref>). However, questions remain regarding appropriate antigen selection for an <italic toggle="yes">A. baumannii</italic> vaccine (Chen <xref ref-type="bibr" rid="CR42">2015</xref>) and the adequacy of animal models to predict human protection (Alving <xref ref-type="bibr" rid="CR6">2002</xref>). In addition, clinical studies would be challenging: though this pathogen is voracious, it occurs infrequently and affects populations for which vaccination would be a challenge. In contrast, several investigational vaccines against <italic toggle="yes">P. aeruginosa</italic> have reached clinical development. Vaccines based on <italic toggle="yes">P. aeruginosa</italic> flagellin (FlaA and FlaB) were assessed in healthy adult volunteers and patients with cystic fibrosis, demonstrating immunogenicity and tolerability and partial protection against infection, respectively (Doring et al. <xref ref-type="bibr" rid="CR56">1995</xref>; Doring et al. <xref ref-type="bibr" rid="CR57">2007</xref>); however, this vaccine was not pursued further. Another vaccine candidate, an octavalent conjugate formulation comprised of the 8 most common <italic toggle="yes">P. aeruginosa</italic> O-types linked individually to recombinant <italic toggle="yes">P. aeruginosa</italic> exoprotein A, generated at the Swiss Serum and Vaccine Institute, induced IgG titers specific to all the administered polysaccharide antigens in Phase 1 clinical studies (Edelman et al. <xref ref-type="bibr" rid="CR58">1994</xref>), but did not offer significant protection against infection with <italic toggle="yes">P. aeruginosa</italic> in patients with cystic fibrosis in efficacy trials (Cryz et al. <xref ref-type="bibr" rid="CR50">1997</xref>). VLA43 (formerly known as IC43, Valneva) is comprised by a fusion of the surface loops of <italic toggle="yes">P. aeruginosa</italic> outer membrane proteins OprI and OprF. A Phase 2/3 evaluation of this vaccine candidate (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01563263">NCT01563263</ext-link>) did not confirm significantly reduced mortality observed in vaccinated patients in an intensive care unit on mechanical ventilation in previous studies (Rello et al. <xref ref-type="bibr" rid="CR198">2017</xref>; Valneva <xref ref-type="bibr" rid="CR232">2016</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01563263?term=NCT01563263&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT01563263?term=NCT01563263&amp;rank=1</ext-link>). Several additional whole cell and subunit <italic toggle="yes">P. aeruginosa</italic> vaccine candidates have recently been evaluated in early stage pre-clinical studies (Hegerle et al. <xref ref-type="bibr" rid="CR92">2018</xref>; Meynet et al. <xref ref-type="bibr" rid="CR154">2018</xref>; Zhang et al. <xref ref-type="bibr" rid="CR258">2018</xref>).</p></sec><sec id="Sec21"><title><italic toggle="yes">Mycobacterium tuberculosis</italic> vaccines</title><p id="Par54"><italic toggle="yes">M. tuberculosis</italic> is the etiologic cause of tuberculosis, a disease that is one of the top 10 causes of death worldwide and the leading cause of death by a single infectious agent. Over 90% of tuberculosis cases occur in low- and middle-income countries. The WHO estimates that 1.8 billion people&#8212;close to one quarter of the world&#8217;s population&#8212;are infected with <italic toggle="yes">M. tuberculosis</italic> globally (World Health Organization <xref ref-type="bibr" rid="CR254">2018</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.tballiance.org/why-new-tb-drugs/global-pandemic">https://www.tballiance.org/why-new-tb-drugs/global-pandemic</ext-link>). Active, drug-susceptible tuberculosis disease is successfully treated with antibiotics, and an estimated 54 million lives were saved through tuberculosis diagnosis and treatment between 2000 and 2017. While the disease burden caused by tuberculosis is gradually falling globally and mortality rates decreased by 42% between 2000 and 2017 (World Health Organization <xref ref-type="bibr" rid="CR254">2018</xref>), multidrug-resistant tuberculosis remains a public health crisis and a health security threat (Koch et al. <xref ref-type="bibr" rid="CR117">2018</xref>). In 2017, there were an estimated 558,000 new cases of tuberculosis with resistance to rifampicin, the most effective first line drug, of which 82% had multidrug-resistant tuberculosis (defined as tuberculosis that is resistant to both rifampicin and isoniazid). In 2017, approximately 8.5% of multi-drug-resistant tuberculosis cases had extensively drug-resistant phenotypes (multidrug resistance plus resistance to at least one drug in both of the two classes of antibiotics: fluoroquinolones and second line injectable agents [amikacin, capreomycin, or kanamycin]), and extensively drug-resistant tuberculosis has been identified in more than 127 countries. AMR leads to longer treatment regimens, prolonged periods of contagiousness, and higher mortality in populations infected with tuberculosis (World Health Organization <xref ref-type="bibr" rid="CR254">2018</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/tuberculosis">https://www.who.int/news-room/fact-sheets/detail/tuberculosis</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.tballiance.org/why-new-tb-drugs/global-pandemic">https://www.tballiance.org/why-new-tb-drugs/global-pandemic</ext-link>).</p><p id="Par55">Bacillus Calmette Gu&#233;rin (BCG) vaccine, composed of an attenuated strain of <italic toggle="yes">Mycobacterium bovis</italic>, is the only available tuberculosis vaccine, and vaccination of newborns in endemic countries results in a reduction of disseminated disease and mortality in young children. Re-administering BCG vaccine does not provide additional protection after a childhood dose, however, and BCG vaccine does not prevent the reactivation of latent tuberculosis to pulmonary disease in the nearly one third of the human population that is already infected and at risk. Given these shortcomings of BCG vaccine, several more modern vaccine approaches are being pursued (Khoshnood et al. <xref ref-type="bibr" rid="CR114">2018</xref>; Raviglione et al. <xref ref-type="bibr" rid="CR197">2012</xref>), that may have a profound impact on tuberculosis disease morbidity and mortality and assist in stemming AMR, through prevention of the initial infection as well as reduction of reactivation of latent infection. Whole cell vaccine candidates that have progressed to advanced clinical development include: VPM1002, double mutant BCG vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03152903?term=NCT03152903&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03152903?term=NCT03152903&amp;rank=1</ext-link>); MTBVAC, live attenuated tuberculosis vaccine (Aguilo et al. <xref ref-type="bibr" rid="CR3">2017</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02933281?term=NCT02933281&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02933281?term=NCT02933281&amp;draw=2&amp;rank=1</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03536117?term=NCT03536117&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03536117?term=NCT03536117&amp;draw=2&amp;rank=1</ext-link>); RUTI&#174;, detoxified vaccine based on fragmented <italic toggle="yes">M. tuberculosis</italic> cells (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02711735?term=NCT02711735&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02711735?term=NCT02711735&amp;draw=2&amp;rank=1</ext-link>); and inactivated vaccines based on <italic toggle="yes">Mycobacterium vaccae, Mycobacterium indicus pranii</italic>, and non-tuberculous mycobacterium related to <italic toggle="yes">M. vaccae</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01979900?term=NCT01979900&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT01979900?term=NCT01979900&amp;rank=1</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02712424?term=NCT02712424&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02712424?term=NCT02712424&amp;rank=1</ext-link>) (Khoshnood et al. <xref ref-type="bibr" rid="CR114">2018</xref>; von Reyn et al. <xref ref-type="bibr" rid="CR242">2010</xref>; Andersen and Scriba <xref ref-type="bibr" rid="CR8">2019</xref>; Sharma et al. <xref ref-type="bibr" rid="CR212">2017</xref>).</p><p id="Par56">Live vectored tuberculosis investigational vaccines that have reached clinical evaluation include Ad5Ag85A, recombinant adenovirus vaccine expressing immunodominant recombinant antigen 85A that is shared by <italic toggle="yes">M. tuberculosis</italic> and BCG (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02337270?term=NCT02337270&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02337270?term=NCT02337270&amp;draw=2&amp;rank=1</ext-link>), and MVA85A, modified vaccinia virus Ankara expressing recombinant antigen 85A (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00953927?term=NCT00953927&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT00953927?term=NCT00953927&amp;draw=2&amp;rank=1</ext-link>). MVA85A was subsequently abandoned due to failure to improve protection against tuberculosis infection compared to BCG vaccine alone in vaccinated infants (Tameris et al. <xref ref-type="bibr" rid="CR219">2013</xref>). Adjuvanted multicomponent subunit vaccine candidates for tuberculosis are also being clinically tested as booster vaccines to prevent active or recurrent tuberculosis disease (Andersen and Scriba <xref ref-type="bibr" rid="CR8">2019</xref>). For example, H4:IC31 (Sanofi-led consortium), has demonstrated partial efficacy (30.5%) against sustained <italic toggle="yes">M. tuberculosis</italic> infection in high risk adolescents primed with BCG vaccine (Nemes et al. <xref ref-type="bibr" rid="CR167">2018</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.aeras.org/candidates">http://www.aeras.org/candidates</ext-link>), and ID93&#8201;+&#8201;GLA-SE (Infectious Disease Research Institute, Quratis) was found to elicit both humoral and cellular immune responses in adults with cured tuberculosis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02465216?term=NCT02465216&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02465216?term=NCT02465216&amp;draw=2&amp;rank=1</ext-link>) (Penn-Nicholson et al. <xref ref-type="bibr" rid="CR184">2018</xref>). The most promising of the subunit tuberculosis vaccine candidates is M72, developed by GlaxoSmithKline (Rixensart, Belgium) and containing two proteins shared by <italic toggle="yes">M. tuberculosis</italic> and BCG. In a Phase 2b study, AS01E-adjuvanted M72 demonstrated an overall 54% efficacy for prevention of pulmonary tuberculosis in HIV negative adults 18 to 50&#160;years of age with latent <italic toggle="yes">M. tuberculosis</italic> infection (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01755598?term=NCT01755598&amp;draw=2&amp;rank=2">https://clinicaltrials.gov/ct2/show/NCT01755598?term=NCT01755598&amp;draw=2&amp;rank=2</ext-link>) (Van Der Meeren et al. <xref ref-type="bibr" rid="CR234">2018</xref>). More work is needed, however, to develop a vaccine that can have broader efficacy for a larger population demographic.</p></sec><sec id="Sec22"><title><italic toggle="yes">Shigella</italic> vaccines</title><p id="Par57">In lower- and middle-income counties, <italic toggle="yes">Shigella</italic> is one of the top 5 causes of moderate to severe diarrhea in children less than 5&#160;years old and contributes to excess mortality and growth impairment (Kotloff et al. <xref ref-type="bibr" rid="CR120">2013</xref>). <italic toggle="yes">Shigella</italic> spp. are identified as priority pathogens by the CDC due to widespread resistance to ampicillin and trimethoprim-sulfamethoxazole and rising resistance to ciprofloxacin and azithromycin (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>).</p><p id="Par58">Several O polysaccharide based glycoconjugate vaccine candidates for <italic toggle="yes">Shigella</italic> have progressed to clinical studies (Table <xref rid="Tab2" ref-type="table">2</xref>) (Barel and Mulard <xref ref-type="bibr" rid="CR17">2019</xref>; Mani et al. <xref ref-type="bibr" rid="CR144">2016</xref>). These include monovalent vaccines developed by the U.S. National Institutes of Health (Cohen et al. <xref ref-type="bibr" rid="CR44">1997</xref>), the Pasteur Institute (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02797236?term=NCT02797236&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02797236?term=NCT02797236&amp;draw=2&amp;rank=1</ext-link>) (Barel and Mulard <xref ref-type="bibr" rid="CR17">2019</xref>), and LimmaTech (Hatz et al. <xref ref-type="bibr" rid="CR90">2015</xref>). However, in order to provide broad coverage against shigellosis, a multivalent vaccine formulation would need to cover the four primary serotypes (<italic toggle="yes">S. sonnei</italic> and <italic toggle="yes">S. flexneri</italic> 2a, 3a, and 6). Several whole cell <italic toggle="yes">Shigella</italic> vaccines have also been tested in clinical studies, including live attenuated <italic toggle="yes">S. flexneri</italic> 2a developed at the University of Maryland Center for Vaccine Development and Global Health (Kotloff et al. <xref ref-type="bibr" rid="CR119">2007</xref>), live attenuated <italic toggle="yes">S. sonnei</italic> (Orr et al. <xref ref-type="bibr" rid="CR176">2005</xref>), and a formalin inactivated <italic toggle="yes">Shigella</italic> preparation developed by the U.S. military (McKenzie et al. <xref ref-type="bibr" rid="CR150">2006</xref>). The GlaxoSmithKline Vaccines Institute for Global Health has developed an outer membrane vesicle vaccine that has progressed through Phase 2 clinical studies in Kenya (Obiero et al. <xref ref-type="bibr" rid="CR174">2017</xref>). The U.S. Army has designed a subunit vaccine for intranasal administration, comprised of a complex of IpaB/D with <italic toggle="yes">S. flexneri</italic> 2a lipopolysaccharide (Invaplex) (Riddle et al. <xref ref-type="bibr" rid="CR202">2011</xref>; Tribble et al. <xref ref-type="bibr" rid="CR227">2010</xref>).</p></sec><sec id="Sec23"><title>Non-typhoidal and paratyphoid <italic toggle="yes">Salmonella</italic> vaccines</title><p id="Par59">Non-typhoidal <italic toggle="yes">Salmonella</italic> is the second most common cause of bacterial gastroenteritis in the U.S., and the most frequent cause of hospitalizations and death due to bacterial enteric disease. In the U.S., rates of non-typhoidal <italic toggle="yes">Salmonella</italic> resistance to antibiotics such as ciprofloxacin have been increasing in recent years, prompting inclusion of non-typhoidal <italic toggle="yes">Salmonella</italic> in the CDC priority list as a serious threat (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>). The CDC estimated that between 2015 and 2017, 212,500 antibiotic-resistant non-typhoidal <italic toggle="yes">Salmonella</italic> infections occurred annually in the U.S., resulting in 70 deaths (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>). Non-typhoidal <italic toggle="yes">Salmonella</italic> vaccine candidates that have progressed to Phase 1 clinical studies include WT05, a live attenuated <italic toggle="yes">S. enterica</italic> serovar Typhimurium (Hindle et al. <xref ref-type="bibr" rid="CR96">2002</xref>), and a trivalent glycoconjugate vaccine comprised of conjugates of O polysaccharides and flagellin from the two dominant circulating <italic toggle="yes">S. enterica</italic> serovars, Typhimurium and Enteritidis, formulated with Typbar-TCV (Table <xref rid="Tab2" ref-type="table">2</xref>) (Baliban et al. <xref ref-type="bibr" rid="CR15">2018</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03981952?term=NCT03981952&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03981952?term=NCT03981952&amp;draw=2&amp;rank=1</ext-link>). Non-typhoidal <italic toggle="yes">Salmonella</italic> vaccine constructs for which clinical studies are planned include Generalized Membrane Module Antigens and O polysaccharide conjugates with CRM<sub>197</sub> developed by the GlaxoSmithKline Vaccines Institute for Global Health.</p><p id="Par60">Paratyphoid fever is clinically indistinguishable from typhoid enteric fever, with <italic toggle="yes">S</italic>. Paratyphi A being the most common <italic toggle="yes">S. enterica</italic> serovar (GBD 2017 Typhoid and Paratyphoid Collaborators <xref ref-type="bibr" rid="CR76">2019</xref>). <italic toggle="yes">S</italic>. Paratyphi A has developed increasing resistance to fluoroquinolones and ciprofloxacin (Parry et al. <xref ref-type="bibr" rid="CR178">2019</xref>). While efficacious typhoid vaccines are licensed and available for use, there are no <italic toggle="yes">S</italic>. Paratyphi A vaccines. Live attenuated vaccine strains and glycoconjugates are being used as platforms for <italic toggle="yes">S</italic>. Paratyphi A vaccine development (World Health Organization <xref ref-type="bibr" rid="CR251">2014b</xref>), and several candidates have been evaluated clinically (Table <xref rid="Tab2" ref-type="table">2</xref>) or pre-clinically (Wahid et al. <xref ref-type="bibr" rid="CR244">2019</xref>; Micoli et al. <xref ref-type="bibr" rid="CR155">2012</xref>; Ali et al. <xref ref-type="bibr" rid="CR5">2014</xref>). An ultimate vaccine formulation would need to include coverage for serovars that are co-endemic in the same areas, bears similar risk factors and disease pathology, and is also an AMR priority.</p></sec><sec id="Sec24"><title><italic toggle="yes">Staphylococcus aureus</italic> vaccines</title><p id="Par61">The Gram positive bacterium <italic toggle="yes">S. aureus</italic> is a common commensal component of human microflora; however, upon breaching a mucosal or epithelial barrier, it becomes an opportunistic pathogen capable of causing various skin and soft tissue infections as well as invasive life threatening disease including bacteremia, toxic shock syndrome, infectious endocarditis, osteomyelitis, and pneumonia (Dayan et al. <xref ref-type="bibr" rid="CR51">2016</xref>; Tong et al. <xref ref-type="bibr" rid="CR226">2015</xref>). <italic toggle="yes">S. aureus</italic> treatment can be complicated by resistance to &#946;-lactams and other classes of antibiotics. Notably, the CDC estimates that methicillin-resistant <italic toggle="yes">S. aureus</italic> contributes to over 70,000 cases of invasive disease and 9000 deaths per year in the U.S. alone (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/mrsa/healthcare/inpatient.html">https://www.cdc.gov/mrsa/healthcare/inpatient.html</ext-link>). Overall, there were 323,700 estimated cases of methicillin-resistant <italic toggle="yes">S. aureus</italic> infections in hospitalized patients and 10,600 deaths in 2017 (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>). Both the CDC and the WHO have placed methicillin-resistant <italic toggle="yes">S. aureus</italic> on their priority lists, highlighting the significance of AMR in this microbial species (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR40">2019</xref>; World Health Organization <xref ref-type="bibr" rid="CR253">2017a</xref>). <italic toggle="yes">S. aureus</italic> has the propensity to develop resistance even to newer antibiotics that have been introduced, such as linezolid, a Gram positive bacterium protein synthesis inhibiting drug introduced in 2000 (Endimiani et al. <xref ref-type="bibr" rid="CR60">2011</xref>), and daptomycin, a Gram positive membrane disrupting drug introduced in 2003 (Marty et al. <xref ref-type="bibr" rid="CR146">2006</xref>). <italic toggle="yes">S. aureus</italic> glycopeptide resistance is currently a source of concern, as this class of antibiotics, including vancomycin, is one of the main resources for combating infections caused by methicillin-resistant <italic toggle="yes">S. aureus</italic>. Given the high disease burden and resistance among <italic toggle="yes">S. aureus</italic> isolates to many classes of antibiotics, a strong rationale exists to develop effective vaccines to protect individuals against this species and to reduce AMR, especially in the older adult population who are at higher risk of disease and more often undergo hospitalization.</p><p id="Par62">As the mechanisms of protection for <italic toggle="yes">S. aureus</italic> are incompletely understood, this has challenged the development of vaccines, and despite extensive efforts there is currently no licensed vaccine to prevent <italic toggle="yes">S. aureus</italic> infection. Several <italic toggle="yes">S. aureus</italic> vaccine candidates developed by Nabi Biopharmaceuticals, Merck and Pfizer did not prove clinical efficacy and were discontinued due to futility (Fattom et al. <xref ref-type="bibr" rid="CR65">2015</xref>; McNeely et al. <xref ref-type="bibr" rid="CR152">2014</xref>; Pfizer <xref ref-type="bibr" rid="CR186">2018</xref>). A 4-component vaccine targeting <italic toggle="yes">S. aureus</italic>, 4C-Staph (Novartis, now GlaxoSmithKline), comprised of five different staphylococcal proteins, including genetically detoxified alpha-toxin hemolysin, surface proteins FhuD2 and Csa1A, and EsxAB protein, a fusion of two secreted virulence factors EsxA and EsxB, administered with a Toll like receptor 7-stimulating adjuvant (Mancini et al. <xref ref-type="bibr" rid="CR143">2016</xref>), has been assessed in a Phase 1 study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01160172?term=NCT01160172&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT01160172?term=NCT01160172&amp;draw=2&amp;rank=1</ext-link>) (Table <xref rid="Tab2" ref-type="table">2</xref>). There is no further information on 4C-Staph clinical development. An investigational vaccine NDV-3 (NovaDigm Therapeutics) contains the recombinant N-terminal portion of the <italic toggle="yes">Candida albicans</italic> agglutinin like sequence 3 protein, which has both sequence and structural homology with cell surface proteins of <italic toggle="yes">S. aureus</italic> (Table <xref rid="Tab2" ref-type="table">2</xref>) (Sheppard et al. <xref ref-type="bibr" rid="CR214">2004</xref>). The efficacy of NDV-3 in preventing <italic toggle="yes">S. aureus</italic> nasal colonization among a population of military recruits who are at increased risk for <italic toggle="yes">S. aureus</italic> colonization and disease has been evaluated in a randomized, placebo-controlled Phase 2 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03455309?term=NCT03455309&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03455309?term=NCT03455309&amp;draw=2&amp;rank=1</ext-link>) and results are pending. A greater understanding of the pathophysiology of <italic toggle="yes">S. aureus</italic> disease and how a vaccine could neutralize the approaches that the bacteria uses to thwart the immune system is needed to develop a vaccine to prevent <italic toggle="yes">S. aureus</italic> infection.</p></sec></sec><sec id="Sec25"><title>Viral vaccines under development</title><sec id="Sec26"><title>Respiratory syncytial virus vaccines</title><p id="Par63">RSV is the leading cause of bronchiolitis and viral pneumonia in infants and can lead to fatal respiratory distress, especially in neonates and young infants with underlying cardio-pulmonary disease. In the U.S., RSV is the leading cause of infant hospitalization, with approximately 50,000 admissions of children 12&#160;months of age and younger occurring annually (American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee <xref ref-type="bibr" rid="CR7">2014</xref>). RSV also causes respiratory illness in older adults, with approximately 100,000 hospitalizations and 5,000 deaths annually in the U.S. among adults 65&#160;years of age and older (Falsey et al. <xref ref-type="bibr" rid="CR64">2005</xref>). Like influenza, RSV infection is associated with the development of bacterial superinfections (Hament et al. <xref ref-type="bibr" rid="CR86">1999</xref>; Rey-Jurado and Kalergis <xref ref-type="bibr" rid="CR201">2017</xref>), including otitis media and pneumonia, which require the use of antibiotics. Furthermore, as described for influenza earlier in this paper, antibiotics are often prescribed inappropriately for treatment of symptoms of a viral disease before the etiological agent has been determined, contributing to AMR.</p><p id="Par64">There is no RSV vaccine currently licensed. RSV vaccine development has been riddled with many failures, primarily due to an incomplete understanding of the structural and immunobiology of this important viral pathogen and technical difficulties in producing an effective vaccine. Currently, there are a variety of RSV vaccine candidates in clinical and pre-clinical development, including live attenuated, whole inactivated, particle based, subunit, nucleic acid, and recombinant vector based, incorporating different antigens (Jares Baglivo and Polack <xref ref-type="bibr" rid="CR107">2019</xref>; PATH <xref ref-type="bibr" rid="CR180">2019</xref>), with the most advanced summarized in Table <xref rid="Tab2" ref-type="table">2</xref>. These vaccines are contemplated for use in maternal immunization to protect infants through maternally transferred antibodies, and young children and elderly through direct vaccination.</p><p id="Par65">The trimeric RSV F surface glycoprotein, particularly its pre-fusion form (RSV pre-F), is the primary target of protective neutralizing antibodies and focus of recent vaccine development (McLellan et al. <xref ref-type="bibr" rid="CR151">2013</xref>; Mousa et al. <xref ref-type="bibr" rid="CR162">2017</xref>; Ngwuta et al. <xref ref-type="bibr" rid="CR169">2015</xref>). The stabilized RSV pre-F subunit vaccine candidate DS-Cav1, developed by the National Institute of Allergy and Infectious Diseases (Sastry et al. <xref ref-type="bibr" rid="CR208">2017</xref>), elicited serum neutralizing antibodies against both A and B subtypes of RSV, targeting pre-fusion epitopes of RSV F in a Phase 1 trial, representing clinical proof of concept for the structure-based RSV vaccine design approach (Crank et al. <xref ref-type="bibr" rid="CR46">2019</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03049488?term=NCT03049488&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03049488?term=NCT03049488&amp;draw=2&amp;rank=1</ext-link>). A stabilized RSV pre-F investigational subunit vaccine undergoing advanced clinical testing is also being developed by GlaxoSmithKline. Phase 2 studies in healthy, non-pregnant women 18&#8211;45&#160;years of age demonstrated boosting of pre-existing RSV immunity by a single dose of all formulations of the vaccine (GSK3003891A) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02360475?term=NCT02360475&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02360475?term=NCT02360475&amp;draw=2&amp;rank=1</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02753413?term=NCT02753413&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02753413?term=NCT02753413&amp;draw=2&amp;rank=1</ext-link>) (Beran et al. <xref ref-type="bibr" rid="CR20">2018</xref>). Pfizer is developing an engineered stabilized RSV pre-F subunit vaccine to protect infants and older adults by maternal or direct immunization, respectively (Table <xref rid="Tab2" ref-type="table">2</xref>). The excellent safety profile and strong immunogenicity of this vaccine candidate (Schmoele-Thoma et al. <xref ref-type="bibr" rid="CR210">2019</xref>) supported its further development. This vaccine has been assessed in several Phase 2 studies in healthy young and older men and non-pregnant women (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03529773">NCT03529773</ext-link>), older adults (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03572062">NCT03572062</ext-link>), young non-pregnant women (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04071158">NCT04071158</ext-link>), and pregnant women (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04032093">NCT04032093</ext-link>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>). Currently, Phase 3 evaluation of the vaccine efficacy and safety in infants born to women vaccinated during pregnancy is ongoing (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04424316">NCT04424316</ext-link>).</p></sec><sec id="Sec27"><title>Next generation influenza vaccines</title><p id="Par66">Next generation influenza vaccines aim to provide broad protection against influenza, eliminating the need for yearly vaccine production campaigns of evolving serotypes. Approaches towards universal influenza vaccine development have been recently extensively reviewed (Elbahesh et al. <xref ref-type="bibr" rid="CR59">2019</xref>; Epstein <xref ref-type="bibr" rid="CR61">2018</xref>; Estrada and Schultz-Cherry <xref ref-type="bibr" rid="CR63">2019</xref>). Several universal (broadly protective) influenza vaccines are currently being evaluated in clinical studies (Table <xref rid="Tab2" ref-type="table">2</xref>). Subunit M-001 vaccine (BiondVax Pharmaceuticals), comprised of several proteins conserved across influenza strains, has recently advanced to a Phase 3 study in adults 50&#160;years of age and older (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03450915?term=NCT03450915&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03450915?term=NCT03450915&amp;draw=2&amp;rank=1</ext-link>). Recombinant vector-based MVA-NP&#8201;+&#8201;M1 vaccine (Vaccitech) (Antrobus et al. <xref ref-type="bibr" rid="CR12">2014</xref>) was assessed in a Phase 2b study which was terminated (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03880474?term=NCT03880474&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03880474?term=NCT03880474&amp;draw=2&amp;rank=1</ext-link>). A lipid encapsulated mRNA platform has been used by Moderna to design vaccines encoding influenza HA proteins that have progressed to Phase 1 clinical evaluation (Bahl et al. <xref ref-type="bibr" rid="CR13">2017</xref>; Feldman et al. <xref ref-type="bibr" rid="CR67">2019</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03076385?term=NCT03076385&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03076385?term=NCT03076385&amp;draw=2&amp;rank=1</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03345043?term=NCT03345043&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03345043?term=NCT03345043&amp;draw=2&amp;rank=1</ext-link>).</p><p id="Par67">Following demonstration of the utility of the mRNA vaccine technology to stop the SARS-CoV-2 pandemic (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/media/releases/2021/p0607-mrna-reduce-risks.html">https://www.cdc.gov/media/releases/2021/p0607-mrna-reduce-risks.html</ext-link>), it is highly likely that this technology will be applied to influenza vaccines and may help to increase their efficacy and time to development.</p></sec><sec id="Sec28"><title>Human immunodeficiency virus vaccines</title><p id="Par68">HIV infection continues to be a major global public health issue. As reported by the WHO, more than 32 million people have died of HIV (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/en/news-room/fact-sheets/detail/hiv-aids">https://www.who.int/en/news-room/fact-sheets/detail/hiv-aids</ext-link>) since the epidemic was first recognized in 1981 (Centers for Disease Control <xref ref-type="bibr" rid="CR34">1981</xref>). In 2018, there were approximately 37.9 million people living with HIV worldwide and 770,000 people died of HIV related causes. The African continent is most affected, with 25.7 million people living with HIV in 2018. HIV infection predisposes patients to opportunistic bacterial co-infections that require frequent use of antibiotics, stimulating development of multidrug resistance. Worldwide, 862,000 HIV positive people fell ill with tuberculosis and 251,000 people died from HIV associated tuberculosis in 2018 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/tb/areas-of-work/tb-hiv/en/">https://www.who.int/tb/areas-of-work/tb-hiv/en/</ext-link>). Infections caused by both Gram positive (<italic toggle="yes">S. pneumoniae, Haemophilus</italic> species, <italic toggle="yes">P. aeruginosa</italic>, and <italic toggle="yes">S. aureus</italic>) (Burack et al. <xref ref-type="bibr" rid="CR27">1994</xref>; Hirschtick et al. <xref ref-type="bibr" rid="CR97">1995</xref>; HIV.gov <xref ref-type="bibr" rid="CR98">2020</xref>; Polsky et al. <xref ref-type="bibr" rid="CR191">1986</xref>) and Gram negative (<italic toggle="yes">Salmonella</italic>, <italic toggle="yes">Shigella</italic>, and <italic toggle="yes">Campylobacter</italic>), have much greater incidence in HIV infected compared with the uninfected population (Angulo and Swerdlow <xref ref-type="bibr" rid="CR10">1995</xref>; Haines et al. <xref ref-type="bibr" rid="CR85">2013</xref>; Huang et al. <xref ref-type="bibr" rid="CR101">2006</xref>; Nelson et al. <xref ref-type="bibr" rid="CR166">1992</xref>; Sanchez et al. <xref ref-type="bibr" rid="CR207">2005</xref>). Multiple studies have reported the isolation of antibiotic-resistant bacterial strains from HIV patients, including methicillin-resistant <italic toggle="yes">S. aureus</italic> (Hidron et al. <xref ref-type="bibr" rid="CR94">2010</xref>), multidrug-resistant <italic toggle="yes">M. tuberculosis</italic> (Campos et al. <xref ref-type="bibr" rid="CR30">2003</xref>), multidrug-resistant <italic toggle="yes">E. coli</italic> (Vignesh et al. <xref ref-type="bibr" rid="CR239">2008</xref>), and expanded spectrum cephalosporin-resistant non-typhoidal <italic toggle="yes">Salmonella</italic> (Miriagou et al. <xref ref-type="bibr" rid="CR156">2004</xref>).</p><p id="Par69">While antiretroviral therapy controls the virus and reduces transmission, it does not, however, eradicate the infection and is associated with substantial cost (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/en/news-room/fact-sheets/detail/hiv-aids">https://www.who.int/en/news-room/fact-sheets/detail/hiv-aids</ext-link>). An effective universal prophylactic HIV vaccine would be a more sustainable approach to prevent HIV, as it would not only prevent this viral infection from occurring in the vaccinated individual but could also potentially reduce the incidence of bacterial infections and, consequently, attendant antibiotic use and spread of antibiotic-resistant strains. Developing such a vaccine is challenging, however, due to the extreme virus diversity, incomplete understanding of mechanisms of immunity, and the challenges in designing immunogens to induce broadly neutralizing antibodies (Hsu and O&#8217;Connell <xref ref-type="bibr" rid="CR100">2017</xref>). There are numerous investigational vaccines against HIV in pre-clinical and early clinical development, among which a few have progressed to clinical efficacy trials (Hsu and O&#8217;Connell <xref ref-type="bibr" rid="CR100">2017</xref>). So far, the only vaccine candidate to have demonstrated at least partial efficacy&#8212;60% one year after vaccination and 31.2% during the 3.5&#160;years after vaccination&#8212;for preventing HIV infection is RV144, a recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]), administered in a heterologous prime-boost regimen with four priming injections followed by two booster injections of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E) in a Phase 3 trial in Thailand (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00223080?term=NCT00223080&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT00223080?term=NCT00223080&amp;draw=2&amp;rank=1</ext-link>) (Rerks-Ngarm et al. <xref ref-type="bibr" rid="CR199">2009</xref>). RV144 is currently undergoing pivotal Phase 2b/3 efficacy clinical evaluation in HIV-seronegative South African adults (National Institute of Allergy and Infectious Diseases (NIAID) <xref ref-type="bibr" rid="CR164">2016</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02968849?term=HVTN+702&amp;cond=HIV&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02968849?term=HVTN+702&amp;cond=HIV&amp;rank=1</ext-link>).</p></sec></sec></sec><sec id="Sec29"><title>Global mobilization utilizing vaccines against antimicrobial resistance</title><p id="Par70">The utility of vaccines as a tool to combat AMR has been broadly recognized (Centers for Disease Control and Prevention <xref ref-type="bibr" rid="CR37">2015</xref>; O&#8217;Neill <xref ref-type="bibr" rid="CR172">2016a</xref>; World Health Organization <xref ref-type="bibr" rid="CR252">2015</xref>). Improving the use of vaccines as an anti AMR tool requires global mobilization of diverse resources from stakeholders across the public health spectrum, including governments, regulatory bodies, academia, the biopharmaceutical industry, healthcare professionals, policymakers, and funding bodies. The Davos Declaration on Antibiotic Resistance, signed by over 80 international companies, called for collective action to create a sustainable market for antibiotics, vaccines, and diagnostics and encourage appropriate use of new and existing treatments (Review on Antimicrobial Resistance <xref ref-type="bibr" rid="CR200">2016</xref>). To date, incremental but measurable progress has been attained towards fulfilling the objectives of the WHO Global Action Plan on AMR (World Health Organization <xref ref-type="bibr" rid="CR252">2015</xref>; The Lancet <xref ref-type="bibr" rid="CR127">2017</xref>). In the U.S., the White House Executive Order identified antibiotic-resistant bacteria as a national security priority (The White House <xref ref-type="bibr" rid="CR221">2014</xref>), and the U.S. National Strategy for Combating Antibiotic Resistant Bacteria named research towards new vaccines and AMR research and development, prevention, surveillance, and control among its key strategic goals (The White House <xref ref-type="bibr" rid="CR222">2015</xref>). Recommendations pertaining to vaccine innovation and uptake relative to AMR were also made by the UK Review on Antimicrobial Resistance (O&#8217;Neill <xref ref-type="bibr" rid="CR173">2016b</xref>), the Chatham House meeting (London, UK) (Chatham House <xref ref-type="bibr" rid="CR41">2017</xref>; Clift and Salisbury <xref ref-type="bibr" rid="CR43">2017</xref>), and the Boston Consulting Group solicited by the UK Wellcome Trust (Boston Consulting Group <xref ref-type="bibr" rid="CR24">2019</xref>). The impact of vaccination on AMR is now also included in the Global Alliance for Vaccines and Immunization&#8217;s (GAVI&#8217;s) evaluation criteria for their vaccine investment strategy (Mok <xref ref-type="bibr" rid="CR159">2018</xref>) and is an important component of their 5&#160;year strategic plan where the alliance committed to continue to scale up vaccines for diseases prone to AMR while incentivizing research in other vaccines that can contribute to fight AMR (GAVI. The Vaccine Alliance <xref ref-type="bibr" rid="CR74">2017</xref>).</p><p id="Par71">Public&#8211;private partnerships and consortia that have been formed to coordinate efforts to address the threat of AMR using various strategies, including vaccines, include global non-profit partnership Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), led by Boston University and funded by the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (part of the Office of the Assistant Secretary for Preparedness and Response), the Bill &amp; Melinda Gates Foundation, the National Institute of Allergy and Infectious Diseases, the UK Wellcome Trust, the UK Government&#8217;s Global Antimicrobial Resistance Innovation Fund, and Germany&#8217;s Federal Ministry of Education and Research. The CARB-X portfolio includes projects dedicated to important bacterial pathogens, including multivalent <italic toggle="yes">S. aureus</italic> toxoid vaccine (Integrated BioTherapeutics), <italic toggle="yes">Klebsiella</italic> vaccine (Vaxxilon), and Group A streptococcus vaccine (Vaxcyte) (CARB-X <xref ref-type="bibr" rid="CR31">2017</xref>&#8211;2018) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://carb-x.org/">https://carb-x.org/</ext-link>).</p></sec><sec id="Sec30"><title>Challenges and future prospects</title><sec id="Sec31"><title>Barriers to maximizing licensed vaccine use</title><p id="Par72">The barriers to maximizing licensed vaccine use in pediatric as well as adult populations are diverse. The healthcare and regulatory barriers may include variability in national immunization laws and regulations, insufficient vaccine supply, lack of knowledge for vaccine indications and contraindications, inadequate national prioritization and budget allocation for vaccination, and a lack of population based systems to collect and consolidate individual vaccination data (Anonymous <xref ref-type="bibr" rid="CR11">2018</xref>; Esposito et al. <xref ref-type="bibr" rid="CR62">2014</xref>; Ventola <xref ref-type="bibr" rid="CR235">2016a</xref>,<xref ref-type="bibr" rid="CR236"> 2016b</xref>). Furthermore, vaccine hesitancy&#8212;defined by reluctance to vaccinate despite the availability of vaccines and seen increasingly in the delay or refusal of parents to vaccinate their children&#8212;is recognized by the WHO as one of the top 10 threats to global health in 2019 (along with AMR) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/emergencies/ten-threats-to-global-health-in-2019">https://www.who.int/emergencies/ten-threats-to-global-health-in-2019</ext-link>). Vaccine hesitancy has already caused a resurgence of several vaccine preventable infectious diseases, including the recent well documented outbreaks of measles in New York (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/measles/cases-outbreaks.html">https://www.cdc.gov/measles/cases-outbreaks.html</ext-link>) and polio in the Philippines (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/csr/don/24-september-2019-polio-outbreak-the-philippines/en/">https://www.who.int/csr/don/24-september-2019-polio-outbreak-the-philippines/en/</ext-link>). Reasons for vaccine hesitancy are complex and include concerns about vaccine safety as well as moral or religious beliefs. Disproven and erroneous associations of the measles-mumps-rubella and hepatitis B pediatric vaccines with the development of autism or chronic fatigue syndrome and multiple sclerosis, respectively (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/vaccinesafety/concerns/autism.html">https://www.cdc.gov/vaccinesafety/concerns/autism.html</ext-link>) (DeStefano et al. <xref ref-type="bibr" rid="CR53">2002</xref>; Glanz et al. <xref ref-type="bibr" rid="CR83">2018</xref>; Klein and Diehl <xref ref-type="bibr" rid="CR115">2004</xref>; Smith and Woods <xref ref-type="bibr" rid="CR216">2010</xref>; Taylor et al. <xref ref-type="bibr" rid="CR220">2014</xref>), are well-known examples of dangerous misinformation that has negatively affected the perception of vaccines and put lives at risk. Another grave common vaccine misconception is that the seasonal influenza vaccine shot can cause influenza illness (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/prevent/misconceptions.htm">https://www.cdc.gov/flu/prevent/misconceptions.htm</ext-link>). The unacceptably low influenza vaccination rate among young healthy people between 18 and 49&#160;years of age (as low as 26% in 2017&#8211;2018) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/fluvaxview/coverage-1718estimates.htm">https://www.cdc.gov/flu/fluvaxview/coverage-1718estimates.htm</ext-link>) impacts herd immunity and bears deadly consequences for the elderly who respond sub-optimally to influenza vaccines and are at highest risk for flu related deaths that occur annually in the tens of thousands in this cohort (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/about/burden/2017-2018.htm">https://www.cdc.gov/flu/about/burden/2017-2018.htm</ext-link>). Additionally, negative public perception of vaccines can lead to consequent vaccine hesitancy, as in the case of Dengvaxia and polio vaccination in the Philippines (Thornton <xref ref-type="bibr" rid="CR223">2019</xref>). Combating the rise in dangerous misinformation through social media and other channels has also opened up as another front on the war against infectious disease (Betsch et al. <xref ref-type="bibr" rid="CR21">2012</xref>; Tomeny et al. <xref ref-type="bibr" rid="CR225">2017</xref>).</p></sec><sec id="Sec32"><title>Efforts towards better utilization of vaccines to optimize their impact on antimicrobial resistance and future prospects</title><p id="Par73">Much remains to be done to increase global access to already licensed vaccines. Global vaccine coverage could be improved by simultaneous licensure in developed and developing countries, faster rollout, improving vaccines delivering logistics, increasing funding, and lowering population reticence to vaccination. Adult vaccination should also be adopted as a healthcare priority at the national level. Changes in regulatory laws and policies are also required, with formal consideration given to vaccination benefits in AMR reduction. National advisory committees on immunization would need to develop the Guidance for Industry that supports including AMR data in label updates and incorporating AMR reduction benefits in health technology assessment and economic modeling. Coverage with licensed vaccines can be also improved through continuing medical education programs communicating the benefits of vaccination for AMR reduction (Jansen et al. <xref ref-type="bibr" rid="CR105">2018a</xref>; Esposito et al. <xref ref-type="bibr" rid="CR62">2014</xref>; Laurent-Ledru et al. <xref ref-type="bibr" rid="CR129">2011</xref>).</p><p id="Par74">New vaccine candidates addressing important bacterial and viral pathogens for which vaccines currently do not exist are under development, as well as vaccines against parasitic infections such as malaria which often predispose children in endemic areas to invasive bacterial coinfections requiring antibiotic treatment (Were et al. <xref ref-type="bibr" rid="CR248">2011</xref>). Incentives that could be provided to enable industry to develop new vaccines that are of public interest but may not be commercially viable would include priority review vouchers, transferable regulatory data and marketing exclusivity, and research and development tax credits. In parallel, sustained investments in developing the human talent pool would provide an experienced workforce to innovate across vaccine research and development (Cawein et al. <xref ref-type="bibr" rid="CR33">2017</xref>).</p><p id="Par75">While much has been accomplished with respect to the development of vaccines and immunization strategies, for many important human pathogens there is no available vaccine or current vaccines are suboptimal. Vaccination strategies and AMR considerations are intertwined in importance and, taken together, will drive development decisions and priorities in the decades to come.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AMR</term><def><p id="Par2">Antimicrobial resistance</p></def></def-item><def-item><term>BCG</term><def><p id="Par3">Bacillus Calmette Gu&#233;rin</p></def></def-item><def-item><term>CARB-X</term><def><p id="Par4">Combating antibiotic-resistant bacteria biopharmaceutical accelerator</p></def></def-item><def-item><term>CDC</term><def><p id="Par5">Centers for disease control and prevention</p></def></def-item><def-item><term>CRM<sub>197</sub></term><def><p id="Par6">Cross-reactive material 197</p></def></def-item><def-item><term>EU</term><def><p id="Par7">European Union</p></def></def-item><def-item><term>GAVI</term><def><p id="Par8">Global alliance for vaccines and immunization</p></def></def-item><def-item><term>GBS</term><def><p id="Par9">Group B streptococcus</p></def></def-item><def-item><term>Hib</term><def><p id="Par10"><italic toggle="yes">Haemophilus influenzae</italic> Type b</p></def></def-item><def-item><term>HIV</term><def><p id="Par11">Human immunodeficiency virus</p></def></def-item><def-item><term>IgA</term><def><p id="Par12">Immunoglobulin A</p></def></def-item><def-item><term>IgG</term><def><p id="Par13">Immunoglobulin G</p></def></def-item><def-item><term>NDM-1</term><def><p id="Par14">New Delhi metallo-&#946;-lactamase 1</p></def></def-item><def-item><term>PCV</term><def><p id="Par15">Polysaccharide conjugate vaccine</p></def></def-item><def-item><term>RSV</term><def><p id="Par16">Respiratory syncytial virus</p></def></def-item><def-item><term>UK</term><def><p id="Par17">United Kingdom</p></def></def-item><def-item><term>U.S.</term><def><p id="Par18">United States</p></def></def-item><def-item><term>WHO</term><def><p id="Par19">World health organization</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank the following Pfizer colleagues: Natasha Kushnir, PhD for scientific writing, Robert Donald, PhD and Kirstin Heinrich, MPH for critical review of the manuscript, and Dawn DeThomas for graphics preparation.</p></ack><notes notes-type="funding-information"><title>Funding</title><p>All authors were employees of Pfizer at time of writing. The article preparation was funded by Pfizer.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adam</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>SE</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>FB</given-names></name><name name-style="western"><surname>Rawte</surname><given-names>P</given-names></name><name name-style="western"><surname>Low</surname><given-names>DE</given-names></name><name name-style="western"><surname>Fisman</surname><given-names>DN</given-names></name></person-group><article-title>Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><issue>24</issue><fpage>4073</fpage><lpage>4078</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.03.075</pub-id><pub-id pub-id-type="pmid">20398617</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adler</surname><given-names>A</given-names></name><name name-style="western"><surname>Miller-Roll</surname><given-names>T</given-names></name><name name-style="western"><surname>Bradenstein</surname><given-names>R</given-names></name><name name-style="western"><surname>Block</surname><given-names>C</given-names></name><name name-style="western"><surname>Mendelson</surname><given-names>B</given-names></name><name name-style="western"><surname>Parizade</surname><given-names>M</given-names></name><name name-style="western"><surname>Paitan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>D</given-names></name><name name-style="western"><surname>Peled</surname><given-names>N</given-names></name><name name-style="western"><surname>Carmeli</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schwaber</surname><given-names>MJ</given-names></name></person-group><article-title>A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole</article-title><source>Diagn Microbiol Infect Dis</source><year>2015</year><volume>83</volume><issue>1</issue><fpage>21</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2015.05.015</pub-id><pub-id pub-id-type="pmid">26116225</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguilo</surname><given-names>N</given-names></name><name name-style="western"><surname>Gonzalo-Asensio</surname><given-names>J</given-names></name><name name-style="western"><surname>Alvarez-Arguedas</surname><given-names>S</given-names></name><name name-style="western"><surname>Marinova</surname><given-names>D</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>AB</given-names></name><name name-style="western"><surname>Uranga</surname><given-names>S</given-names></name><name name-style="western"><surname>Spallek</surname><given-names>R</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M</given-names></name><name name-style="western"><surname>Audran</surname><given-names>R</given-names></name><name name-style="western"><surname>Spertini</surname><given-names>F</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name></person-group><article-title>Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>16085</fpage><pub-id pub-id-type="doi">10.1038/ncomms16085</pub-id><pub-id pub-id-type="pmid">28706226</pub-id><pub-id pub-id-type="pmcid">PMC5519979</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alderson</surname><given-names>MR</given-names></name></person-group><article-title>Status of research and development of pediatric vaccines for Streptococcus pneumoniae</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><issue>26</issue><fpage>2959</fpage><lpage>2961</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.03.107</pub-id><pub-id pub-id-type="pmid">27083428</pub-id><pub-id pub-id-type="pmcid">PMC4906266</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>A</given-names></name><name name-style="western"><surname>An</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Cui</surname><given-names>C</given-names></name><name name-style="western"><surname>Haque</surname><given-names>A</given-names></name><name name-style="western"><surname>Carbis</surname><given-names>R</given-names></name></person-group><article-title>Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid</article-title><source>Human Vaccine Immunother</source><year>2014</year><volume>10</volume><issue>6</issue><fpage>1494</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.4161/hv.28130</pub-id><pub-id pub-id-type="pmcid">PMC5396222</pub-id><pub-id pub-id-type="pmid">24603090</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>CR</given-names></name></person-group><article-title>Design and selection of vaccine adjuvants: animal models and human trials</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><issue>Suppl 3</issue><fpage>S56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(02)00174-3</pub-id><pub-id pub-id-type="pmid">12184368</pub-id></element-citation></ref><ref id="CR7"><mixed-citation publication-type="other">American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134(2): 415&#8211;420 10.1542/peds.2014-1665<pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2014-1665</pub-id><pub-id pub-id-type="pmid">25070315</pub-id></mixed-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>P</given-names></name><name name-style="western"><surname>Scriba</surname><given-names>TJ</given-names></name></person-group><article-title>Moving tuberculosis vaccines from theory to practice</article-title><source>Nat Rev Immunol</source><year>2019</year><volume>19</volume><issue>9</issue><fpage>550</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0174-z</pub-id><pub-id pub-id-type="pmid">31114037</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>JR</given-names></name><name name-style="western"><surname>Qamar</surname><given-names>FN</given-names></name><name name-style="western"><surname>Charles</surname><given-names>RC</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>ET</given-names></name></person-group><article-title>Extensively drug-resistant typhoid&#8212;are conjugate vaccines arriving just in time?</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><issue>16</issue><fpage>1493</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1803926</pub-id><pub-id pub-id-type="pmid">30332569</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angulo</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Swerdlow</surname><given-names>DL</given-names></name></person-group><article-title>Bacterial enteric infections in persons infected with human immunodeficiency virus</article-title><source>Clin Infect Dis</source><year>1995</year><volume>21</volume><issue>Suppl 1</issue><fpage>S84</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1093/clinids/21.supplement_1.s84</pub-id><pub-id pub-id-type="pmid">8547518</pub-id></element-citation></ref><ref id="CR11"><mixed-citation publication-type="other">Anonymous (2018) Addressing barriers to optimal community-based vaccination. AJMC Perspect 9&#8211;12</mixed-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antrobus</surname><given-names>RD</given-names></name><name name-style="western"><surname>Berthoud</surname><given-names>TK</given-names></name><name name-style="western"><surname>Mullarkey</surname><given-names>CE</given-names></name><name name-style="western"><surname>Hoschler</surname><given-names>K</given-names></name><name name-style="western"><surname>Coughlan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zambon</surname><given-names>M</given-names></name><name name-style="western"><surname>Hill</surname><given-names>AV</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>SC</given-names></name></person-group><article-title>Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses</article-title><source>Mol Ther</source><year>2014</year><volume>22</volume><issue>1</issue><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1038/mt.2013.162</pub-id><pub-id pub-id-type="pmid">23831594</pub-id><pub-id pub-id-type="pmcid">PMC3978791</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahl</surname><given-names>K</given-names></name><name name-style="western"><surname>Senn</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Yuzhakov</surname><given-names>O</given-names></name><name name-style="western"><surname>Bulychev</surname><given-names>A</given-names></name><name name-style="western"><surname>Brito</surname><given-names>LA</given-names></name><name name-style="western"><surname>Hassett</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Laska</surname><given-names>ME</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M</given-names></name><name name-style="western"><surname>Almarsson</surname><given-names>O</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>AM</given-names></name><name name-style="western"><surname>Watson</surname><given-names>M</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T</given-names></name><name name-style="western"><surname>Ciaramella</surname><given-names>G</given-names></name></person-group><article-title>Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses</article-title><source>Mol Ther</source><year>2017</year><volume>25</volume><issue>6</issue><fpage>1316</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.03.035</pub-id><pub-id pub-id-type="pmid">28457665</pub-id><pub-id pub-id-type="pmcid">PMC5475249</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Rench</surname><given-names>MA</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>M</given-names></name><name name-style="western"><surname>Paoletti</surname><given-names>LC</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>DL</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>MS</given-names></name></person-group><article-title>Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III</article-title><source>J Infect Dis</source><year>2003</year><volume>188</volume><issue>1</issue><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1086/375536</pub-id><pub-id pub-id-type="pmid">12825173</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baliban</surname><given-names>SM</given-names></name><name name-style="western"><surname>Allen</surname><given-names>JC</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>B</given-names></name><name name-style="western"><surname>Amin</surname><given-names>MN</given-names></name><name name-style="western"><surname>Lees</surname><given-names>A</given-names></name><name name-style="western"><surname>Rao</surname><given-names>RN</given-names></name><name name-style="western"><surname>Naidu</surname><given-names>G</given-names></name><name name-style="western"><surname>Venkatesan</surname><given-names>R</given-names></name><name name-style="western"><surname>Rao</surname><given-names>DY</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>VK</given-names></name><name name-style="western"><surname>Ella</surname><given-names>KM</given-names></name><name name-style="western"><surname>Levine</surname><given-names>MM</given-names></name><name name-style="western"><surname>Simon</surname><given-names>R</given-names></name></person-group><article-title>Immunogenicity and induction of functional antibodies in rabbits immunized with a trivalent typhoid-invasive nontyphoidal salmonella glycoconjugate formulation</article-title><source>Molecules</source><year>2018</year><pub-id pub-id-type="doi">10.3390/molecules23071749</pub-id><pub-id pub-id-type="pmcid">PMC6099966</pub-id><pub-id pub-id-type="pmid">30018230</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balsells</surname><given-names>E</given-names></name><name name-style="western"><surname>Guillot</surname><given-names>L</given-names></name><name name-style="western"><surname>Nair</surname><given-names>H</given-names></name><name name-style="western"><surname>Kyaw</surname><given-names>MH</given-names></name></person-group><article-title>Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis</article-title><source>PLoS ONE</source><year>2017</year><pub-id pub-id-type="doi">10.1371/journal.pone.0177113</pub-id><pub-id pub-id-type="pmcid">PMC5423631</pub-id><pub-id pub-id-type="pmid">28486544</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barel</surname><given-names>LA</given-names></name><name name-style="western"><surname>Mulard</surname><given-names>LA</given-names></name></person-group><article-title>Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human</article-title><source>Human Vaccine Immunother</source><year>2019</year><volume>15</volume><issue>6</issue><fpage>1338</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1080/21645515.2019.1606972</pub-id><pub-id pub-id-type="pmcid">PMC6663142</pub-id><pub-id pub-id-type="pmid">31158047</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartlett</surname><given-names>JG</given-names></name><name name-style="western"><surname>Gerding</surname><given-names>DN</given-names></name></person-group><article-title>Clinical recognition and diagnosis of Clostridium difficile infection</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><issue>Suppl 1</issue><fpage>S12</fpage><lpage>S18</lpage><pub-id pub-id-type="doi">10.1086/521863</pub-id><pub-id pub-id-type="pmid">18177217</pub-id></element-citation></ref><ref id="CR19"><mixed-citation publication-type="other">Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ, Group ES (2011) Clostridium difficile infection in Europe: a hospital-based survey Lancet 377(9759): 63&#8211;73 10.1016/S0140-6736(10)61266-4<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(10)61266-4</pub-id><pub-id pub-id-type="pmid">21084111</pub-id></mixed-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beran</surname><given-names>J</given-names></name><name name-style="western"><surname>Lickliter</surname><given-names>JD</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>TF</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C</given-names></name><name name-style="western"><surname>Chu</surname><given-names>L</given-names></name><name name-style="western"><surname>Domachowske</surname><given-names>JB</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>P</given-names></name><name name-style="western"><surname>Withanage</surname><given-names>K</given-names></name><name name-style="western"><surname>Fissette</surname><given-names>LA</given-names></name><name name-style="western"><surname>David</surname><given-names>MP</given-names></name><name name-style="western"><surname>Maleux</surname><given-names>K</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>AC</given-names></name><name name-style="western"><surname>Picciolato</surname><given-names>M</given-names></name><name name-style="western"><surname>Dieussaert</surname><given-names>I</given-names></name></person-group><article-title>Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: results from 2 phase 2 trials</article-title><source>J Infect Dis</source><year>2018</year><volume>217</volume><issue>10</issue><fpage>1616</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy065</pub-id><pub-id pub-id-type="pmid">29401325</pub-id><pub-id pub-id-type="pmcid">PMC5913599</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Betsch</surname><given-names>C</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>NT</given-names></name><name name-style="western"><surname>Brocard</surname><given-names>P</given-names></name><name name-style="western"><surname>Davies</surname><given-names>P</given-names></name><name name-style="western"><surname>Gaissmaier</surname><given-names>W</given-names></name><name name-style="western"><surname>Haase</surname><given-names>N</given-names></name><name name-style="western"><surname>Leask</surname><given-names>J</given-names></name><name name-style="western"><surname>Renkewitz</surname><given-names>F</given-names></name><name name-style="western"><surname>Renner</surname><given-names>B</given-names></name><name name-style="western"><surname>Reyna</surname><given-names>VF</given-names></name><name name-style="western"><surname>Rossmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Sachse</surname><given-names>K</given-names></name><name name-style="western"><surname>Schachinger</surname><given-names>A</given-names></name><name name-style="western"><surname>Siegrist</surname><given-names>M</given-names></name><name name-style="western"><surname>Stryk</surname><given-names>M</given-names></name></person-group><article-title>Opportunities and challenges of Web 2.0 for vaccination decisions</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><issue>25</issue><fpage>3727</fpage><lpage>3733</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.02.025</pub-id><pub-id pub-id-type="pmid">22365840</pub-id></element-citation></ref><ref id="CR22"><mixed-citation publication-type="other">Bhatti MW (2019) Pakistan approaches Indian firm to buy vaccine against XDR typhoid. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.thenews.com.pk/print/431240-pakistan-approaches-indian-firm-to-buy-vaccine-against-xdr-typhoid">https://www.thenews.com.pk/print/431240-pakistan-approaches-indian-firm-to-buy-vaccine-against-xdr-typhoid</ext-link>. Accessed 29 Sept 2019</mixed-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Block</surname><given-names>SL</given-names></name><name name-style="western"><surname>Heikkinen</surname><given-names>T</given-names></name><name name-style="western"><surname>Toback</surname><given-names>SL</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>CS</given-names></name></person-group><article-title>The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children</article-title><source>Pediatr Infect Dis J</source><year>2011</year><volume>30</volume><issue>3</issue><fpage>203</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1097/INF.0b013e3181faac7c</pub-id><pub-id pub-id-type="pmid">20935591</pub-id></element-citation></ref><ref id="CR24"><mixed-citation publication-type="other">Boston Consulting Group (2019) Vaccines to tackle drug resistant infections. An evaluation of R&amp;D opportunities. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://vaccinesforamr.org/wp-content/uploads/2018/09/Vaccines_for_AMR.pdf">https://vaccinesforamr.org/wp-content/uploads/2018/09/Vaccines_for_AMR.pdf</ext-link>. Accessed 8 Aug 2019</mixed-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braye</surname><given-names>K</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>J</given-names></name><name name-style="western"><surname>Davis</surname><given-names>D</given-names></name><name name-style="western"><surname>Catling</surname><given-names>C</given-names></name><name name-style="western"><surname>Monk</surname><given-names>A</given-names></name><name name-style="western"><surname>Foureur</surname><given-names>M</given-names></name></person-group><article-title>Effectiveness of intrapartum antibiotic prophylaxis for early-onset group B Streptococcal infection: an integrative review</article-title><source>Women Birth</source><year>2018</year><volume>31</volume><issue>4</issue><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.wombi.2017.10.012</pub-id><pub-id pub-id-type="pmid">29129472</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breiman</surname><given-names>RF</given-names></name><name name-style="western"><surname>Butler</surname><given-names>JC</given-names></name><name name-style="western"><surname>Tenover</surname><given-names>FC</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>JA</given-names></name><name name-style="western"><surname>Facklam</surname><given-names>RR</given-names></name></person-group><article-title>Emergence of drug-resistant pneumococcal infections in the United States</article-title><source>JAMA</source><year>1994</year><volume>271</volume><issue>23</issue><fpage>1831</fpage><lpage>1835</lpage><pub-id pub-id-type="doi">10.1001/jama.1994.03510470035031</pub-id><pub-id pub-id-type="pmid">8196139</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burack</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>JA</given-names></name><name name-style="western"><surname>Saint-Maurice</surname><given-names>D</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>MA</given-names></name></person-group><article-title>Microbiology of community-acquired bacterial pneumonia in persons with and at risk for human immunodeficiency virus type 1 infection Implications for rational empiric antibiotic therapy</article-title><source>Arch Intern Med</source><year>1994</year><volume>154</volume><issue>22</issue><fpage>2589</fpage><lpage>2596</lpage><pub-id pub-id-type="doi">10.1001/archinte.1994.00420220085010</pub-id><pub-id pub-id-type="pmid">7979856</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butler</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Cetron</surname><given-names>MS</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>JA</given-names></name><name name-style="western"><surname>Facklam</surname><given-names>RR</given-names></name><name name-style="western"><surname>Breiman</surname><given-names>RF</given-names></name></person-group><article-title>The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention&#8217;s Pneumococcal Sentinel Surveillance System</article-title><source>J Infect Dis</source><year>1996</year><volume>174</volume><issue>5</issue><fpage>986</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1093/infdis/174.5.986</pub-id><pub-id pub-id-type="pmid">8896499</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buurman</surname><given-names>ET</given-names></name><name name-style="western"><surname>Timofeyeva</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kodali</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mininni</surname><given-names>T</given-names></name><name name-style="western"><surname>Moghazeh</surname><given-names>S</given-names></name><name name-style="western"><surname>Pavliakova</surname><given-names>D</given-names></name><name name-style="western"><surname>Singer</surname><given-names>C</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Handke</surname><given-names>LD</given-names></name><name name-style="western"><surname>Lotvin</surname><given-names>J</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>AK</given-names></name><name name-style="western"><surname>Scully</surname><given-names>IL</given-names></name><name name-style="western"><surname>Donald</surname><given-names>RGK</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>KU</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>AS</given-names></name></person-group><article-title>A novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the prevention of neonatal roup B streptococcal infections by maternal immunization</article-title><source>J Infect Dis</source><year>2019</year><volume>220</volume><issue>1</issue><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz062</pub-id><pub-id pub-id-type="pmid">30778554</pub-id><pub-id pub-id-type="pmcid">PMC6548902</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>PE</given-names></name><name name-style="western"><surname>Suarez</surname><given-names>PG</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>J</given-names></name><name name-style="western"><surname>Zavala</surname><given-names>D</given-names></name><name name-style="western"><surname>Arevalo</surname><given-names>J</given-names></name><name name-style="western"><surname>Ticona</surname><given-names>E</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Hooton</surname><given-names>TM</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>KK</given-names></name></person-group><article-title>Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons</article-title><source>Peru Emerg Infect Dis</source><year>2003</year><volume>9</volume><issue>12</issue><fpage>1571</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.3201/eid0912.020731</pub-id><pub-id pub-id-type="pmid">14720398</pub-id><pub-id pub-id-type="pmcid">PMC3034326</pub-id></element-citation></ref><ref id="CR31"><mixed-citation publication-type="other">CARB-X (2017&#8211;2018) Progress against superbugs. Annual report 2017&#8211;2018. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://carb-x.org/wp-content/uploads/2018/09/CARB-X_AR-2017-18.pdf">https://carb-x.org/wp-content/uploads/2018/09/CARB-X_AR-2017-18.pdf</ext-link>. Accessed 23 Sept 2019</mixed-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmona Martinez</surname><given-names>A</given-names></name><name name-style="western"><surname>Prymula</surname><given-names>R</given-names></name><name name-style="western"><surname>Miranda Valdivieso</surname><given-names>M</given-names></name><name name-style="western"><surname>Otero Reigada</surname><given-names>MDC</given-names></name><name name-style="western"><surname>Merino Arribas</surname><given-names>JM</given-names></name><name name-style="western"><surname>Brzostek</surname><given-names>J</given-names></name><name name-style="western"><surname>Szenborn</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruzkova</surname><given-names>R</given-names></name><name name-style="western"><surname>Horn</surname><given-names>MR</given-names></name><name name-style="western"><surname>Jackowska</surname><given-names>T</given-names></name><name name-style="western"><surname>Centeno-Malfaz</surname><given-names>F</given-names></name><name name-style="western"><surname>Traskine</surname><given-names>M</given-names></name><name name-style="western"><surname>Dobbelaere</surname><given-names>K</given-names></name><name name-style="western"><surname>Borys</surname><given-names>D</given-names></name></person-group><article-title>Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: results from a phase II, randomised, multicentre study</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><issue>1</issue><fpage>176</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.07.023</pub-id><pub-id pub-id-type="pmid">30054160</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cawein</surname><given-names>A</given-names></name><name name-style="western"><surname>Emini</surname><given-names>E</given-names></name><name name-style="western"><surname>Watson</surname><given-names>M</given-names></name><name name-style="western"><surname>Dailey</surname><given-names>J</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>J</given-names></name><name name-style="western"><surname>Tresnan</surname><given-names>D</given-names></name><name name-style="western"><surname>Evans</surname><given-names>T</given-names></name><name name-style="western"><surname>Plotkin</surname><given-names>S</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>W</given-names></name></person-group><article-title>Human capital gaps in vaccine development: an issue for global vaccine development and global health</article-title><source>Ann N Y Acad Sci</source><year>2017</year><volume>1395</volume><issue>1</issue><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/nyas.13316</pub-id><pub-id pub-id-type="pmid">28229472</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control</collab></person-group><article-title>Pneumocystis pneumonia&#8211;Los Angeles</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>1981</year><volume>30</volume><issue>21</issue><fpage>250</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">6265753</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group><article-title>Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children&#8211;United States, 1998&#8211;2000</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2002</year><volume>51</volume><issue>11</issue><fpage>234</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">11925021</pub-id></element-citation></ref><ref id="CR36"><mixed-citation publication-type="other">Centers for Disease Control and Prevention (2013a) Antibiotic resistance threats in the United States, 2013. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf">https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf</ext-link>. Accessed 11 Jun 2019</mixed-citation></ref><ref id="CR37"><mixed-citation publication-type="other">Centers for Disease Control and Prevention (2015) National action plan for combating antibiotic-resistant bacteria. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf">https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf</ext-link>. Accessed 15 Jun 2019</mixed-citation></ref><ref id="CR38"><mixed-citation publication-type="other">Centers for Disease Control and Prevention (2016) ABCs report: haemophilus influenzae, 2014. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/abcs/reports-findings/survreports/hib14.html">https://www.cdc.gov/abcs/reports-findings/survreports/hib14.html</ext-link>. Accessed 3 Aug 2019</mixed-citation></ref><ref id="CR39"><mixed-citation publication-type="other">Centers for Disease Control and Prevention (2017) Health, United States, 2017. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/data/hus/hus17.pdf">https://www.cdc.gov/nchs/data/hus/hus17.pdf</ext-link>. Accessed 17 Sept 2019</mixed-citation></ref><ref id="CR40"><mixed-citation publication-type="other">Centers for Disease Control and Prevention (2019) Antibiotic resistance threats in the United States, 2019, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf">https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf</ext-link>. Accessed 15 Nov 2019</mixed-citation></ref><ref id="CR41"><mixed-citation publication-type="other">Chatham House (2017) The value of vaccines in the avoidance of antimicrobial resistance. Centre on global health security, The Royal Institute of International Affairs. Meeting Summary. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.chathamhouse.org/sites/default/files/events/2017-03-30-amr-vaccines-meeting-summary.pdf">https://www.chathamhouse.org/sites/default/files/events/2017-03-30-amr-vaccines-meeting-summary.pdf</ext-link>. Accessed 12 Jul 2019</mixed-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Current advances and challenges in the development of Acinetobacter vaccines</article-title><source>Human Vaccine Immunother</source><year>2015</year><volume>11</volume><issue>10</issue><fpage>2495</fpage><lpage>2500</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1052354</pub-id><pub-id pub-id-type="pmcid">PMC4635877</pub-id><pub-id pub-id-type="pmid">26158773</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clift</surname><given-names>C</given-names></name><name name-style="western"><surname>Salisbury</surname><given-names>DM</given-names></name></person-group><article-title>Enhancing the role of vaccines in combatting antimicrobial resistance</article-title><source>Vaccine</source><year>2017</year><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.09.053</pub-id><pub-id pub-id-type="pmcid">PMC5714609</pub-id><pub-id pub-id-type="pmid">29153150</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>D</given-names></name><name name-style="western"><surname>Ashkenazi</surname><given-names>S</given-names></name><name name-style="western"><surname>Green</surname><given-names>MS</given-names></name><name name-style="western"><surname>Gdalevich</surname><given-names>M</given-names></name><name name-style="western"><surname>Robin</surname><given-names>G</given-names></name><name name-style="western"><surname>Slepon</surname><given-names>R</given-names></name><name name-style="western"><surname>Yavzori</surname><given-names>M</given-names></name><name name-style="western"><surname>Orr</surname><given-names>N</given-names></name><name name-style="western"><surname>Block</surname><given-names>C</given-names></name><name name-style="western"><surname>Ashkenazi</surname><given-names>I</given-names></name><name name-style="western"><surname>Shemer</surname><given-names>J</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>DN</given-names></name><name name-style="western"><surname>Hale</surname><given-names>TL</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>JC</given-names></name><name name-style="western"><surname>Pavliakova</surname><given-names>D</given-names></name><name name-style="western"><surname>Schneerson</surname><given-names>R</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>JB</given-names></name></person-group><article-title>Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults</article-title><source>Lancet</source><year>1997</year><volume>349</volume><issue>9046</issue><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)06255-1</pub-id><pub-id pub-id-type="pmid">9111538</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>R</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JF</given-names></name><name name-style="western"><surname>Chalumeau</surname><given-names>M</given-names></name><name name-style="western"><surname>Levy</surname><given-names>C</given-names></name></person-group><article-title>Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries</article-title><source>Expert Rev Vaccines</source><year>2017</year><volume>16</volume><issue>6</issue><fpage>625</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1080/14760584.2017.1320221</pub-id><pub-id pub-id-type="pmid">28409537</pub-id></element-citation></ref><ref id="CR46"><mixed-citation publication-type="other">Crank MC, Ruckwardt TJ, Chen M, Morabito KM, Phung E, Costner PJ, Holman LA, Hickman SP, Berkowitz NM, Gordon IJ, Yamshchikov GV, Gaudinski MR, Kumar A, Chang LA, Moin SM, Hill JP, DiPiazza AT, Schwartz RM, Kueltzo L, Cooper JW, Chen P, Stein JA, Carlton K, Gall JG, Nason MC, Kwong PD, Chen GL, Mascola JR, McLellan JS, Ledgerwood JE, Graham BS, Team VRCS (2019) A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365(6452): 505&#8211;509 10.1126/science.aav9033<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aav9033</pub-id><pub-id pub-id-type="pmid">31371616</pub-id></mixed-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cross</surname><given-names>A</given-names></name><name name-style="western"><surname>Artenstein</surname><given-names>A</given-names></name><name name-style="western"><surname>Que</surname><given-names>J</given-names></name><name name-style="western"><surname>Fredeking</surname><given-names>T</given-names></name><name name-style="western"><surname>Furer</surname><given-names>E</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>JC</given-names></name><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers</article-title><source>J Infect Dis</source><year>1994</year><volume>170</volume><issue>4</issue><fpage>834</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1093/infdis/170.4.834</pub-id><pub-id pub-id-type="pmid">7523536</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crump</surname><given-names>JA</given-names></name><name name-style="western"><surname>Luby</surname><given-names>SP</given-names></name><name name-style="western"><surname>Mintz</surname><given-names>ED</given-names></name></person-group><article-title>The global burden of typhoid fever</article-title><source>Bull World Health Organ</source><year>2004</year><volume>82</volume><issue>5</issue><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">15298225</pub-id><pub-id pub-id-type="pmcid">PMC2622843</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Mortimer</surname><given-names>P</given-names></name><name name-style="western"><surname>Cross</surname><given-names>AS</given-names></name><name name-style="western"><surname>Furer</surname><given-names>E</given-names></name><name name-style="western"><surname>Germanier</surname><given-names>R</given-names></name></person-group><article-title>Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans</article-title><source>Vaccine</source><year>1986</year><volume>4</volume><issue>1</issue><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/0264-410x(86)90092-7</pub-id><pub-id pub-id-type="pmid">3962447</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Lang</surname><given-names>A</given-names></name><name name-style="western"><surname>Rudeberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Wedgwood</surname><given-names>J</given-names></name><name name-style="western"><surname>Que</surname><given-names>JU</given-names></name><name name-style="western"><surname>Furer</surname><given-names>E</given-names></name><name name-style="western"><surname>Schaad</surname><given-names>U</given-names></name></person-group><article-title>Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine</article-title><source>Behring Inst Mitt</source><year>1997</year><volume>98</volume><fpage>345</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">9382759</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dayan</surname><given-names>GH</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>N</given-names></name><name name-style="western"><surname>Scully</surname><given-names>IL</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D</given-names></name><name name-style="western"><surname>Begier</surname><given-names>E</given-names></name><name name-style="western"><surname>Eiden</surname><given-names>J</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>KU</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>AS</given-names></name></person-group><article-title>Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention</article-title><source>Expert Rev Vaccines</source><year>2016</year><volume>15</volume><issue>11</issue><fpage>1373</fpage><lpage>1392</lpage><pub-id pub-id-type="doi">10.1080/14760584.2016.1179583</pub-id><pub-id pub-id-type="pmid">27118628</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dbaibo</surname><given-names>G</given-names></name><name name-style="western"><surname>Amanullah</surname><given-names>A</given-names></name><name name-style="western"><surname>Claeys</surname><given-names>C</given-names></name><name name-style="western"><surname>Izu</surname><given-names>A</given-names></name><name name-style="western"><surname>Jain</surname><given-names>VK</given-names></name><name name-style="western"><surname>Kosalaraksa</surname><given-names>P</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>L</given-names></name><name name-style="western"><surname>Soni</surname><given-names>J</given-names></name><name name-style="western"><surname>Yanni</surname><given-names>E</given-names></name><name name-style="western"><surname>Zaman</surname><given-names>K</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>B</given-names></name><name name-style="western"><surname>Ariza</surname><given-names>M</given-names></name><name name-style="western"><surname>Arroba Basanta</surname><given-names>ML</given-names></name><name name-style="western"><surname>Bavdekar</surname><given-names>A</given-names></name><name name-style="western"><surname>Carmona</surname><given-names>A</given-names></name><name name-style="western"><surname>Cousin</surname><given-names>L</given-names></name><name name-style="western"><surname>Danier</surname><given-names>J</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Diez-Domingo</surname><given-names>J</given-names></name><name name-style="western"><surname>Dinleyici</surname><given-names>EC</given-names></name><name name-style="western"><surname>Faust</surname><given-names>SN</given-names></name><name name-style="western"><surname>Garcia-Sicilia</surname><given-names>J</given-names></name><name name-style="western"><surname>Gomez-Go</surname><given-names>GD</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>MLA</given-names></name><name name-style="western"><surname>Hacimustafaoglu</surname><given-names>M</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>SM</given-names></name><name name-style="western"><surname>Jackowska</surname><given-names>T</given-names></name><name name-style="western"><surname>Kant</surname><given-names>S</given-names></name><name name-style="western"><surname>Lucero</surname><given-names>M</given-names></name><name name-style="western"><surname>Mares Bermudez</surname><given-names>J</given-names></name><name name-style="western"><surname>Martinon-Torres</surname><given-names>F</given-names></name><name name-style="western"><surname>Montellano</surname><given-names>M</given-names></name><name name-style="western"><surname>Prymula</surname><given-names>R</given-names></name><name name-style="western"><surname>Puthanakit</surname><given-names>T</given-names></name><name name-style="western"><surname>Ruzkova</surname><given-names>R</given-names></name><name name-style="western"><surname>Sadowska-Krawczenko</surname><given-names>I</given-names></name><name name-style="western"><surname>Szymanski</surname><given-names>H</given-names></name><name name-style="western"><surname>Ulied</surname><given-names>A</given-names></name><name name-style="western"><surname>Woo</surname><given-names>W</given-names></name><name name-style="western"><surname>Schuind</surname><given-names>A</given-names></name><name name-style="western"><surname>Innis</surname><given-names>BL</given-names></name><name name-style="western"><surname>Flu</surname><given-names>VECSG</given-names></name></person-group><article-title>Quadrivalent influenza vaccine prevents illness and reduces healthcare utilization across diverse geographic regions during five influenza aeasons: a randomized clinical trial</article-title><source>Pediatr Infect Dis J</source><year>2020</year><volume>39</volume><issue>1</issue><fpage>e1</fpage><lpage>e10</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000002504</pub-id><pub-id pub-id-type="pmid">31725115</pub-id><pub-id pub-id-type="pmcid">PMC7004464</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeStefano</surname><given-names>F</given-names></name><name name-style="western"><surname>Verstraeten</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>RT</given-names></name></person-group><article-title>Hepatitis B vaccine and risk of multiple sclerosis</article-title><source>Expert Rev Vaccines</source><year>2002</year><volume>1</volume><issue>4</issue><fpage>461</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1586/14760584.1.4.461</pub-id><pub-id pub-id-type="pmid">12901584</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donskey</surname><given-names>CJ</given-names></name></person-group><article-title>Clostridium difficile in Older Adults</article-title><source>Infect Dis Clin North Am</source><year>2017</year><volume>31</volume><issue>4</issue><fpage>743</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2017.07.003</pub-id><pub-id pub-id-type="pmid">29079158</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donta</surname><given-names>ST</given-names></name><name name-style="western"><surname>Peduzzi</surname><given-names>P</given-names></name><name name-style="western"><surname>Cross</surname><given-names>AS</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Haakenson</surname><given-names>C</given-names></name><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Kauffman</surname><given-names>C</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>S</given-names></name><name name-style="western"><surname>Gafford</surname><given-names>G</given-names></name><name name-style="western"><surname>Elliston</surname><given-names>D</given-names></name><name name-style="western"><surname>Beam</surname><given-names>TR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>John</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Ribner</surname><given-names>B</given-names></name><name name-style="western"><surname>Cantey</surname><given-names>R</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>CH</given-names></name><name name-style="western"><surname>Ellison</surname><given-names>RT</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Young</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Hamill</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Leaf</surname><given-names>H</given-names></name><name name-style="western"><surname>Schein</surname><given-names>RM</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C</given-names></name><name name-style="western"><surname>Abrutyn</surname><given-names>E</given-names></name><name name-style="western"><surname>Griffiss</surname><given-names>JM</given-names></name><name name-style="western"><surname>Slagle</surname><given-names>D</given-names></name><etal/></person-group><article-title>Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The federal hyperimmune immunoglobulin trial study group</article-title><source>J Infect Dis</source><year>1996</year><volume>174</volume><issue>3</issue><fpage>537</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1093/infdis/174.3.537</pub-id><pub-id pub-id-type="pmid">8769611</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doring</surname><given-names>G</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>C</given-names></name><name name-style="western"><surname>Weber</surname><given-names>U</given-names></name><name name-style="western"><surname>Mohr-Pennert</surname><given-names>A</given-names></name><name name-style="western"><surname>Dorner</surname><given-names>F</given-names></name></person-group><article-title>Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals</article-title><source>Am J Respir Crit Care Med</source><year>1995</year><volume>151</volume><issue>4</issue><fpage>983</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1164/ajrccm/151.4.983</pub-id><pub-id pub-id-type="pmid">7697276</pub-id></element-citation></ref><ref id="CR57"><mixed-citation publication-type="other">Doring G, Meisner C, Stern M, Flagella Vaccine Trial Study G (2007) A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A 104(26): 11020&#8211;11025 10.1073/pnas.0702403104<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0702403104</pub-id><pub-id pub-id-type="pmcid">PMC1904125</pub-id><pub-id pub-id-type="pmid">17585011</pub-id></mixed-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edelman</surname><given-names>R</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>DN</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>SS</given-names></name><name name-style="western"><surname>McClain</surname><given-names>JB</given-names></name><name name-style="western"><surname>Cross</surname><given-names>AS</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>JC</given-names></name><name name-style="western"><surname>Que</surname><given-names>JU</given-names></name><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names></name></person-group><article-title>Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously</article-title><source>Vaccine</source><year>1994</year><volume>12</volume><issue>14</issue><fpage>1288</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(94)80054-4</pub-id><pub-id pub-id-type="pmid">7856293</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elbahesh</surname><given-names>H</given-names></name><name name-style="western"><surname>Saletti</surname><given-names>G</given-names></name><name name-style="western"><surname>Gerlach</surname><given-names>T</given-names></name><name name-style="western"><surname>Rimmelzwaan</surname><given-names>GF</given-names></name></person-group><article-title>Broadly protective influenza vaccines: design and production platforms</article-title><source>Curr Opin Virol</source><year>2019</year><volume>34</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2018.11.005</pub-id><pub-id pub-id-type="pmid">30497050</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Endimiani</surname><given-names>A</given-names></name><name name-style="western"><surname>Blackford</surname><given-names>M</given-names></name><name name-style="western"><surname>Dasenbrook</surname><given-names>EC</given-names></name><name name-style="western"><surname>Reed</surname><given-names>MD</given-names></name><name name-style="western"><surname>Bajaksouszian</surname><given-names>S</given-names></name><name name-style="western"><surname>Hujer</surname><given-names>AM</given-names></name><name name-style="western"><surname>Rudin</surname><given-names>SD</given-names></name><name name-style="western"><surname>Hujer</surname><given-names>KM</given-names></name><name name-style="western"><surname>Perreten</surname><given-names>V</given-names></name><name name-style="western"><surname>Rice</surname><given-names>LB</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>MR</given-names></name><name name-style="western"><surname>Konstan</surname><given-names>MW</given-names></name><name name-style="western"><surname>Bonomo</surname><given-names>RA</given-names></name></person-group><article-title>Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland</article-title><source>Ohio Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><issue>4</issue><fpage>1684</fpage><lpage>1692</lpage><pub-id pub-id-type="doi">10.1128/AAC.01308-10</pub-id><pub-id pub-id-type="pmid">21263048</pub-id><pub-id pub-id-type="pmcid">PMC3067150</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>SL</given-names></name></person-group><article-title>Universal influenza vaccines: progress in achieving broad cross-protection in vivo</article-title><source>Am J Epidemiol</source><year>2018</year><volume>187</volume><issue>12</issue><fpage>2603</fpage><lpage>2614</lpage><pub-id pub-id-type="doi">10.1093/aje/kwy145</pub-id><pub-id pub-id-type="pmid">30084906</pub-id><pub-id pub-id-type="pmcid">PMC6887936</pub-id></element-citation></ref><ref id="CR62"><mixed-citation publication-type="other">Esposito S, Principi N, Cornaglia G, Group EVS (2014) Barriers to the vaccination of children and adolescents and possible solutions. Clin Microbiol Infect 20(Suppl 5): 25&#8211;31 10.1111/1469-0691.12447<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1469-0691.12447</pub-id><pub-id pub-id-type="pmid">24354949</pub-id></mixed-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estrada</surname><given-names>LD</given-names></name><name name-style="western"><surname>Schultz-Cherry</surname><given-names>S</given-names></name></person-group><article-title>Development of a universal influenza vaccine</article-title><source>J Immunol</source><year>2019</year><volume>202</volume><issue>2</issue><fpage>392</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1801054</pub-id><pub-id pub-id-type="pmid">30617121</pub-id><pub-id pub-id-type="pmcid">PMC6327971</pub-id></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name><name name-style="western"><surname>Hennessey</surname><given-names>PA</given-names></name><name name-style="western"><surname>Formica</surname><given-names>MA</given-names></name><name name-style="western"><surname>Cox</surname><given-names>C</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>EE</given-names></name></person-group><article-title>Respiratory syncytial virus infection in elderly and high-risk adults</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>17</issue><fpage>1749</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043951</pub-id><pub-id pub-id-type="pmid">15858184</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattom</surname><given-names>A</given-names></name><name name-style="western"><surname>Matalon</surname><given-names>A</given-names></name><name name-style="western"><surname>Buerkert</surname><given-names>J</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>K</given-names></name><name name-style="western"><surname>Damaso</surname><given-names>S</given-names></name><name name-style="western"><surname>Boutriau</surname><given-names>D</given-names></name></person-group><article-title>Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study</article-title><source>Human Vaccine Immunother</source><year>2015</year><volume>11</volume><issue>3</issue><fpage>632</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.4161/hv.34414</pub-id><pub-id pub-id-type="pmcid">PMC4514248</pub-id><pub-id pub-id-type="pmid">25483694</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>C</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>R</given-names></name></person-group><article-title>Epidemiology, virulence factors and management of the pneumococcus</article-title><source>F1000Res</source><year>2016</year><pub-id pub-id-type="doi">10.12688/f1000research.9283.1</pub-id><pub-id pub-id-type="pmcid">PMC5031122</pub-id><pub-id pub-id-type="pmid">27703671</pub-id></element-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>RA</given-names></name><name name-style="western"><surname>Fuhr</surname><given-names>R</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I</given-names></name><name name-style="western"><surname>Mick Ribeiro</surname><given-names>A</given-names></name><name name-style="western"><surname>Panther</surname><given-names>L</given-names></name><name name-style="western"><surname>Watson</surname><given-names>M</given-names></name><name name-style="western"><surname>Senn</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M</given-names></name><name name-style="western"><surname>Almarsson</surname><given-names>PHS</given-names></name><name name-style="western"><surname>Laska</surname><given-names>ME</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T</given-names></name><name name-style="western"><surname>Ciaramella</surname><given-names>G</given-names></name></person-group><article-title>mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><issue>25</issue><fpage>3326</fpage><lpage>3334</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.074</pub-id><pub-id pub-id-type="pmid">31079849</pub-id></element-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleming-Dutra</surname><given-names>KE</given-names></name><name name-style="western"><surname>Hersh</surname><given-names>AL</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Bartoces</surname><given-names>M</given-names></name><name name-style="western"><surname>Enns</surname><given-names>EA</given-names></name><name name-style="western"><surname>File</surname><given-names>TM</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Finkelstein</surname><given-names>JA</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hyun</surname><given-names>DY</given-names></name><name name-style="western"><surname>Linder</surname><given-names>JA</given-names></name><name name-style="western"><surname>Lynfield</surname><given-names>R</given-names></name><name name-style="western"><surname>Margolis</surname><given-names>DJ</given-names></name><name name-style="western"><surname>May</surname><given-names>LS</given-names></name><name name-style="western"><surname>Merenstein</surname><given-names>D</given-names></name><name name-style="western"><surname>Metlay</surname><given-names>JP</given-names></name><name name-style="western"><surname>Newland</surname><given-names>JG</given-names></name><name name-style="western"><surname>Piccirillo</surname><given-names>JF</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>RM</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>GV</given-names></name><name name-style="western"><surname>Suda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Woo</surname><given-names>TM</given-names></name><name name-style="western"><surname>Zetts</surname><given-names>RM</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>LA</given-names></name></person-group><article-title>Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010&#8211;2011</article-title><source>JAMA</source><year>2016</year><volume>315</volume><issue>17</issue><fpage>1864</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.4151</pub-id><pub-id pub-id-type="pmid">27139059</pub-id></element-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forthal</surname><given-names>DN</given-names></name></person-group><article-title>Functions of Antibodies</article-title><source>Microbiol Spectr</source><year>2014</year><volume>2</volume><issue>4</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.AID-0019-2014</pub-id><pub-id pub-id-type="pmcid">PMC4159104</pub-id><pub-id pub-id-type="pmid">25215264</pub-id></element-citation></ref><ref id="CR70"><mixed-citation publication-type="other">Freeman J, Vernon J, Morris K, Nicholson S, Todhunter S, Longshaw C, Wilcox MH, Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes&#8217; Study G (2015) Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect 10.1016/j.cmi.2014.09.017<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2017.10.008</pub-id><pub-id pub-id-type="pmid">29066403</pub-id></mixed-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frenck</surname><given-names>RW</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Ervin</surname><given-names>J</given-names></name><name name-style="western"><surname>Chu</surname><given-names>L</given-names></name><name name-style="western"><surname>Abbanat</surname><given-names>D</given-names></name><name name-style="western"><surname>Spiessens</surname><given-names>B</given-names></name><name name-style="western"><surname>Go</surname><given-names>O</given-names></name><name name-style="western"><surname>Haazen</surname><given-names>W</given-names></name><name name-style="western"><surname>van den Dobbelsteen</surname><given-names>G</given-names></name><name name-style="western"><surname>Poolman</surname><given-names>J</given-names></name><name name-style="western"><surname>Thoelen</surname><given-names>S</given-names></name><name name-style="western"><surname>Ibarra de Palacios</surname><given-names>P</given-names></name></person-group><article-title>Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial</article-title><source>Lancet Infect Dis</source><year>2019</year><volume>19</volume><issue>6</issue><fpage>631</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30803-X</pub-id><pub-id pub-id-type="pmid">31079947</pub-id></element-citation></ref><ref id="CR72"><mixed-citation publication-type="other">G7 Summit (2015) Leaders&#700; Declaration. Schloss Elmau, Germany, 7&#8211;8 June 2015. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://sustainabledevelopment.un.org/content/documents/7320LEADERS%20STATEMENT_FINAL_CLEAN.pdf">https://sustainabledevelopment.un.org/content/documents/7320LEADERS%20STATEMENT_FINAL_CLEAN.pdf</ext-link>. Accessed 23 Aug 2019</mixed-citation></ref><ref id="CR73"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gagneux-Brunon</surname><given-names>A</given-names></name><name name-style="western"><surname>Lucht</surname><given-names>F</given-names></name><name name-style="western"><surname>Launay</surname><given-names>O</given-names></name><name name-style="western"><surname>Berthelot</surname><given-names>P</given-names></name><name name-style="western"><surname>Botelho-Nevers</surname><given-names>E</given-names></name></person-group><article-title>Vaccines for healthcare-associated infections: present, future, and expectations</article-title><source>Expert Rev Vaccines</source><year>2018</year><volume>17</volume><issue>5</issue><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1080/14760584.2018.1470507</pub-id><pub-id pub-id-type="pmid">29697286</pub-id></element-citation></ref><ref id="CR74"><mixed-citation publication-type="other">GAVI. The Vaccine Alliance (2017) Monitoring &amp; evaluation framework. Gavi strategy 2016&#8211;2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gavi.org/about/strategy/phase-iv-2016-20/">https://www.gavi.org/about/strategy/phase-iv-2016-20/</ext-link>. Accessed 14 Sept 2019</mixed-citation></ref><ref id="CR75"><mixed-citation publication-type="other">Gaynes R, Edwards JR, National Nosocomial Infections Surveillance S (2005) Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41(6): 848&#8211;854 10.1086/432803<pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/432803</pub-id><pub-id pub-id-type="pmid">16107985</pub-id></mixed-citation></ref><ref id="CR76"><mixed-citation publication-type="other">GBD 2017 Typhoid and Paratyphoid Collaborators (2019) The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis 19(4): 369&#8211;381 10.1016/S1473-3099(18)30685-6<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(18)30685-6</pub-id><pub-id pub-id-type="pmcid">PMC6437314</pub-id><pub-id pub-id-type="pmid">30792131</pub-id></mixed-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gellatly</surname><given-names>SL</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>RE</given-names></name></person-group><article-title>Pseudomonas aeruginosa: new insights into pathogenesis and host defenses</article-title><source>Pathog Dis</source><year>2013</year><volume>67</volume><issue>3</issue><fpage>159</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1111/2049-632X.12033</pub-id><pub-id pub-id-type="pmid">23620179</pub-id></element-citation></ref><ref id="CR78"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerding</surname><given-names>DN</given-names></name></person-group><article-title>Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem</article-title><source>Clin Infect Dis</source><year>2004</year><volume>38</volume><issue>5</issue><fpage>646</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1086/382084</pub-id><pub-id pub-id-type="pmid">14986247</pub-id></element-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerding</surname><given-names>DN</given-names></name><name name-style="western"><surname>Muto</surname><given-names>CA</given-names></name><name name-style="western"><surname>Owens</surname><given-names>RC</given-names><suffix>Jr</suffix></name></person-group><article-title>Measures to control and prevent Clostridium difficile infection</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><issue>Suppl 1</issue><fpage>S43</fpage><lpage>S49</lpage><pub-id pub-id-type="doi">10.1086/521861</pub-id><pub-id pub-id-type="pmid">18177221</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giannasca</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>ZX</given-names></name><name name-style="western"><surname>Lei</surname><given-names>WD</given-names></name><name name-style="western"><surname>Boden</surname><given-names>JA</given-names></name><name name-style="western"><surname>Giel</surname><given-names>MA</given-names></name><name name-style="western"><surname>Monath</surname><given-names>TP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>WD</given-names><suffix>Jr</suffix></name></person-group><article-title>Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters</article-title><source>Infect Immun</source><year>1999</year><volume>67</volume><issue>2</issue><fpage>527</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1128/IAI.67.2.527-538.1999</pub-id><pub-id pub-id-type="pmid">9916055</pub-id><pub-id pub-id-type="pmcid">PMC96351</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giaquinto</surname><given-names>C</given-names></name><name name-style="western"><surname>Dominiak-Felden</surname><given-names>G</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>P</given-names></name><name name-style="western"><surname>Myint</surname><given-names>TT</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>YA</given-names></name><name name-style="western"><surname>Spoulou</surname><given-names>V</given-names></name><name name-style="western"><surname>Mast</surname><given-names>TC</given-names></name><name name-style="western"><surname>Staat</surname><given-names>MA</given-names></name></person-group><article-title>Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries</article-title><source>Human Vaccine</source><year>2011</year><volume>7</volume><issue>7</issue><fpage>734</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.4161/hv.7.7.15511</pub-id><pub-id pub-id-type="pmid">21734466</pub-id></element-citation></ref><ref id="CR82"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giufre</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardines</surname><given-names>R</given-names></name><name name-style="western"><surname>Caporali</surname><given-names>MG</given-names></name><name name-style="western"><surname>Accogli</surname><given-names>M</given-names></name><name name-style="western"><surname>D&#8217;Ancona</surname><given-names>F</given-names></name><name name-style="western"><surname>Cerquetti</surname><given-names>M</given-names></name></person-group><article-title>Ten years of Hib vaccination in Italy: prevalence of non-encapsulated Haemophilus influenzae among invasive isolates and the possible impact on antibiotic resistance</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>22</issue><fpage>3857</fpage><lpage>3862</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.03.059</pub-id><pub-id pub-id-type="pmid">21459175</pub-id></element-citation></ref><ref id="CR83"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glanz</surname><given-names>JM</given-names></name><name name-style="western"><surname>Newcomer</surname><given-names>SR</given-names></name><name name-style="western"><surname>Daley</surname><given-names>MF</given-names></name><name name-style="western"><surname>DeStefano</surname><given-names>F</given-names></name><name name-style="western"><surname>Groom</surname><given-names>HC</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>BJ</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>NL</given-names></name><name name-style="western"><surname>McClure</surname><given-names>DL</given-names></name><name name-style="western"><surname>Narwaney</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Nordin</surname><given-names>JD</given-names></name><name name-style="western"><surname>Zerbo</surname><given-names>O</given-names></name></person-group><article-title>Association between estimated cumulative vaccine antigen exposure through the first 23 months of life and non-vaccine-targeted infections from 24 through 47 months of age</article-title><source>JAMA</source><year>2018</year><volume>319</volume><issue>9</issue><fpage>906</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.0708</pub-id><pub-id pub-id-type="pmid">29509866</pub-id><pub-id pub-id-type="pmcid">PMC5885913</pub-id></element-citation></ref><ref id="CR84"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrant</surname><given-names>RL</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lima</surname><given-names>NL</given-names></name><name name-style="western"><surname>Crane</surname><given-names>J</given-names></name></person-group><article-title>Diarrhea in developed and developing countries: magnitude, special settings, and etiologies</article-title><source>Rev Infect Dis</source><year>1990</year><volume>12</volume><issue>Suppl 1</issue><fpage>S41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1093/clinids/12.supplement_1.s41</pub-id><pub-id pub-id-type="pmid">2406855</pub-id><pub-id pub-id-type="pmcid">PMC7792920</pub-id></element-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haines</surname><given-names>CF</given-names></name><name name-style="western"><surname>Moore</surname><given-names>RD</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>JG</given-names></name><name name-style="western"><surname>Sears</surname><given-names>CL</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>SE</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>K</given-names></name><name name-style="western"><surname>Gebo</surname><given-names>KA</given-names></name></person-group><article-title>Clostridium difficile in a HIV-infected cohort: incidence, risk factors, and clinical outcomes</article-title><source>AIDS</source><year>2013</year><volume>27</volume><issue>17</issue><fpage>2799</fpage><lpage>2807</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000432450.37863.e9</pub-id><pub-id pub-id-type="pmid">23842125</pub-id><pub-id pub-id-type="pmcid">PMC3880635</pub-id></element-citation></ref><ref id="CR86"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hament</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kimpen</surname><given-names>JL</given-names></name><name name-style="western"><surname>Fleer</surname><given-names>A</given-names></name><name name-style="western"><surname>Wolfs</surname><given-names>TF</given-names></name></person-group><article-title>Respiratory viral infection predisposing for bacterial disease: a concise review</article-title><source>FEMS Immunol Med Microbiol</source><year>1999</year><volume>26</volume><issue>3&#8211;4</issue><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.1999.tb01389.x</pub-id><pub-id pub-id-type="pmid">10575129</pub-id></element-citation></ref><ref id="CR87"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampton</surname><given-names>LM</given-names></name><name name-style="western"><surname>Farley</surname><given-names>MM</given-names></name><name name-style="western"><surname>Schaffner</surname><given-names>W</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Reingold</surname><given-names>A</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>LH</given-names></name><name name-style="western"><surname>Lynfield</surname><given-names>R</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>NM</given-names></name><name name-style="western"><surname>Petit</surname><given-names>S</given-names></name><name name-style="western"><surname>Gershman</surname><given-names>K</given-names></name><name name-style="western"><surname>Baumbach</surname><given-names>J</given-names></name><name name-style="western"><surname>Beall</surname><given-names>B</given-names></name><name name-style="western"><surname>Jorgensen</surname><given-names>J</given-names></name><name name-style="western"><surname>Glennen</surname><given-names>A</given-names></name><name name-style="western"><surname>Zell</surname><given-names>ER</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M</given-names></name></person-group><article-title>Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines</article-title><source>J Infect Dis</source><year>2012</year><volume>205</volume><issue>3</issue><fpage>401</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir755</pub-id><pub-id pub-id-type="pmid">22158567</pub-id></element-citation></ref><ref id="CR88"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardelid</surname><given-names>P</given-names></name><name name-style="western"><surname>Ghebremichael-Weldeselassie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Whitaker</surname><given-names>H</given-names></name><name name-style="western"><surname>Rait</surname><given-names>G</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>R</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>I</given-names></name></person-group><article-title>Effectiveness of live attenuated influenza vaccine in preventing amoxicillin prescribing in preschool children: a self-controlled case series study</article-title><source>J Antimicrob Chemother</source><year>2018</year><volume>73</volume><issue>3</issue><fpage>779</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx463</pub-id><pub-id pub-id-type="pmid">29228207</pub-id></element-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hargreaves</surname><given-names>RM</given-names></name><name name-style="western"><surname>Slack</surname><given-names>MP</given-names></name><name name-style="western"><surname>Howard</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E</given-names></name><name name-style="western"><surname>Ramsay</surname><given-names>ME</given-names></name></person-group><article-title>Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme</article-title><source>BMJ</source><year>1996</year><volume>312</volume><issue>7024</issue><fpage>160</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1136/bmj.312.7024.160</pub-id><pub-id pub-id-type="pmid">8563536</pub-id><pub-id pub-id-type="pmcid">PMC2349799</pub-id></element-citation></ref><ref id="CR90"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatz</surname><given-names>CF</given-names></name><name name-style="western"><surname>Bally</surname><given-names>B</given-names></name><name name-style="western"><surname>Rohrer</surname><given-names>S</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>R</given-names></name><name name-style="western"><surname>Kramme</surname><given-names>S</given-names></name><name name-style="western"><surname>Siegrist</surname><given-names>CA</given-names></name><name name-style="western"><surname>Wacker</surname><given-names>M</given-names></name><name name-style="western"><surname>Alaimo</surname><given-names>C</given-names></name><name name-style="western"><surname>Fonck</surname><given-names>VG</given-names></name></person-group><article-title>Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized Phase I study</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><issue>36</issue><fpage>4594</fpage><lpage>4601</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.06.102</pub-id><pub-id pub-id-type="pmid">26162850</pub-id></element-citation></ref><ref id="CR91"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>M</given-names></name><name name-style="western"><surname>Miyajima</surname><given-names>F</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>P</given-names></name><name name-style="western"><surname>Ellison</surname><given-names>L</given-names></name><name name-style="western"><surname>Pickard</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Martin</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Connor</surname><given-names>TR</given-names></name><name name-style="western"><surname>Harris</surname><given-names>SR</given-names></name><name name-style="western"><surname>Fairley</surname><given-names>D</given-names></name><name name-style="western"><surname>Bamford</surname><given-names>KB</given-names></name><name name-style="western"><surname>D&#8217;Arc</surname><given-names>S</given-names></name><name name-style="western"><surname>Brazier</surname><given-names>J</given-names></name><name name-style="western"><surname>Brown</surname><given-names>D</given-names></name><name name-style="western"><surname>Coia</surname><given-names>JE</given-names></name><name name-style="western"><surname>Douce</surname><given-names>G</given-names></name><name name-style="western"><surname>Gerding</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Koh</surname><given-names>TH</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name><name name-style="western"><surname>Senoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Louie</surname><given-names>T</given-names></name><name name-style="western"><surname>Michell</surname><given-names>S</given-names></name><name name-style="western"><surname>Butt</surname><given-names>E</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Brown</surname><given-names>NM</given-names></name><name name-style="western"><surname>Riley</surname><given-names>T</given-names></name><name name-style="western"><surname>Songer</surname><given-names>G</given-names></name><name name-style="western"><surname>Wilcox</surname><given-names>M</given-names></name><name name-style="western"><surname>Pirmohamed</surname><given-names>M</given-names></name><name name-style="western"><surname>Kuijper</surname><given-names>E</given-names></name><name name-style="western"><surname>Hawkey</surname><given-names>P</given-names></name><name name-style="western"><surname>Wren</surname><given-names>BW</given-names></name><name name-style="western"><surname>Dougan</surname><given-names>G</given-names></name><name name-style="western"><surname>Parkhill</surname><given-names>J</given-names></name><name name-style="western"><surname>Lawley</surname><given-names>TD</given-names></name></person-group><article-title>Emergence and global spread of epidemic healthcare-associated Clostridium difficile</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><issue>1</issue><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/ng.2478</pub-id><pub-id pub-id-type="pmid">23222960</pub-id><pub-id pub-id-type="pmcid">PMC3605770</pub-id></element-citation></ref><ref id="CR92"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hegerle</surname><given-names>N</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>J</given-names></name><name name-style="western"><surname>Amin</surname><given-names>MN</given-names></name><name name-style="western"><surname>Ollivault-Shiflett</surname><given-names>M</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>B</given-names></name><name name-style="western"><surname>Laufer</surname><given-names>RS</given-names></name><name name-style="western"><surname>Shridhar</surname><given-names>S</given-names></name><name name-style="western"><surname>Brammer</surname><given-names>J</given-names></name><name name-style="western"><surname>Toapanta</surname><given-names>FR</given-names></name><name name-style="western"><surname>Holder</surname><given-names>IA</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>MF</given-names></name><name name-style="western"><surname>Lees</surname><given-names>A</given-names></name><name name-style="western"><surname>Tennant</surname><given-names>SM</given-names></name><name name-style="western"><surname>Cross</surname><given-names>AS</given-names></name><name name-style="western"><surname>Simon</surname><given-names>R</given-names></name></person-group><article-title>Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa</article-title><source>PLoS ONE</source><year>2018</year><pub-id pub-id-type="doi">10.1371/journal.pone.0203143</pub-id><pub-id pub-id-type="pmcid">PMC6126813</pub-id><pub-id pub-id-type="pmid">30188914</pub-id></element-citation></ref><ref id="CR93"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heilmann</surname><given-names>KP</given-names></name><name name-style="western"><surname>Rice</surname><given-names>CL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>AL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Beekmann</surname><given-names>SE</given-names></name><name name-style="western"><surname>Pfaller</surname><given-names>MA</given-names></name><name name-style="western"><surname>Richter</surname><given-names>SS</given-names></name><name name-style="western"><surname>Doern</surname><given-names>GV</given-names></name></person-group><article-title>Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><issue>6</issue><fpage>2561</fpage><lpage>2564</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.6.2561-2564.2005</pub-id><pub-id pub-id-type="pmid">15917574</pub-id><pub-id pub-id-type="pmcid">PMC1140551</pub-id></element-citation></ref><ref id="CR94"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hidron</surname><given-names>AI</given-names></name><name name-style="western"><surname>Kempker</surname><given-names>R</given-names></name><name name-style="western"><surname>Moanna</surname><given-names>A</given-names></name><name name-style="western"><surname>Rimland</surname><given-names>D</given-names></name></person-group><article-title>Methicillin-resistant Staphylococcus aureus in HIV-infected patients</article-title><source>Infect Drug Resist</source><year>2010</year><volume>3</volume><fpage>73</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.2147/IDR.S7641</pub-id><pub-id pub-id-type="pmid">21694896</pub-id><pub-id pub-id-type="pmcid">PMC3108732</pub-id></element-citation></ref><ref id="CR95"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hillier</surname><given-names>SL</given-names></name><name name-style="western"><surname>Ferrieri</surname><given-names>P</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>MS</given-names></name><name name-style="western"><surname>Ewell</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>D</given-names></name><name name-style="western"><surname>Fine</surname><given-names>P</given-names></name><name name-style="western"><surname>Carey</surname><given-names>V</given-names></name><name name-style="western"><surname>Meyn</surname><given-names>L</given-names></name><name name-style="western"><surname>Hoagland</surname><given-names>D</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>DL</given-names></name><name name-style="western"><surname>Paoletti</surname><given-names>LC</given-names></name><name name-style="western"><surname>Hill</surname><given-names>H</given-names></name><name name-style="western"><surname>Baker</surname><given-names>CJ</given-names></name></person-group><article-title>A Phase 2, randomized, control trial of Group B Streptococcus (GBS) Type III capsular polysaccharide-tetanus toxoid (GBS III-TT) vaccine to prevent vaginal colonization with GBS III</article-title><source>Clin Infect Dis</source><year>2019</year><volume>68</volume><issue>12</issue><fpage>2079</fpage><lpage>2086</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy838</pub-id><pub-id pub-id-type="pmid">30281066</pub-id><pub-id pub-id-type="pmcid">PMC7317289</pub-id></element-citation></ref><ref id="CR96"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hindle</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chatfield</surname><given-names>SN</given-names></name><name name-style="western"><surname>Phillimore</surname><given-names>J</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>CA</given-names></name><name name-style="western"><surname>Ghaem-Maghami</surname><given-names>M</given-names></name><name name-style="western"><surname>Sexton</surname><given-names>A</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>FR</given-names></name><name name-style="western"><surname>Everest</surname><given-names>P</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Pickard</surname><given-names>D</given-names></name><name name-style="western"><surname>Holden</surname><given-names>DW</given-names></name><name name-style="western"><surname>Dougan</surname><given-names>G</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>GE</given-names></name><name name-style="western"><surname>House</surname><given-names>D</given-names></name><name name-style="western"><surname>Santangelo</surname><given-names>JD</given-names></name><name name-style="western"><surname>Khan</surname><given-names>SA</given-names></name><name name-style="western"><surname>Shea</surname><given-names>JE</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>RG</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>DJ</given-names></name></person-group><article-title>Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers</article-title><source>Infect Immun</source><year>2002</year><volume>70</volume><issue>7</issue><fpage>3457</fpage><lpage>3467</lpage><pub-id pub-id-type="doi">10.1128/iai.70.7.3457-3467.2002</pub-id><pub-id pub-id-type="pmid">12065485</pub-id><pub-id pub-id-type="pmcid">PMC128087</pub-id></element-citation></ref><ref id="CR97"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirschtick</surname><given-names>RE</given-names></name><name name-style="western"><surname>Glassroth</surname><given-names>J</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>MC</given-names></name><name name-style="western"><surname>Wilcosky</surname><given-names>TC</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kvale</surname><given-names>PA</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>N</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Mangura</surname><given-names>BT</given-names></name><name name-style="western"><surname>Hopewell</surname><given-names>PC</given-names></name></person-group><article-title>Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary complications of HIV infection study group</article-title><source>N Engl J Med</source><year>1995</year><volume>333</volume><issue>13</issue><fpage>845</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1056/NEJM199509283331305</pub-id><pub-id pub-id-type="pmid">7651475</pub-id></element-citation></ref><ref id="CR98"><mixed-citation publication-type="other">HIV.gov (2020) Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</ext-link>. Accessed 20 Sept 2020</mixed-citation></ref><ref id="CR99"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holden</surname><given-names>MT</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>LY</given-names></name><name name-style="western"><surname>Kurt</surname><given-names>K</given-names></name><name name-style="western"><surname>Weinert</surname><given-names>LA</given-names></name><name name-style="western"><surname>Mather</surname><given-names>AE</given-names></name><name name-style="western"><surname>Harris</surname><given-names>SR</given-names></name><name name-style="western"><surname>Strommenger</surname><given-names>B</given-names></name><name name-style="western"><surname>Layer</surname><given-names>F</given-names></name><name name-style="western"><surname>Witte</surname><given-names>W</given-names></name><name name-style="western"><surname>de Lencastre</surname><given-names>H</given-names></name><name name-style="western"><surname>Skov</surname><given-names>R</given-names></name><name name-style="western"><surname>Westh</surname><given-names>H</given-names></name><name name-style="western"><surname>Zemlickova</surname><given-names>H</given-names></name><name name-style="western"><surname>Coombs</surname><given-names>G</given-names></name><name name-style="western"><surname>Kearns</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hill</surname><given-names>RL</given-names></name><name name-style="western"><surname>Edgeworth</surname><given-names>J</given-names></name><name name-style="western"><surname>Gould</surname><given-names>I</given-names></name><name name-style="western"><surname>Gant</surname><given-names>V</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>J</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>GF</given-names></name><name name-style="western"><surname>McAdam</surname><given-names>PR</given-names></name><name name-style="western"><surname>Templeton</surname><given-names>KE</given-names></name><name name-style="western"><surname>McCann</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Castillo-Ramirez</surname><given-names>S</given-names></name><name name-style="western"><surname>Feil</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>LO</given-names></name><name name-style="western"><surname>Enright</surname><given-names>MC</given-names></name><name name-style="western"><surname>Balloux</surname><given-names>F</given-names></name><name name-style="western"><surname>Aanensen</surname><given-names>DM</given-names></name><name name-style="western"><surname>Spratt</surname><given-names>BG</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>JR</given-names></name><name name-style="western"><surname>Parkhill</surname><given-names>J</given-names></name><name name-style="western"><surname>Achtman</surname><given-names>M</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>SD</given-names></name><name name-style="western"><surname>Nubel</surname><given-names>U</given-names></name></person-group><article-title>A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic</article-title><source>Genome Res</source><year>2013</year><volume>23</volume><issue>4</issue><fpage>653</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1101/gr.147710.112</pub-id><pub-id pub-id-type="pmid">23299977</pub-id><pub-id pub-id-type="pmcid">PMC3613582</pub-id></element-citation></ref><ref id="CR100"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>DC</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>RJ</given-names></name></person-group><article-title>Progress in HIV vaccine development</article-title><source>Hum Vaccin Immunother</source><year>2017</year><volume>13</volume><issue>5</issue><fpage>1018</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1276138</pub-id><pub-id pub-id-type="pmid">28281871</pub-id><pub-id pub-id-type="pmcid">PMC5443372</pub-id></element-citation></ref><ref id="CR101"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>DB</given-names></name><name name-style="western"><surname>Mohanty</surname><given-names>A</given-names></name><name name-style="western"><surname>DuPont</surname><given-names>HL</given-names></name><name name-style="western"><surname>Okhuysen</surname><given-names>PC</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>T</given-names></name></person-group><article-title>A review of an emerging enteric pathogen: enteroaggregative Escherichia coli</article-title><source>J Med Microbiol</source><year>2006</year><volume>55</volume><issue>Pt 10</issue><fpage>1303</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.46674-0</pub-id><pub-id pub-id-type="pmid">17005776</pub-id></element-citation></ref><ref id="CR102"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huttner</surname><given-names>A</given-names></name><name name-style="western"><surname>Hatz</surname><given-names>C</given-names></name><name name-style="western"><surname>van den Dobbelsteen</surname><given-names>G</given-names></name><name name-style="western"><surname>Abbanat</surname><given-names>D</given-names></name><name name-style="western"><surname>Hornacek</surname><given-names>A</given-names></name><name name-style="western"><surname>Frolich</surname><given-names>R</given-names></name><name name-style="western"><surname>Dreyer</surname><given-names>AM</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P</given-names></name><name name-style="western"><surname>Davies</surname><given-names>T</given-names></name><name name-style="western"><surname>Fae</surname><given-names>K</given-names></name><name name-style="western"><surname>van den Nieuwenhof</surname><given-names>I</given-names></name><name name-style="western"><surname>Thoelen</surname><given-names>S</given-names></name><name name-style="western"><surname>de Valliere</surname><given-names>S</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>A</given-names></name><name name-style="western"><surname>Bernasconi</surname><given-names>E</given-names></name><name name-style="western"><surname>Viereck</surname><given-names>V</given-names></name><name name-style="western"><surname>Kavvadias</surname><given-names>T</given-names></name><name name-style="western"><surname>Kling</surname><given-names>K</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>G</given-names></name><name name-style="western"><surname>Hulder</surname><given-names>T</given-names></name><name name-style="western"><surname>Groger</surname><given-names>S</given-names></name><name name-style="western"><surname>Scheiner</surname><given-names>D</given-names></name><name name-style="western"><surname>Alaimo</surname><given-names>C</given-names></name><name name-style="western"><surname>Harbarth</surname><given-names>S</given-names></name><name name-style="western"><surname>Poolman</surname><given-names>J</given-names></name><name name-style="western"><surname>Fonck</surname><given-names>VG</given-names></name></person-group><article-title>Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial</article-title><source>Lancet Infect Dis</source><year>2017</year><volume>17</volume><issue>5</issue><fpage>528</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30108-1</pub-id><pub-id pub-id-type="pmid">28238601</pub-id></element-citation></ref><ref id="CR103"><mixed-citation publication-type="other">Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, Hoffmann S, Valentiner-Branth P, Lambertsen L, Danish Pneumococcal Surveillance Collaboration G (2012) Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine 30(26): 3944&#8211;3950 10.1016/j.vaccine.2012.03.060<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2012.03.060</pub-id><pub-id pub-id-type="pmid">22504662</pub-id></mixed-citation></ref><ref id="CR104"><mixed-citation publication-type="other">Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, Wu P, Kyncl J, Ang LW, Park M, Redlberger-Fritz M, Yu H, Espenhain L, Krishnan A, Emukule G, van Asten L, Pereira da Silva S, Aungkulanon S, Buchholz U, Widdowson MA, Bresee JS, Global Seasonal Influenza-associated Mortality Collaborator N (2018) Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391(10127): 1285&#8211;1300 10.1016/S0140-6736(17)33293-2<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)33293-2</pub-id><pub-id pub-id-type="pmcid">PMC5935243</pub-id><pub-id pub-id-type="pmid">29248255</pub-id></mixed-citation></ref><ref id="CR105"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>KU</given-names></name><name name-style="western"><surname>Knirsch</surname><given-names>C</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>AS</given-names></name></person-group><article-title>The role of vaccines in preventing bacterial antimicrobial resistance</article-title><source>Nat Med</source><year>2018</year><volume>24</volume><issue>1</issue><fpage>10</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1038/nm.4465</pub-id><pub-id pub-id-type="pmid">29315295</pub-id></element-citation></ref><ref id="CR106"><mixed-citation publication-type="other">Jansen KU, Gruber WC, Simon R, Wassil J, Anderson AS (2021) The role of vaccines in combating antimicrobial resistance. In: Panwar H, Sharma C, Lichtfouse E (eds) Sustainable agriculture reviews. Mitigation of antimicrobial resistance vol 2, Natural and Synthetic Approaches, Springer Nature, Switzerland AG, pp 347&#8211;430</mixed-citation></ref><ref id="CR107"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jares Baglivo</surname><given-names>S</given-names></name><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name></person-group><article-title>The long road to protect infants against severe RSV lower respiratory tract illness</article-title><source>F1000Res</source><year>2019</year><pub-id pub-id-type="doi">10.12688/f1000research.18749.1</pub-id><pub-id pub-id-type="pmcid">PMC6498742</pub-id><pub-id pub-id-type="pmid">31105933</pub-id></element-citation></ref><ref id="CR108"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>RN</given-names></name></person-group><article-title>Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia</article-title><source>Clin Infect Dis</source><year>2010</year><volume>51</volume><issue>Suppl 1</issue><fpage>S81</fpage><lpage>S87</lpage><pub-id pub-id-type="doi">10.1086/653053</pub-id><pub-id pub-id-type="pmid">20597676</pub-id></element-citation></ref><ref id="CR109"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>C</given-names></name><name name-style="western"><surname>Togawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shindo</surname><given-names>N</given-names></name></person-group><article-title>Bacterial and viral infections associated with influenza</article-title><source>Influenza Other Respir Viruses</source><year>2013</year><volume>7</volume><issue>Suppl 2</issue><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1111/irv.12089</pub-id><pub-id pub-id-type="pmid">24034494</pub-id><pub-id pub-id-type="pmcid">PMC5909385</pub-id></element-citation></ref><ref id="CR110"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamtchoua</surname><given-names>T</given-names></name><name name-style="western"><surname>Bologa</surname><given-names>M</given-names></name><name name-style="western"><surname>Hopfer</surname><given-names>R</given-names></name><name name-style="western"><surname>Neveu</surname><given-names>D</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Corde</surname><given-names>N</given-names></name><name name-style="western"><surname>Pouzet</surname><given-names>C</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>G</given-names></name><name name-style="western"><surname>Gurunathan</surname><given-names>S</given-names></name></person-group><article-title>Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><issue>2</issue><fpage>327</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.005</pub-id><pub-id pub-id-type="pmid">23153437</pub-id></element-citation></ref><ref id="CR111"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kash</surname><given-names>JC</given-names></name><name name-style="western"><surname>Taubenberger</surname><given-names>JK</given-names></name></person-group><article-title>The role of viral, host, and secondary bacterial factors in influenza pathogenesis</article-title><source>Am J Pathol</source><year>2015</year><volume>185</volume><issue>6</issue><fpage>1528</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2014.08.030</pub-id><pub-id pub-id-type="pmid">25747532</pub-id><pub-id pub-id-type="pmcid">PMC4450310</pub-id></element-citation></ref><ref id="CR112"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>CP</given-names></name><name name-style="western"><surname>Pothoulakis</surname><given-names>C</given-names></name><name name-style="western"><surname>LaMont</surname><given-names>JT</given-names></name></person-group><article-title>Clostridium difficile colitis</article-title><source>N Engl J Med</source><year>1994</year><volume>330</volume><issue>4</issue><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1056/NEJM199401273300406</pub-id><pub-id pub-id-type="pmid">8043060</pub-id></element-citation></ref><ref id="CR113"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kennedy</surname><given-names>DA</given-names></name><name name-style="western"><surname>Read</surname><given-names>AF</given-names></name></person-group><article-title>Why does drug resistance readily evolve but vaccine resistance does not?</article-title><source>Proc Biol Sci</source><year>2017</year><pub-id pub-id-type="doi">10.1098/rspb.2016.2562</pub-id><pub-id pub-id-type="pmcid">PMC5378080</pub-id><pub-id pub-id-type="pmid">28356449</pub-id></element-citation></ref><ref id="CR114"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoshnood</surname><given-names>S</given-names></name><name name-style="western"><surname>Heidary</surname><given-names>M</given-names></name><name name-style="western"><surname>Haeili</surname><given-names>M</given-names></name><name name-style="western"><surname>Drancourt</surname><given-names>M</given-names></name><name name-style="western"><surname>Darban-Sarokhalil</surname><given-names>D</given-names></name><name name-style="western"><surname>Nasiri</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lohrasbi</surname><given-names>V</given-names></name></person-group><article-title>Novel vaccine candidates against Mycobacterium tuberculosis</article-title><source>Int J Biol Macromol</source><year>2018</year><volume>120</volume><issue>Pt A</issue><fpage>180</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.08.037</pub-id><pub-id pub-id-type="pmid">30098365</pub-id></element-citation></ref><ref id="CR115"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>KC</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>EB</given-names></name></person-group><article-title>Relationship between MMR vaccine and autism</article-title><source>Ann Pharmacother</source><year>2004</year><volume>38</volume><issue>7&#8211;8</issue><fpage>1297</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1345/aph.1D293</pub-id><pub-id pub-id-type="pmid">15173555</pub-id></element-citation></ref><ref id="CR116"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klemm</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Shakoor</surname><given-names>S</given-names></name><name name-style="western"><surname>Page</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Qamar</surname><given-names>FN</given-names></name><name name-style="western"><surname>Judge</surname><given-names>K</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>DK</given-names></name><name name-style="western"><surname>Wong</surname><given-names>VK</given-names></name><name name-style="western"><surname>Dallman</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S</given-names></name><name name-style="western"><surname>Shaheen</surname><given-names>G</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>S</given-names></name><name name-style="western"><surname>Yousafzai</surname><given-names>MT</given-names></name><name name-style="western"><surname>Saleem</surname><given-names>MK</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dougan</surname><given-names>G</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>R</given-names></name></person-group><article-title>Emergence of an extensively drug-resistant Salmonella enterica Serovar Typhi clone harboring a Promiscuous plasmid encoding resistance to Fluoroquinolones and third-generation Cephalosporins</article-title><source>Mbio</source><year>2018</year><pub-id pub-id-type="doi">10.1128/mBio.00105-18</pub-id><pub-id pub-id-type="pmcid">PMC5821095</pub-id><pub-id pub-id-type="pmid">29463654</pub-id></element-citation></ref><ref id="CR117"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>A</given-names></name><name name-style="western"><surname>Cox</surname><given-names>H</given-names></name><name name-style="western"><surname>Mizrahi</surname><given-names>V</given-names></name></person-group><article-title>Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment</article-title><source>Curr Opin Pharmacol</source><year>2018</year><volume>42</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2018.05.013</pub-id><pub-id pub-id-type="pmid">29885623</pub-id><pub-id pub-id-type="pmcid">PMC6219890</pub-id></element-citation></ref><ref id="CR118"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohanski</surname><given-names>MA</given-names></name><name name-style="western"><surname>Dwyer</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Collins</surname><given-names>JJ</given-names></name></person-group><article-title>How antibiotics kill bacteria: from targets to networks</article-title><source>Nat Rev Microbiol</source><year>2010</year><volume>8</volume><issue>6</issue><fpage>423</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2333</pub-id><pub-id pub-id-type="pmid">20440275</pub-id><pub-id pub-id-type="pmcid">PMC2896384</pub-id></element-citation></ref><ref id="CR119"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotloff</surname><given-names>KL</given-names></name><name name-style="western"><surname>Simon</surname><given-names>JK</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>MF</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>MB</given-names></name><name name-style="western"><surname>Wooden</surname><given-names>SL</given-names></name><name name-style="western"><surname>Livio</surname><given-names>S</given-names></name><name name-style="western"><surname>Nataro</surname><given-names>JP</given-names></name><name name-style="western"><surname>Blackwelder</surname><given-names>WC</given-names></name><name name-style="western"><surname>Barry</surname><given-names>EM</given-names></name><name name-style="western"><surname>Picking</surname><given-names>W</given-names></name><name name-style="western"><surname>Levine</surname><given-names>MM</given-names></name></person-group><article-title>Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media</article-title><source>Human Vaccine</source><year>2007</year><volume>3</volume><issue>6</issue><fpage>268</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.4161/hv.4746</pub-id><pub-id pub-id-type="pmid">17938573</pub-id></element-citation></ref><ref id="CR120"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotloff</surname><given-names>KL</given-names></name><name name-style="western"><surname>Nataro</surname><given-names>JP</given-names></name><name name-style="western"><surname>Blackwelder</surname><given-names>WC</given-names></name><name name-style="western"><surname>Nasrin</surname><given-names>D</given-names></name><name name-style="western"><surname>Farag</surname><given-names>TH</given-names></name><name name-style="western"><surname>Panchalingam</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sow</surname><given-names>SO</given-names></name><name name-style="western"><surname>Sur</surname><given-names>D</given-names></name><name name-style="western"><surname>Breiman</surname><given-names>RF</given-names></name><name name-style="western"><surname>Faruque</surname><given-names>AS</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>AK</given-names></name><name name-style="western"><surname>Saha</surname><given-names>D</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>PL</given-names></name><name name-style="western"><surname>Tamboura</surname><given-names>B</given-names></name><name name-style="western"><surname>Sanogo</surname><given-names>D</given-names></name><name name-style="western"><surname>Onwuchekwa</surname><given-names>U</given-names></name><name name-style="western"><surname>Manna</surname><given-names>B</given-names></name><name name-style="western"><surname>Ramamurthy</surname><given-names>T</given-names></name><name name-style="western"><surname>Kanungo</surname><given-names>S</given-names></name><name name-style="western"><surname>Ochieng</surname><given-names>JB</given-names></name><name name-style="western"><surname>Omore</surname><given-names>R</given-names></name><name name-style="western"><surname>Oundo</surname><given-names>JO</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>A</given-names></name><name name-style="western"><surname>Das</surname><given-names>SK</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>S</given-names></name><name name-style="western"><surname>Quadri</surname><given-names>F</given-names></name><name name-style="western"><surname>Adegbola</surname><given-names>RA</given-names></name><name name-style="western"><surname>Antonio</surname><given-names>M</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Akinsola</surname><given-names>A</given-names></name><name name-style="western"><surname>Mandomando</surname><given-names>I</given-names></name><name name-style="western"><surname>Nhampossa</surname><given-names>T</given-names></name><name name-style="western"><surname>Acacio</surname><given-names>S</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>K</given-names></name><name name-style="western"><surname>O&#8217;Reilly</surname><given-names>CE</given-names></name><name name-style="western"><surname>Mintz</surname><given-names>ED</given-names></name><name name-style="western"><surname>Berkeley</surname><given-names>LY</given-names></name><name name-style="western"><surname>Muhsen</surname><given-names>K</given-names></name><name name-style="western"><surname>Sommerfelt</surname><given-names>H</given-names></name><name name-style="western"><surname>Robins-Browne</surname><given-names>RM</given-names></name><name name-style="western"><surname>Levine</surname><given-names>MM</given-names></name></person-group><article-title>Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study</article-title><source>Lancet</source><year>2013</year><volume>382</volume><issue>9888</issue><fpage>209</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60844-2</pub-id><pub-id pub-id-type="pmid">23680352</pub-id></element-citation></ref><ref id="CR121"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuehne</surname><given-names>SA</given-names></name><name name-style="western"><surname>Cartman</surname><given-names>ST</given-names></name><name name-style="western"><surname>Heap</surname><given-names>JT</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>ML</given-names></name><name name-style="western"><surname>Cockayne</surname><given-names>A</given-names></name><name name-style="western"><surname>Minton</surname><given-names>NP</given-names></name></person-group><article-title>The role of toxin A and toxin B in Clostridium difficile infection</article-title><source>Nature</source><year>2010</year><volume>467</volume><issue>7316</issue><fpage>711</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1038/nature09397</pub-id><pub-id pub-id-type="pmid">20844489</pub-id></element-citation></ref><ref id="CR122"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwong</surname><given-names>JC</given-names></name><name name-style="western"><surname>Maaten</surname><given-names>S</given-names></name><name name-style="western"><surname>Upshur</surname><given-names>RE</given-names></name><name name-style="western"><surname>Patrick</surname><given-names>DM</given-names></name><name name-style="western"><surname>Marra</surname><given-names>F</given-names></name></person-group><article-title>The effect of universal influenza immunization on antibiotic prescriptions: an ecological study</article-title><source>Clin Infect Dis</source><year>2009</year><volume>49</volume><issue>5</issue><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1086/605087</pub-id><pub-id pub-id-type="pmid">19624280</pub-id></element-citation></ref><ref id="CR123"><mixed-citation publication-type="other">Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG, Active Bacterial Core Surveillance of the Emerging Infections Program N (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumonia. N Engl J Med 354(14): 1455&#8211;1463 10.1056/NEJMoa051642<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa051642</pub-id><pub-id pub-id-type="pmid">16598044</pub-id></mixed-citation></ref><ref id="CR124"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyne</surname><given-names>L</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>CP</given-names></name></person-group><article-title>Prospects for a vaccine for Clostridium difficile</article-title><source>BioDrugs</source><year>1998</year><volume>10</volume><issue>3</issue><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.2165/00063030-199810030-00001</pub-id><pub-id pub-id-type="pmid">18020593</pub-id></element-citation></ref><ref id="CR125"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyne</surname><given-names>L</given-names></name><name name-style="western"><surname>Warny</surname><given-names>M</given-names></name><name name-style="western"><surname>Qamar</surname><given-names>A</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>CP</given-names></name></person-group><article-title>Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea</article-title><source>Lancet</source><year>2001</year><volume>357</volume><issue>9251</issue><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)03592-3</pub-id><pub-id pub-id-type="pmid">11213096</pub-id></element-citation></ref><ref id="CR126"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>CC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>SH</given-names></name><name name-style="western"><surname>Liao</surname><given-names>CH</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>WH</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>PR</given-names></name></person-group><article-title>Decline in the incidence of invasive pneumococcal disease at a medical center in Taiwan, 2000&#8211;2012</article-title><source>BMC Infect Dis</source><year>2014</year><volume>14</volume><fpage>76</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-14-76</pub-id><pub-id pub-id-type="pmid">24512501</pub-id><pub-id pub-id-type="pmcid">PMC3927834</pub-id></element-citation></ref><ref id="CR127"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lancet</surname><given-names>T</given-names></name></person-group><article-title>National progress on antimicrobial resistance</article-title><source>Lancet</source><year>2017</year><volume>389</volume><issue>10084</issue><fpage>2082</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31433-2</pub-id><pub-id pub-id-type="pmid">28560991</pub-id></element-citation></ref><ref id="CR128"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langermann</surname><given-names>S</given-names></name><name name-style="western"><surname>Mollby</surname><given-names>R</given-names></name><name name-style="western"><surname>Burlein</surname><given-names>JE</given-names></name><name name-style="western"><surname>Palaszynski</surname><given-names>SR</given-names></name><name name-style="western"><surname>Auguste</surname><given-names>CG</given-names></name><name name-style="western"><surname>DeFusco</surname><given-names>A</given-names></name><name name-style="western"><surname>Strouse</surname><given-names>R</given-names></name><name name-style="western"><surname>Schenerman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Pinkner</surname><given-names>JS</given-names></name><name name-style="western"><surname>Winberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Guldevall</surname><given-names>L</given-names></name><name name-style="western"><surname>Soderhall</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Normark</surname><given-names>S</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>S</given-names></name></person-group><article-title>Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli</article-title><source>J Infect Dis</source><year>2000</year><volume>181</volume><issue>2</issue><fpage>774</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1086/315258</pub-id><pub-id pub-id-type="pmid">10669375</pub-id></element-citation></ref><ref id="CR129"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laurent-Ledru</surname><given-names>V</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>A</given-names></name><name name-style="western"><surname>Monsonego</surname><given-names>J</given-names></name></person-group><article-title>Civil society: a critical new advocate for vaccination in Europe</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>4</issue><fpage>624</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.11.004</pub-id><pub-id pub-id-type="pmid">21081178</pub-id></element-citation></ref><ref id="CR130"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laxminarayan</surname><given-names>R</given-names></name><name name-style="western"><surname>Matsoso</surname><given-names>P</given-names></name><name name-style="western"><surname>Pant</surname><given-names>S</given-names></name><name name-style="western"><surname>Brower</surname><given-names>C</given-names></name><name name-style="western"><surname>Rottingen</surname><given-names>JA</given-names></name><name name-style="western"><surname>Klugman</surname><given-names>K</given-names></name><name name-style="western"><surname>Davies</surname><given-names>S</given-names></name></person-group><article-title>Access to effective antimicrobials: a worldwide challenge</article-title><source>Lancet</source><year>2016</year><volume>387</volume><issue>10014</issue><fpage>168</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00474-2</pub-id><pub-id pub-id-type="pmid">26603918</pub-id></element-citation></ref><ref id="CR131"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leffler</surname><given-names>DA</given-names></name><name name-style="western"><surname>Lamont</surname><given-names>JT</given-names></name></person-group><article-title>Clostridium difficile infection</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>16</issue><fpage>1539</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1403772</pub-id><pub-id pub-id-type="pmid">25875259</pub-id></element-citation></ref><ref id="CR132"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>G</given-names></name><name name-style="western"><surname>Maes</surname><given-names>C</given-names></name><name name-style="western"><surname>Willekens</surname><given-names>J</given-names></name><name name-style="western"><surname>De Boever</surname><given-names>F</given-names></name><name name-style="western"><surname>de Rooij</surname><given-names>R</given-names></name><name name-style="western"><surname>Martell</surname><given-names>L</given-names></name><name name-style="western"><surname>Bedell</surname><given-names>L</given-names></name><name name-style="western"><surname>Wittke</surname><given-names>F</given-names></name><name name-style="western"><surname>Slobod</surname><given-names>K</given-names></name><name name-style="western"><surname>Dull</surname><given-names>P</given-names></name></person-group><article-title>A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><issue>15</issue><fpage>1786</fpage><lpage>1791</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.044</pub-id><pub-id pub-id-type="pmid">26928074</pub-id></element-citation></ref><ref id="CR133"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>G</given-names></name><name name-style="western"><surname>Bebia</surname><given-names>Z</given-names></name><name name-style="western"><surname>Maes</surname><given-names>C</given-names></name><name name-style="western"><surname>Aerssens</surname><given-names>A</given-names></name><name name-style="western"><surname>De Boever</surname><given-names>F</given-names></name><name name-style="western"><surname>Grassano</surname><given-names>L</given-names></name><name name-style="western"><surname>Buffi</surname><given-names>G</given-names></name><name name-style="western"><surname>Margarit</surname><given-names>I</given-names></name><name name-style="western"><surname>Karsten</surname><given-names>A</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S</given-names></name><name name-style="western"><surname>Slobod</surname><given-names>K</given-names></name><name name-style="western"><surname>Corsaro</surname><given-names>B</given-names></name><name name-style="western"><surname>Henry</surname><given-names>O</given-names></name></person-group><article-title>Safety and immunogenicity of a second dose of an investigational maternal trivalent Group B streptococcus vaccine in non-pregnant women 4&#8211;6 years after a first dose: results from a phase 2 trial</article-title><source>Clin Infect Dis</source><year>2019</year><pub-id pub-id-type="doi">10.1093/cid/ciz737</pub-id><pub-id pub-id-type="pmcid">PMC7286364</pub-id><pub-id pub-id-type="pmid">31394574</pub-id></element-citation></ref><ref id="CR134"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lessa</surname><given-names>FC</given-names></name><name name-style="western"><surname>Mu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bamberg</surname><given-names>WM</given-names></name><name name-style="western"><surname>Beldavs</surname><given-names>ZG</given-names></name><name name-style="western"><surname>Dumyati</surname><given-names>GK</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>JR</given-names></name><name name-style="western"><surname>Farley</surname><given-names>MM</given-names></name><name name-style="western"><surname>Holzbauer</surname><given-names>SM</given-names></name><name name-style="western"><surname>Meek</surname><given-names>JI</given-names></name><name name-style="western"><surname>Phipps</surname><given-names>EC</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>LE</given-names></name><name name-style="western"><surname>Winston</surname><given-names>LG</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></name><name name-style="western"><surname>Limbago</surname><given-names>BM</given-names></name><name name-style="western"><surname>Fridkin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Gerding</surname><given-names>DN</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>LC</given-names></name></person-group><article-title>Burden of Clostridium difficile infection in the United States</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>9</issue><fpage>825</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1408913</pub-id><pub-id pub-id-type="pmid">25714160</pub-id><pub-id pub-id-type="pmcid">PMC10966662</pub-id></element-citation></ref><ref id="CR135"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>MM</given-names></name><name name-style="western"><surname>Simon</surname><given-names>R</given-names></name></person-group><article-title>The gathering storm: is untreatable typhoid fever on the way?</article-title><source>Mbio</source><year>2018</year><pub-id pub-id-type="doi">10.1128/mBio.00482-18</pub-id><pub-id pub-id-type="pmcid">PMC5874914</pub-id><pub-id pub-id-type="pmid">29559573</pub-id></element-citation></ref><ref id="CR136"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>SB</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>B</given-names></name></person-group><article-title>Antibacterial resistance worldwide: causes, challenges and responses</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><issue>12 Suppl</issue><fpage>S122</fpage><lpage>S129</lpage><pub-id pub-id-type="doi">10.1038/nm1145</pub-id><pub-id pub-id-type="pmid">15577930</pub-id></element-citation></ref><ref id="CR137"><mixed-citation publication-type="other">Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F, Lopez P, Macias-Parra M, Ortega-Barria E, Rivera-Medina DM, Rivera L, Pavia-Ruz N, Nunez E, Damaso S, Ruiz-Palacios GM, De Vos B, O&#8217;Ryan M, Gillard P, Bouckenooghe A, Human Rotavirus Vaccine Study G (2008) Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 371(9619): 1181&#8211;1189 10.1016/S0140-6736(08)60524-3<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(08)60524-3</pub-id><pub-id pub-id-type="pmid">18395579</pub-id></mixed-citation></ref><ref id="CR138"><mixed-citation publication-type="other">Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, Group OPTCS (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364(5): 422&#8211;431 10.1056/NEJMoa0910812<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0910812</pub-id><pub-id pub-id-type="pmid">21288078</pub-id></mixed-citation></ref><ref id="CR139"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowy</surname><given-names>I</given-names></name><name name-style="western"><surname>Molrine</surname><given-names>DC</given-names></name><name name-style="western"><surname>Leav</surname><given-names>BA</given-names></name><name name-style="western"><surname>Blair</surname><given-names>BM</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>R</given-names></name><name name-style="western"><surname>Gerding</surname><given-names>DN</given-names></name><name name-style="western"><surname>Nichol</surname><given-names>G</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>WD</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Leney</surname><given-names>M</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>S</given-names></name><name name-style="western"><surname>Hay</surname><given-names>CA</given-names></name><name name-style="western"><surname>Ambrosino</surname><given-names>DM</given-names></name></person-group><article-title>Treatment with monoclonal antibodies against Clostridium difficile toxins</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>3</issue><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0907635</pub-id><pub-id pub-id-type="pmid">20089970</pub-id></element-citation></ref><ref id="CR140"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sui</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name></person-group><article-title>Epidemiology of Group B streptococcus isolated from pregnant women in Beijing</article-title><source>China Clin Microbiol Infect</source><year>2014</year><volume>20</volume><issue>6</issue><fpage>O370</fpage><lpage>O373</lpage><pub-id pub-id-type="doi">10.1111/1469-0691.12416</pub-id><pub-id pub-id-type="pmid">24118553</pub-id></element-citation></ref><ref id="CR141"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Klugman</surname><given-names>KP</given-names></name><name name-style="western"><surname>Vaccine Trialist</surname><given-names>G</given-names></name></person-group><article-title>A role for Streptococcus pneumoniae in virus-associated pneumonia</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><issue>8</issue><fpage>811</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1038/nm1077</pub-id><pub-id pub-id-type="pmid">15247911</pub-id><pub-id pub-id-type="pmcid">PMC7095883</pub-id></element-citation></ref><ref id="CR142"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magill</surname><given-names>SS</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>JR</given-names></name><name name-style="western"><surname>Bamberg</surname><given-names>W</given-names></name><name name-style="western"><surname>Beldavs</surname><given-names>ZG</given-names></name><name name-style="western"><surname>Dumyati</surname><given-names>G</given-names></name><name name-style="western"><surname>Kainer</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lynfield</surname><given-names>R</given-names></name><name name-style="western"><surname>Maloney</surname><given-names>M</given-names></name><name name-style="western"><surname>McAllister-Hollod</surname><given-names>L</given-names></name><name name-style="western"><surname>Nadle</surname><given-names>J</given-names></name><name name-style="western"><surname>Ray</surname><given-names>SM</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>DL</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>LE</given-names></name><name name-style="western"><surname>Fridkin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Healthcare-Associated</surname><given-names>EIP</given-names></name><name name-style="western"><surname>I, Antimicrobial Use Prevalence Survey T, </surname></name></person-group><article-title>Multistate point-prevalence survey of health care-associated infections</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>13</issue><fpage>1198</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1306801</pub-id><pub-id pub-id-type="pmid">24670166</pub-id><pub-id pub-id-type="pmcid">PMC4648343</pub-id></element-citation></ref><ref id="CR143"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancini</surname><given-names>F</given-names></name><name name-style="western"><surname>Monaci</surname><given-names>E</given-names></name><name name-style="western"><surname>Lofano</surname><given-names>G</given-names></name><name name-style="western"><surname>Torre</surname><given-names>A</given-names></name><name name-style="western"><surname>Bacconi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tavarini</surname><given-names>S</given-names></name><name name-style="western"><surname>Sammicheli</surname><given-names>C</given-names></name><name name-style="western"><surname>Arcidiacono</surname><given-names>L</given-names></name><name name-style="western"><surname>Galletti</surname><given-names>B</given-names></name><name name-style="western"><surname>Laera</surname><given-names>D</given-names></name><name name-style="western"><surname>Pallaoro</surname><given-names>M</given-names></name><name name-style="western"><surname>Tuscano</surname><given-names>G</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>MR</given-names></name><name name-style="western"><surname>Bensi</surname><given-names>G</given-names></name><name name-style="western"><surname>Grandi</surname><given-names>G</given-names></name><name name-style="western"><surname>Rossi-Paccani</surname><given-names>S</given-names></name><name name-style="western"><surname>Nuti</surname><given-names>S</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Soldaini</surname><given-names>E</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S</given-names></name></person-group><article-title>One dose of Staphylococcus aureus 4C-Staph vaccine formulated with a Novel TLR7-dependent adjuvant rapidly protects mice through antibodies, effector CD4+ T cells, and IL-17A</article-title><source>PLoS ONE</source><year>2016</year><pub-id pub-id-type="doi">10.1371/journal.pone.0147767</pub-id><pub-id pub-id-type="pmcid">PMC4727907</pub-id><pub-id pub-id-type="pmid">26812180</pub-id></element-citation></ref><ref id="CR144"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mani</surname><given-names>S</given-names></name><name name-style="western"><surname>Wierzba</surname><given-names>T</given-names></name><name name-style="western"><surname>Walker</surname><given-names>RI</given-names></name></person-group><article-title>Status of vaccine research and development for Shigella</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><issue>26</issue><fpage>2887</fpage><lpage>2894</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.075</pub-id><pub-id pub-id-type="pmid">26979135</pub-id></element-citation></ref><ref id="CR145"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchisio</surname><given-names>P</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>S</given-names></name><name name-style="western"><surname>Bianchini</surname><given-names>S</given-names></name><name name-style="western"><surname>Dusi</surname><given-names>E</given-names></name><name name-style="western"><surname>Fusi</surname><given-names>M</given-names></name><name name-style="western"><surname>Nazzari</surname><given-names>E</given-names></name><name name-style="western"><surname>Picchi</surname><given-names>R</given-names></name><name name-style="western"><surname>Galeone</surname><given-names>C</given-names></name><name name-style="western"><surname>Principi</surname><given-names>N</given-names></name></person-group><article-title>Efficacy of injectable trivalent virosomal-adjuvanted inactivated influenza vaccine in preventing acute otitis media in children with recurrent complicated or noncomplicated acute otitis media</article-title><source>Pediatr Infect Dis J</source><year>2009</year><volume>28</volume><issue>10</issue><fpage>855</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1097/INF.0b013e3181a487b4</pub-id><pub-id pub-id-type="pmid">19564812</pub-id></element-citation></ref><ref id="CR146"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marty</surname><given-names>FM</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>WW</given-names></name><name name-style="western"><surname>Wennersten</surname><given-names>CB</given-names></name><name name-style="western"><surname>Venkataraman</surname><given-names>L</given-names></name><name name-style="western"><surname>Albano</surname><given-names>E</given-names></name><name name-style="western"><surname>Alyea</surname><given-names>EP</given-names></name><name name-style="western"><surname>Gold</surname><given-names>HS</given-names></name><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>SK</given-names></name></person-group><article-title>Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis</article-title><source>J Clin Microbiol</source><year>2006</year><volume>44</volume><issue>2</issue><fpage>595</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1128/JCM.44.2.595-597.2006</pub-id><pub-id pub-id-type="pmid">16455920</pub-id><pub-id pub-id-type="pmcid">PMC1392688</pub-id></element-citation></ref><ref id="CR147"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonald</surname><given-names>LC</given-names></name><name name-style="western"><surname>Gerding</surname><given-names>DN</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S</given-names></name><name name-style="western"><surname>Bakken</surname><given-names>JS</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>KC</given-names></name><name name-style="western"><surname>Coffin</surname><given-names>SE</given-names></name><name name-style="western"><surname>Dubberke</surname><given-names>ER</given-names></name><name name-style="western"><surname>Garey</surname><given-names>KW</given-names></name><name name-style="western"><surname>Gould</surname><given-names>CV</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>C</given-names></name><name name-style="western"><surname>Loo</surname><given-names>V</given-names></name><name name-style="western"><surname>Shaklee Sammons</surname><given-names>J</given-names></name><name name-style="western"><surname>Sandora</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Wilcox</surname><given-names>MH</given-names></name></person-group><article-title>Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases Society of America (IDSA) and society for healthcare epidemiology of America (SHEA)</article-title><source>Clin Infect Dis</source><year>2018</year><volume>66</volume><issue>7</issue><fpage>987</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy149</pub-id><pub-id pub-id-type="pmid">29562266</pub-id></element-citation></ref><ref id="CR148"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McFarland</surname><given-names>LV</given-names></name></person-group><article-title>Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients</article-title><source>Am J Infect Control</source><year>1995</year><volume>23</volume><issue>5</issue><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/0196-6553(95)90060-8</pub-id><pub-id pub-id-type="pmid">8585641</pub-id></element-citation></ref><ref id="CR149"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGann</surname><given-names>P</given-names></name><name name-style="western"><surname>Snesrud</surname><given-names>E</given-names></name><name name-style="western"><surname>Maybank</surname><given-names>R</given-names></name><name name-style="western"><surname>Corey</surname><given-names>B</given-names></name><name name-style="western"><surname>Ong</surname><given-names>AC</given-names></name><name name-style="western"><surname>Clifford</surname><given-names>R</given-names></name><name name-style="western"><surname>Hinkle</surname><given-names>M</given-names></name><name name-style="western"><surname>Whitman</surname><given-names>T</given-names></name><name name-style="western"><surname>Lesho</surname><given-names>E</given-names></name><name name-style="western"><surname>Schaecher</surname><given-names>KE</given-names></name></person-group><article-title>Escherichia coli Harboring mcr-1 and blaCTX-M on a Novel IncF plasmid: first report of mcr-1 in the United States</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><issue>7</issue><fpage>4420</fpage><lpage>4421</lpage><pub-id pub-id-type="doi">10.1128/AAC.01103-16</pub-id><pub-id pub-id-type="pmid">27230792</pub-id><pub-id pub-id-type="pmcid">PMC4914657</pub-id></element-citation></ref><ref id="CR150"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKenzie</surname><given-names>R</given-names></name><name name-style="western"><surname>Walker</surname><given-names>RI</given-names></name><name name-style="western"><surname>Nabors</surname><given-names>GS</given-names></name><name name-style="western"><surname>Van De Verg</surname><given-names>LL</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>C</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>G</given-names></name><name name-style="western"><surname>Forbes</surname><given-names>E</given-names></name><name name-style="western"><surname>Tian</surname><given-names>JH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HH</given-names></name><name name-style="western"><surname>Pace</surname><given-names>JL</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Bourgeois</surname><given-names>AL</given-names></name></person-group><article-title>Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><issue>18</issue><fpage>3735</fpage><lpage>3745</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.07.014</pub-id><pub-id pub-id-type="pmid">16095766</pub-id></element-citation></ref><ref id="CR151"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLellan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Leung</surname><given-names>S</given-names></name><name name-style="western"><surname>Graepel</surname><given-names>KW</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Baxa</surname><given-names>U</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>E</given-names></name><name name-style="western"><surname>Beaumont</surname><given-names>T</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>PD</given-names></name><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name></person-group><article-title>Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody</article-title><source>Science</source><year>2013</year><volume>340</volume><issue>6136</issue><fpage>1113</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1126/science.1234914</pub-id><pub-id pub-id-type="pmid">23618766</pub-id><pub-id pub-id-type="pmcid">PMC4459498</pub-id></element-citation></ref><ref id="CR152"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeely</surname><given-names>TB</given-names></name><name name-style="western"><surname>Shah</surname><given-names>NA</given-names></name><name name-style="western"><surname>Fridman</surname><given-names>A</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A</given-names></name><name name-style="western"><surname>Hartzel</surname><given-names>JS</given-names></name><name name-style="western"><surname>Keshari</surname><given-names>RS</given-names></name><name name-style="western"><surname>Lupu</surname><given-names>F</given-names></name><name name-style="western"><surname>DiNubile</surname><given-names>MJ</given-names></name></person-group><article-title>Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S aureus infections: an analysis of possible contributing host factors</article-title><source>Human Vaccine Immunother</source><year>2014</year><volume>10</volume><issue>12</issue><fpage>3513</fpage><lpage>3516</lpage><pub-id pub-id-type="doi">10.4161/hv.34407</pub-id><pub-id pub-id-type="pmcid">PMC4514053</pub-id><pub-id pub-id-type="pmid">25483690</pub-id></element-citation></ref><ref id="CR153"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mertz</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TH</given-names></name><name name-style="western"><surname>Johnstone</surname><given-names>J</given-names></name><name name-style="western"><surname>Lam</surname><given-names>PP</given-names></name><name name-style="western"><surname>Science</surname><given-names>M</given-names></name><name name-style="western"><surname>Kuster</surname><given-names>SP</given-names></name><name name-style="western"><surname>Fadel</surname><given-names>SA</given-names></name><name name-style="western"><surname>Tran</surname><given-names>D</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>E</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>N</given-names></name><name name-style="western"><surname>Loeb</surname><given-names>M</given-names></name></person-group><article-title>Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis</article-title><source>BMJ</source><year>2013</year><pub-id pub-id-type="doi">10.1136/bmj.f5061</pub-id><pub-id pub-id-type="pmcid">PMC3805492</pub-id><pub-id pub-id-type="pmid">23974637</pub-id></element-citation></ref><ref id="CR154"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meynet</surname><given-names>E</given-names></name><name name-style="western"><surname>Laurin</surname><given-names>D</given-names></name><name name-style="western"><surname>Lenormand</surname><given-names>JL</given-names></name><name name-style="western"><surname>Camara</surname><given-names>B</given-names></name><name name-style="western"><surname>Toussaint</surname><given-names>B</given-names></name><name name-style="western"><surname>Le Gouellec</surname><given-names>A</given-names></name></person-group><article-title>Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><issue>14</issue><fpage>1893</fpage><lpage>1900</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.040</pub-id><pub-id pub-id-type="pmid">29506924</pub-id></element-citation></ref><ref id="CR155"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Micoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Rondini</surname><given-names>S</given-names></name><name name-style="western"><surname>Gavini</surname><given-names>M</given-names></name><name name-style="western"><surname>Lanzilao</surname><given-names>L</given-names></name><name name-style="western"><surname>Medaglini</surname><given-names>D</given-names></name><name name-style="western"><surname>Saul</surname><given-names>A</given-names></name><name name-style="western"><surname>Martin</surname><given-names>LB</given-names></name></person-group><article-title>O: 2-CRM(197) conjugates against Salmonella Paratyphi A</article-title><source>PLoS ONE</source><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0047039</pub-id><pub-id pub-id-type="pmcid">PMC3492368</pub-id><pub-id pub-id-type="pmid">23144798</pub-id></element-citation></ref><ref id="CR156"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miriagou</surname><given-names>V</given-names></name><name name-style="western"><surname>Tassios</surname><given-names>PT</given-names></name><name name-style="western"><surname>Legakis</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Tzouvelekis</surname><given-names>LS</given-names></name></person-group><article-title>Expanded-spectrum cephalosporin resistance in non-typhoid Salmonella</article-title><source>Int J Antimicrob Agents</source><year>2004</year><volume>23</volume><issue>6</issue><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2004.03.006</pub-id><pub-id pub-id-type="pmid">15194124</pub-id></element-citation></ref><ref id="CR157"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moffitt</surname><given-names>K</given-names></name><name name-style="western"><surname>Malley</surname><given-names>R</given-names></name></person-group><article-title>Rationale and prospects for novel pneumococcal vaccines</article-title><source>Hum Vaccin Immunother</source><year>2016</year><volume>12</volume><issue>2</issue><fpage>383</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1087625</pub-id><pub-id pub-id-type="pmid">26535755</pub-id><pub-id pub-id-type="pmcid">PMC5049723</pub-id></element-citation></ref><ref id="CR158"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mogasale</surname><given-names>V</given-names></name><name name-style="western"><surname>Maskery</surname><given-names>B</given-names></name><name name-style="western"><surname>Ochiai</surname><given-names>RL</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name><name name-style="western"><surname>Mogasale</surname><given-names>VV</given-names></name><name name-style="western"><surname>Ramani</surname><given-names>E</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YE</given-names></name><name name-style="western"><surname>Park</surname><given-names>JK</given-names></name><name name-style="western"><surname>Wierzba</surname><given-names>TF</given-names></name></person-group><article-title>Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment</article-title><source>Lancet Glob Health</source><year>2014</year><volume>2</volume><issue>10</issue><fpage>e570</fpage><lpage>e580</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(14)70301-8</pub-id><pub-id pub-id-type="pmid">25304633</pub-id></element-citation></ref><ref id="CR159"><mixed-citation publication-type="other">Mok W (2018) Vaccine investment strategy: short list. Gavi, The vaccine alliance. Board Meeting. Geneva, Switzerland, 6&#8211;7 June 2018, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gavi.org/about/governance/gavi-board/minutes/2018/6-june/">https://www.gavi.org/about/governance/gavi-board/minutes/2018/6-june/</ext-link>. Accessed 7 Oct 2019</mixed-citation></ref><ref id="CR160"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>DE</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>DW</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>SC</given-names></name></person-group><article-title>Secondary bacterial infections associated with Influenza pandemics</article-title><source>Front Microbiol</source><year>2017</year><volume>8</volume><fpage>1041</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.01041</pub-id><pub-id pub-id-type="pmid">28690590</pub-id><pub-id pub-id-type="pmcid">PMC5481322</pub-id></element-citation></ref><ref id="CR161"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moura</surname><given-names>I</given-names></name><name name-style="western"><surname>Spigaglia</surname><given-names>P</given-names></name><name name-style="western"><surname>Barbanti</surname><given-names>F</given-names></name><name name-style="western"><surname>Mastrantonio</surname><given-names>P</given-names></name></person-group><article-title>Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes</article-title><source>J Antimicrob Chemother</source><year>2013</year><volume>68</volume><issue>2</issue><fpage>362</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1093/jac/dks420</pub-id><pub-id pub-id-type="pmid">23104495</pub-id></element-citation></ref><ref id="CR162"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mousa</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kose</surname><given-names>N</given-names></name><name name-style="western"><surname>Matta</surname><given-names>P</given-names></name><name name-style="western"><surname>Gilchuk</surname><given-names>P</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein</article-title><source>Nat Microbiol</source><year>2017</year><volume>2</volume><fpage>16271</fpage><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.271</pub-id><pub-id pub-id-type="pmid">28134924</pub-id><pub-id pub-id-type="pmcid">PMC5463187</pub-id></element-citation></ref><ref id="CR163"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N&#8217;Cho</surname><given-names>HS</given-names></name><name name-style="western"><surname>Masunda</surname><given-names>KPE</given-names></name><name name-style="western"><surname>Mukeredzi</surname><given-names>I</given-names></name><name name-style="western"><surname>Manangazira</surname><given-names>P</given-names></name><name name-style="western"><surname>Govore</surname><given-names>E</given-names></name><name name-style="western"><surname>Duri</surname><given-names>C</given-names></name><name name-style="western"><surname>Aubert</surname><given-names>RD</given-names></name><name name-style="western"><surname>Martin</surname><given-names>H</given-names></name><name name-style="western"><surname>Gonese</surname><given-names>E</given-names></name><name name-style="western"><surname>Vere</surname><given-names>M</given-names></name><name name-style="western"><surname>Tippett Barr</surname><given-names>BA</given-names></name><name name-style="western"><surname>Balachandra</surname><given-names>S</given-names></name><name name-style="western"><surname>Strysko</surname><given-names>J</given-names></name><name name-style="western"><surname>Davis</surname><given-names>WW</given-names></name><name name-style="western"><surname>Appiah</surname><given-names>GD</given-names></name><name name-style="western"><surname>Mintz</surname><given-names>E</given-names></name></person-group><article-title>Notes from the field: typhoid fever outbreak&#8212;Harare, Zimbabwe, October 2017-February 2018</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2019</year><volume>68</volume><issue>2</issue><fpage>44</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6802a5</pub-id><pub-id pub-id-type="pmid">30653487</pub-id></element-citation></ref><ref id="CR164"><mixed-citation publication-type="other">National Institute of Allergy and Infectious Diseases (NIAID) (2016) Large-scale HIV vaccine trial to launch in South Africa. NIH-funded study will test safety, efficacy of vaccine regimen. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.niaid.nih.gov/news-events/large-scale-hiv-vaccine-trial-launch-south-africa">https://www.niaid.nih.gov/news-events/large-scale-hiv-vaccine-trial-launch-south-africa</ext-link>. Accessed 11 Jul 2019</mixed-citation></ref><ref id="CR165"><mixed-citation publication-type="other">National Vaccine Advisory Committee (2016) A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria: recommendations from the national vaccine advisory committee. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.hhs.gov/sites/default/files/nvpo/nvac/reports/nvac-antibioticresistance.pdf">https://www.hhs.gov/sites/default/files/nvpo/nvac/reports/nvac-antibioticresistance.pdf</ext-link>. Accessed 14 Sept 2019<pub-id pub-id-type="pmcid">PMC4716466</pub-id><pub-id pub-id-type="pmid">26843664</pub-id></mixed-citation></ref><ref id="CR166"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>MR</given-names></name><name name-style="western"><surname>Shanson</surname><given-names>DC</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>DA</given-names></name><name name-style="western"><surname>Gazzard</surname><given-names>BG</given-names></name></person-group><article-title>Salmonella, Campylobacter and Shigella in HIV-seropositive patients</article-title><source>AIDS</source><year>1992</year><volume>6</volume><issue>12</issue><fpage>1495</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1097/00002030-199212000-00012</pub-id><pub-id pub-id-type="pmid">1362879</pub-id></element-citation></ref><ref id="CR167"><mixed-citation publication-type="other">Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M, Team CS (2018) Prevention of M. tuberculosis infection with H4: IC31 vaccine or BCG revaccination. N Engl J Med 379(2): 138&#8211;149 10.1056/NEJMoa1714021<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1714021</pub-id><pub-id pub-id-type="pmcid">PMC5937161</pub-id><pub-id pub-id-type="pmid">29996082</pub-id></mixed-citation></ref><ref id="CR168"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nesta</surname><given-names>B</given-names></name><name name-style="western"><surname>Pizza</surname><given-names>M</given-names></name></person-group><article-title>Vaccines against Escherichia coli</article-title><source>Curr Top Microbiol Immunol</source><year>2018</year><volume>416</volume><fpage>213</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1007/82_2018_111</pub-id><pub-id pub-id-type="pmid">30062594</pub-id></element-citation></ref><ref id="CR169"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngwuta</surname><given-names>JO</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>M</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>HM</given-names></name><name name-style="western"><surname>Moin</surname><given-names>SM</given-names></name><name name-style="western"><surname>Killikelly</surname><given-names>AM</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>GY</given-names></name><name name-style="western"><surname>Druz</surname><given-names>A</given-names></name><name name-style="western"><surname>Georgiev</surname><given-names>IS</given-names></name><name name-style="western"><surname>Rundlet</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Sastry</surname><given-names>M</given-names></name><name name-style="western"><surname>Stewart-Jones</surname><given-names>GB</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Nason</surname><given-names>MC</given-names></name><name name-style="western"><surname>Capella</surname><given-names>C</given-names></name><name name-style="western"><surname>Peeples</surname><given-names>ME</given-names></name><name name-style="western"><surname>Ledgerwood</surname><given-names>JE</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>PD</given-names></name><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name></person-group><article-title>Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera</article-title><source>Sci Transl Med</source><year>2015</year><pub-id pub-id-type="doi">10.1126/scitranslmed.aac4241</pub-id><pub-id pub-id-type="pmcid">PMC4672383</pub-id><pub-id pub-id-type="pmid">26468324</pub-id></element-citation></ref><ref id="CR170"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nordmann</surname><given-names>P</given-names></name><name name-style="western"><surname>Naas</surname><given-names>T</given-names></name><name name-style="western"><surname>Poirel</surname><given-names>L</given-names></name></person-group><article-title>Global spread of Carbapenemase-producing Enterobacteriaceae</article-title><source>Emerg Infect Dis</source><year>2011</year><volume>17</volume><issue>10</issue><fpage>1791</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.3201/eid1710.110655</pub-id><pub-id pub-id-type="pmid">22000347</pub-id><pub-id pub-id-type="pmcid">PMC3310682</pub-id></element-citation></ref><ref id="CR171"><mixed-citation publication-type="other">O&#8217;Neill J (2014) Antimicrobial resistance: tackling a crisis for the health and wealth of nations. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1pdf">https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1pdf</ext-link>. Accessed 8 Jan 2020</mixed-citation></ref><ref id="CR172"><mixed-citation publication-type="other">O&#8217;Neill J (2016a) Tackling drug-resistant infections globally: Final report and recommendations. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.amr-review.org/sites/default/files/160518_Final%20paper_with%20coverpdf">https://www.amr-review.org/sites/default/files/160518_Final%20paper_with%20coverpdf</ext-link>. Accessed 18 Jun 2019</mixed-citation></ref><ref id="CR173"><mixed-citation publication-type="other">O&#8217;Neill J (2016b) Vaccines and alternative appoaches: Reducing our dependence on antimicrobials. The review on antimicrobial resistance. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.amr-review.org/sites/default/files/Vaccines%20and%20alternatives_v4_LRpdf">https://www.amr-review.org/sites/default/files/Vaccines%20and%20alternatives_v4_LRpdf</ext-link>. Accessed 17 Jun 2019</mixed-citation></ref><ref id="CR174"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obiero</surname><given-names>CW</given-names></name><name name-style="western"><surname>Ndiaye</surname><given-names>AGW</given-names></name><name name-style="western"><surname>Scire</surname><given-names>AS</given-names></name><name name-style="western"><surname>Kaunyangi</surname><given-names>BM</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>E</given-names></name><name name-style="western"><surname>Gone</surname><given-names>AM</given-names></name><name name-style="western"><surname>Schutte</surname><given-names>LD</given-names></name><name name-style="western"><surname>Riccucci</surname><given-names>D</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>J</given-names></name><name name-style="western"><surname>Saul</surname><given-names>A</given-names></name><name name-style="western"><surname>Martin</surname><given-names>LB</given-names></name><name name-style="western"><surname>Bejon</surname><given-names>P</given-names></name><name name-style="western"><surname>Njuguna</surname><given-names>P</given-names></name><name name-style="western"><surname>Podda</surname><given-names>A</given-names></name></person-group><article-title>A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a Shigellosis-Endemic Country</article-title><source>Front Immunol</source><year>2017</year><pub-id pub-id-type="doi">10.3389/fimmu.2017.01884</pub-id><pub-id pub-id-type="pmcid">PMC5763125</pub-id><pub-id pub-id-type="pmid">29375556</pub-id></element-citation></ref><ref id="CR175"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olaru</surname><given-names>ID</given-names></name><name name-style="western"><surname>Mtapuri-Zinyowera</surname><given-names>S</given-names></name><name name-style="western"><surname>Feasey</surname><given-names>N</given-names></name><name name-style="western"><surname>Ferrand</surname><given-names>RA</given-names></name><name name-style="western"><surname>Kranzer</surname><given-names>K</given-names></name></person-group><article-title>Typhoid Vi-conjugate vaccine for outbreak control in Zimbabwe</article-title><source>Lancet Infect Dis</source><year>2019</year><volume>19</volume><issue>9</issue><fpage>930</fpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30425-6</pub-id><pub-id pub-id-type="pmid">31478515</pub-id></element-citation></ref><ref id="CR176"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orr</surname><given-names>N</given-names></name><name name-style="western"><surname>Katz</surname><given-names>DE</given-names></name><name name-style="western"><surname>Atsmon</surname><given-names>J</given-names></name><name name-style="western"><surname>Radu</surname><given-names>P</given-names></name><name name-style="western"><surname>Yavzori</surname><given-names>M</given-names></name><name name-style="western"><surname>Halperin</surname><given-names>T</given-names></name><name name-style="western"><surname>Sela</surname><given-names>T</given-names></name><name name-style="western"><surname>Kayouf</surname><given-names>R</given-names></name><name name-style="western"><surname>Klein</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ambar</surname><given-names>R</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>MK</given-names></name><name name-style="western"><surname>Venkatesan</surname><given-names>MM</given-names></name><name name-style="western"><surname>Hale</surname><given-names>TL</given-names></name></person-group><article-title>Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers</article-title><source>Infect Immun</source><year>2005</year><volume>73</volume><issue>12</issue><fpage>8027</fpage><lpage>8032</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.12.8027-8032.2005</pub-id><pub-id pub-id-type="pmid">16299296</pub-id><pub-id pub-id-type="pmcid">PMC1307051</pub-id></element-citation></ref><ref id="CR177"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozgur</surname><given-names>SK</given-names></name><name name-style="western"><surname>Beyazova</surname><given-names>U</given-names></name><name name-style="western"><surname>Kemaloglu</surname><given-names>YK</given-names></name><name name-style="western"><surname>Maral</surname><given-names>I</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>F</given-names></name><name name-style="western"><surname>Camurdan</surname><given-names>AD</given-names></name><name name-style="western"><surname>Kizil</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dinc</surname><given-names>E</given-names></name><name name-style="western"><surname>Tuzun</surname><given-names>H</given-names></name></person-group><article-title>Effectiveness of inactivated influenza vaccine for prevention of otitis media in children</article-title><source>Pediatr Infect Dis J</source><year>2006</year><volume>25</volume><issue>5</issue><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1097/01.inf.0000217370.83948.51</pub-id><pub-id pub-id-type="pmid">16645502</pub-id></element-citation></ref><ref id="CR178"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parry</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>I</given-names></name><name name-style="western"><surname>Walia</surname><given-names>K</given-names></name><name name-style="western"><surname>Rupali</surname><given-names>P</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S</given-names></name><name name-style="western"><surname>Basnyat</surname><given-names>B</given-names></name></person-group><article-title>Multidrug resistant enteric fever in South Asia: unmet medical needs and opportunities</article-title><source>BMJ</source><year>2019</year><pub-id pub-id-type="doi">10.1136/bmj.k5322</pub-id><pub-id pub-id-type="pmcid">PMC6340381</pub-id><pub-id pub-id-type="pmid">30670452</pub-id></element-citation></ref><ref id="CR179"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>MM</given-names></name><name name-style="western"><surname>Steele</surname><given-names>D</given-names></name><name name-style="western"><surname>Gentsch</surname><given-names>JR</given-names></name><name name-style="western"><surname>Wecker</surname><given-names>J</given-names></name><name name-style="western"><surname>Glass</surname><given-names>RI</given-names></name><name name-style="western"><surname>Parashar</surname><given-names>UD</given-names></name></person-group><article-title>Real-world impact of rotavirus vaccination</article-title><source>Pediatr Infect Dis J</source><year>2011</year><volume>30</volume><issue>1 Suppl</issue><fpage>S1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/INF.0b013e3181fefa1f</pub-id><pub-id pub-id-type="pmid">21183833</pub-id></element-citation></ref><ref id="CR180"><mixed-citation publication-type="other">PATH (2019) RSV vaccine and mAb snapshot. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pathazureedge.net/media/documents/RSV-snapshot-2019_08_28_High_Resolution_PDFpdf">https://pathazureedge.net/media/documents/RSV-snapshot-2019_08_28_High_Resolution_PDFpdf</ext-link>. Accessed 17 Oct 2019</mixed-citation></ref><ref id="CR181"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peltola</surname><given-names>H</given-names></name><name name-style="western"><surname>Rod</surname><given-names>TO</given-names></name><name name-style="western"><surname>Jonsdottir</surname><given-names>K</given-names></name><name name-style="western"><surname>Bottiger</surname><given-names>M</given-names></name><name name-style="western"><surname>Coolidge</surname><given-names>JA</given-names></name></person-group><article-title>Life-threatening Haemophilus influenzae infections in Scandinavia: a five-country analysis of the incidence and the main clinical and bacteriologic characteristics</article-title><source>Rev Infect Dis</source><year>1990</year><volume>12</volume><issue>4</issue><fpage>708</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1093/clinids/12.4.708</pub-id><pub-id pub-id-type="pmid">2385772</pub-id></element-citation></ref><ref id="CR182"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peltola</surname><given-names>H</given-names></name><name name-style="western"><surname>Aavitsland</surname><given-names>P</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>KG</given-names></name><name name-style="western"><surname>Jonsdottir</surname><given-names>KE</given-names></name><name name-style="western"><surname>Nokleby</surname><given-names>H</given-names></name><name name-style="western"><surname>Romanus</surname><given-names>V</given-names></name></person-group><article-title>Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia</article-title><source>J Infect Dis</source><year>1999</year><volume>179</volume><issue>1</issue><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1086/314535</pub-id><pub-id pub-id-type="pmid">9841843</pub-id></element-citation></ref><ref id="CR183"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jin</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HB</given-names></name><name name-style="western"><surname>Stratton</surname><given-names>CW</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B</given-names></name><name name-style="western"><surname>Tang</surname><given-names>YW</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name></person-group><article-title>Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing</article-title><source>J Clin Microbiol</source><year>2017</year><volume>55</volume><issue>7</issue><fpage>1998</fpage><lpage>2008</lpage><pub-id pub-id-type="doi">10.1128/JCM.02250-16</pub-id><pub-id pub-id-type="pmid">28404671</pub-id><pub-id pub-id-type="pmcid">PMC5483901</pub-id></element-citation></ref><ref id="CR184"><mixed-citation publication-type="other">Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M, team T-s (2018) Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med 6(4): 287&#8211;298 10.1016/S2213-2600(18)30077-8<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(18)30077-8</pub-id><pub-id pub-id-type="pmid">29595510</pub-id></mixed-citation></ref><ref id="CR185"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pepin</surname><given-names>J</given-names></name><name name-style="western"><surname>Valiquette</surname><given-names>L</given-names></name><name name-style="western"><surname>Cossette</surname><given-names>B</given-names></name></person-group><article-title>Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec</article-title><source>CMAJ</source><year>2005</year><volume>173</volume><issue>9</issue><fpage>1037</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1503/cmaj.050978</pub-id><pub-id pub-id-type="pmid">16179431</pub-id><pub-id pub-id-type="pmcid">PMC1266326</pub-id></element-citation></ref><ref id="CR186"><mixed-citation publication-type="other">Pfizer (2018) Independent data monitoring committee recommends discontinuation of the phase 2b STRIVE clinical trial of staphylococcus aureus vaccine following planned interim analysis. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/independent_data_monitoring_committee_recommends_discontinuation_of_the_phase_2b_strive_clinical_trial_of_staphylococcus_aureus_vaccine_following_planned_interim_analysis">https://www.pfizer.com/news/press-release/press-release-detail/independent_data_monitoring_committee_recommends_discontinuation_of_the_phase_2b_strive_clinical_trial_of_staphylococcus_aureus_vaccine_following_planned_interim_analysis</ext-link>. Accessed 21 Aug 2019</mixed-citation></ref><ref id="CR187"><mixed-citation publication-type="other">Pfizer (2021) PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine). Prescribing information. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/149987/download">https://www.fda.gov/media/149987/download</ext-link>. Accessed 13 June, 2021</mixed-citation></ref><ref id="CR188"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilishvili</surname><given-names>T</given-names></name><name name-style="western"><surname>Lexau</surname><given-names>C</given-names></name><name name-style="western"><surname>Farley</surname><given-names>MM</given-names></name><name name-style="western"><surname>Hadler</surname><given-names>J</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>LH</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>NM</given-names></name><name name-style="western"><surname>Reingold</surname><given-names>A</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Schaffner</surname><given-names>W</given-names></name><name name-style="western"><surname>Craig</surname><given-names>AS</given-names></name><name name-style="western"><surname>Smith</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Beall</surname><given-names>BW</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>CG</given-names></name><name name-style="western"><surname>Moore</surname><given-names>MR</given-names></name><name name-style="western"><surname>Surveillance</surname><given-names>ABC</given-names></name><name name-style="western"><surname>Emerging Infections Program</surname><given-names>N</given-names></name></person-group><article-title>Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine</article-title><source>J Infect Dis</source><year>2010</year><volume>201</volume><issue>1</issue><fpage>32</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1086/648593</pub-id><pub-id pub-id-type="pmid">19947881</pub-id></element-citation></ref><ref id="CR189"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polage</surname><given-names>CR</given-names></name><name name-style="western"><surname>Gyorke</surname><given-names>CE</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>MA</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>JL</given-names></name><name name-style="western"><surname>Chin</surname><given-names>DL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>HH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>Tang</surname><given-names>YW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>LW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>S</given-names></name><name name-style="western"><surname>Romano</surname><given-names>PS</given-names></name><name name-style="western"><surname>Panacek</surname><given-names>EA</given-names></name><name name-style="western"><surname>Goodell</surname><given-names>PB</given-names></name><name name-style="western"><surname>Solnick</surname><given-names>JV</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>SH</given-names></name></person-group><article-title>Overdiagnosis of clostridium difficile infection in the molecular test era</article-title><source>JAMA Intern Med</source><year>2015</year><volume>175</volume><issue>11</issue><fpage>1792</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2015.4114</pub-id><pub-id pub-id-type="pmid">26348734</pub-id><pub-id pub-id-type="pmcid">PMC4948649</pub-id></element-citation></ref><ref id="CR190"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>SL</given-names></name><name name-style="western"><surname>Malpica-Llanos</surname><given-names>T</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>IK</given-names></name><name name-style="western"><surname>Fischer-Walker</surname><given-names>C</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>S</given-names></name><name name-style="western"><surname>Walker</surname><given-names>N</given-names></name></person-group><article-title>Estimating the herd immunity effect of rotavirus vaccine</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><issue>32</issue><fpage>3795</fpage><lpage>3800</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.06.064</pub-id><pub-id pub-id-type="pmid">26116250</pub-id></element-citation></ref><ref id="CR191"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polsky</surname><given-names>B</given-names></name><name name-style="western"><surname>Gold</surname><given-names>JW</given-names></name><name name-style="western"><surname>Whimbey</surname><given-names>E</given-names></name><name name-style="western"><surname>Dryjanski</surname><given-names>J</given-names></name><name name-style="western"><surname>Brown</surname><given-names>AE</given-names></name><name name-style="western"><surname>Schiffman</surname><given-names>G</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>D</given-names></name></person-group><article-title>Bacterial pneumonia in patients with the acquired immunodeficiency syndrome</article-title><source>Ann Intern Med</source><year>1986</year><volume>104</volume><issue>1</issue><fpage>38</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-104-1-38</pub-id><pub-id pub-id-type="pmid">3484420</pub-id></element-citation></ref><ref id="CR192"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poolman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Wacker</surname><given-names>M</given-names></name></person-group><article-title>Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field</article-title><source>J Infect Dis</source><year>2016</year><volume>213</volume><issue>1</issue><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv429</pub-id><pub-id pub-id-type="pmid">26333944</pub-id><pub-id pub-id-type="pmcid">PMC4676548</pub-id></element-citation></ref><ref id="CR193"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasso</surname><given-names>JE</given-names></name><name name-style="western"><surname>Deng</surname><given-names>JC</given-names></name></person-group><article-title>Postviral complications: bacterial pneumonia</article-title><source>Clin Chest Med</source><year>2017</year><volume>38</volume><issue>1</issue><fpage>127</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.ccm.2016.11.006</pub-id><pub-id pub-id-type="pmid">28159155</pub-id><pub-id pub-id-type="pmcid">PMC5324726</pub-id></element-citation></ref><ref id="CR194"><mixed-citation publication-type="other">Pray L (2008) Antibiotic R&amp;D: resolving the paradox between unmet medical need and commercial incentive. Needham, MA: Cambridge Healthtech Institute</mixed-citation></ref><ref id="CR195"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prymula</surname><given-names>R</given-names></name><name name-style="western"><surname>Szenborn</surname><given-names>L</given-names></name><name name-style="western"><surname>Silfverdal</surname><given-names>SA</given-names></name><name name-style="western"><surname>Wysocki</surname><given-names>J</given-names></name><name name-style="western"><surname>Albrecht</surname><given-names>P</given-names></name><name name-style="western"><surname>Traskine</surname><given-names>M</given-names></name><name name-style="western"><surname>Gardev</surname><given-names>A</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Borys</surname><given-names>D</given-names></name></person-group><article-title>Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: results from a randomized phase II study in infants</article-title><source>Vaccine</source><year>2017</year><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.07.008</pub-id><pub-id pub-id-type="pmid">28729019</pub-id></element-citation></ref><ref id="CR196"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qamar</surname><given-names>FN</given-names></name><name name-style="western"><surname>Yousafzai</surname><given-names>MT</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>M</given-names></name><name name-style="western"><surname>Kazi</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lohana</surname><given-names>H</given-names></name><name name-style="western"><surname>Karim</surname><given-names>S</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A</given-names></name><name name-style="western"><surname>Hotwani</surname><given-names>A</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>S</given-names></name><name name-style="western"><surname>Kabir</surname><given-names>F</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>F</given-names></name><name name-style="western"><surname>Memon</surname><given-names>NM</given-names></name><name name-style="western"><surname>Domki</surname><given-names>MH</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>R</given-names></name></person-group><article-title>Outbreak investigation of ceftriaxone-resistant Salmonella enterica serotype Typhi and its risk factors among the general population in Hyderabad, Pakistan: a matched case-control study</article-title><source>Lancet Infect Dis</source><year>2018</year><volume>18</volume><issue>12</issue><fpage>1368</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30483-3</pub-id><pub-id pub-id-type="pmid">30507460</pub-id></element-citation></ref><ref id="CR197"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raviglione</surname><given-names>M</given-names></name><name name-style="western"><surname>Marais</surname><given-names>B</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>K</given-names></name><name name-style="western"><surname>Lonnroth</surname><given-names>K</given-names></name><name name-style="western"><surname>Getahun</surname><given-names>H</given-names></name><name name-style="western"><surname>Migliori</surname><given-names>GB</given-names></name><name name-style="western"><surname>Harries</surname><given-names>AD</given-names></name><name name-style="western"><surname>Nunn</surname><given-names>P</given-names></name><name name-style="western"><surname>Lienhardt</surname><given-names>C</given-names></name><name name-style="western"><surname>Graham</surname><given-names>S</given-names></name><name name-style="western"><surname>Chakaya</surname><given-names>J</given-names></name><name name-style="western"><surname>Weyer</surname><given-names>K</given-names></name><name name-style="western"><surname>Cole</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>SH</given-names></name><name name-style="western"><surname>Zumla</surname><given-names>A</given-names></name></person-group><article-title>Scaling up interventions to achieve global tuberculosis control: progress and new developments</article-title><source>Lancet</source><year>2012</year><volume>379</volume><issue>9829</issue><fpage>1902</fpage><lpage>1913</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60727-2</pub-id><pub-id pub-id-type="pmid">22608339</pub-id></element-citation></ref><ref id="CR198"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rello</surname><given-names>J</given-names></name><name name-style="western"><surname>Krenn</surname><given-names>CG</given-names></name><name name-style="western"><surname>Locker</surname><given-names>G</given-names></name><name name-style="western"><surname>Pilger</surname><given-names>E</given-names></name><name name-style="western"><surname>Madl</surname><given-names>C</given-names></name><name name-style="western"><surname>Balica</surname><given-names>L</given-names></name><name name-style="western"><surname>Dugernier</surname><given-names>T</given-names></name><name name-style="western"><surname>Laterre</surname><given-names>PF</given-names></name><name name-style="western"><surname>Spapen</surname><given-names>H</given-names></name><name name-style="western"><surname>Depuydt</surname><given-names>P</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bogar</surname><given-names>L</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Volgyes</surname><given-names>B</given-names></name><name name-style="western"><surname>Manez</surname><given-names>R</given-names></name><name name-style="western"><surname>Cakar</surname><given-names>N</given-names></name><name name-style="western"><surname>Ramazanoglu</surname><given-names>A</given-names></name><name name-style="western"><surname>Topeli</surname><given-names>A</given-names></name><name name-style="western"><surname>Mastruzzo</surname><given-names>MA</given-names></name><name name-style="western"><surname>Jasovich</surname><given-names>A</given-names></name><name name-style="western"><surname>Remolif</surname><given-names>CG</given-names></name><name name-style="western"><surname>Del Carmen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Andresen Hernandez</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ruiz Balart</surname><given-names>C</given-names></name><name name-style="western"><surname>Kremer</surname><given-names>I</given-names></name><name name-style="western"><surname>Molnar</surname><given-names>Z</given-names></name><name name-style="western"><surname>von Sonnenburg</surname><given-names>F</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>A</given-names></name><name name-style="western"><surname>Joannidis</surname><given-names>M</given-names></name><name name-style="western"><surname>Burgmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Welte</surname><given-names>T</given-names></name><name name-style="western"><surname>Klingler</surname><given-names>A</given-names></name><name name-style="western"><surname>Hochreiter</surname><given-names>R</given-names></name><name name-style="western"><surname>Westritschnig</surname><given-names>K</given-names></name></person-group><article-title>A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients</article-title><source>Crit Care</source><year>2017</year><volume>21</volume><issue>1</issue><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/s13054-017-1601-9</pub-id><pub-id pub-id-type="pmid">28159015</pub-id><pub-id pub-id-type="pmcid">PMC5291979</pub-id></element-citation></ref><ref id="CR199"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaewkungwal</surname><given-names>J</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>J</given-names></name><name name-style="western"><surname>Paris</surname><given-names>R</given-names></name><name name-style="western"><surname>Premsri</surname><given-names>N</given-names></name><name name-style="western"><surname>Namwat</surname><given-names>C</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>M</given-names></name><name name-style="western"><surname>Adams</surname><given-names>E</given-names></name><name name-style="western"><surname>Benenson</surname><given-names>M</given-names></name><name name-style="western"><surname>Gurunathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Tartaglia</surname><given-names>J</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>JG</given-names></name><name name-style="western"><surname>Francis</surname><given-names>DP</given-names></name><name name-style="western"><surname>Stablein</surname><given-names>D</given-names></name><name name-style="western"><surname>Birx</surname><given-names>DL</given-names></name><name name-style="western"><surname>Chunsuttiwat</surname><given-names>S</given-names></name><name name-style="western"><surname>Khamboonruang</surname><given-names>C</given-names></name><name name-style="western"><surname>Thongcharoen</surname><given-names>P</given-names></name><name name-style="western"><surname>Robb</surname><given-names>ML</given-names></name><name name-style="western"><surname>Michael</surname><given-names>NL</given-names></name><name name-style="western"><surname>Kunasol</surname><given-names>P</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Investigators</surname><given-names>M-T</given-names></name></person-group><article-title>Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><issue>23</issue><fpage>2209</fpage><lpage>2220</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0908492</pub-id><pub-id pub-id-type="pmid">19843557</pub-id></element-citation></ref><ref id="CR200"><mixed-citation publication-type="other">Review on Antimicrobial Resistance (2016) Declaration by the pharmaceutical, biotechnology and diagnostics industries on combating antimicrobial resistance. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.amr-review.org/sites/default/files/Declaration_of_Support_for_Combating_AMR_Jan_2016pdf">https://www.amr-review.org/sites/default/files/Declaration_of_Support_for_Combating_AMR_Jan_2016pdf</ext-link>. Accessed 16 Jun 2019</mixed-citation></ref><ref id="CR201"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rey-Jurado</surname><given-names>E</given-names></name><name name-style="western"><surname>Kalergis</surname><given-names>AM</given-names></name></person-group><article-title>Immunological features of respiratory syncytial virus-caused pneumonia-implications for vaccine design</article-title><source>Int J Mol Sci</source><year>2017</year><pub-id pub-id-type="doi">10.3390/ijms18030556</pub-id><pub-id pub-id-type="pmcid">PMC5372572</pub-id><pub-id pub-id-type="pmid">28273842</pub-id></element-citation></ref><ref id="CR202"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riddle</surname><given-names>MS</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>RW</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C</given-names></name><name name-style="western"><surname>Porter</surname><given-names>C</given-names></name><name name-style="western"><surname>Baqar</surname><given-names>S</given-names></name><name name-style="western"><surname>Kordis</surname><given-names>A</given-names></name><name name-style="western"><surname>Gilliland</surname><given-names>T</given-names></name><name name-style="western"><surname>Lapa</surname><given-names>J</given-names></name><name name-style="western"><surname>Coughlin</surname><given-names>M</given-names></name><name name-style="western"><surname>Soltis</surname><given-names>C</given-names></name><name name-style="western"><surname>Jones</surname><given-names>E</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>J</given-names></name><name name-style="western"><surname>Keiser</surname><given-names>PB</given-names></name><name name-style="western"><surname>Ranallo</surname><given-names>RT</given-names></name><name name-style="western"><surname>Gormley</surname><given-names>R</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M</given-names></name><name name-style="western"><surname>Turbyfill</surname><given-names>KR</given-names></name><name name-style="western"><surname>Tribble</surname><given-names>D</given-names></name><name name-style="western"><surname>Oaks</surname><given-names>EV</given-names></name></person-group><article-title>Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>40</issue><fpage>7009</fpage><lpage>7019</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.033</pub-id><pub-id pub-id-type="pmid">21787825</pub-id></element-citation></ref><ref id="CR203"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riddle</surname><given-names>MS</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>RW</given-names></name><name name-style="western"><surname>Di Paolo</surname><given-names>C</given-names></name><name name-style="western"><surname>Porter</surname><given-names>CK</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>RL</given-names></name><name name-style="western"><surname>Clarkson</surname><given-names>KA</given-names></name><name name-style="western"><surname>Weerts</surname><given-names>HE</given-names></name><name name-style="western"><surname>Duplessis</surname><given-names>C</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>A</given-names></name><name name-style="western"><surname>Alaimo</surname><given-names>C</given-names></name><name name-style="western"><surname>Paolino</surname><given-names>K</given-names></name><name name-style="western"><surname>Gormley</surname><given-names>R</given-names></name><name name-style="western"><surname>Gambillara Fonck</surname><given-names>V</given-names></name></person-group><article-title>Safety and immunogenicity of a candidate bioconjugate vaccine against shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study</article-title><source>Clin Vaccine Immunol</source><year>2016</year><volume>23</volume><issue>12</issue><fpage>908</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1128/CVI.00224-16</pub-id><pub-id pub-id-type="pmid">27581434</pub-id><pub-id pub-id-type="pmcid">PMC5139601</pub-id></element-citation></ref><ref id="CR204"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>F</given-names></name><name name-style="western"><surname>Roovers</surname><given-names>S</given-names></name><name name-style="western"><surname>Fano</surname><given-names>M</given-names></name><name name-style="western"><surname>Harloff-Helleberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Kirkensgaard</surname><given-names>JJK</given-names></name><name name-style="western"><surname>Hejnaes</surname><given-names>K</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>P</given-names></name><name name-style="western"><surname>Foged</surname><given-names>C</given-names></name></person-group><article-title>Temperature-induced self-assembly of the Group B Streptococcus (GBS) fusion antigen GBS-NN</article-title><source>Mol Pharm</source><year>2018</year><volume>15</volume><issue>7</issue><fpage>2584</fpage><lpage>2593</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00101</pub-id><pub-id pub-id-type="pmid">29745668</pub-id></element-citation></ref><ref id="CR205"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>S</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>S</given-names></name><name name-style="western"><surname>Tariq</surname><given-names>R</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>AN</given-names></name><name name-style="western"><surname>Tosh</surname><given-names>PK</given-names></name><name name-style="western"><surname>Pardi</surname><given-names>DS</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>S</given-names></name></person-group><article-title>Increasing antibiotic resistance in Clostridioides difficile: a systematic review and meta-analysis</article-title><source>Anaerobe</source><year>2019</year><volume>58</volume><fpage>35</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.anaerobe.2019.102072</pub-id><pub-id pub-id-type="pmid">31330183</pub-id></element-citation></ref><ref id="CR206"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahastrabuddhe</surname><given-names>S</given-names></name><name name-style="western"><surname>Saluja</surname><given-names>T</given-names></name></person-group><article-title>Overview of the typhoid conjugate vaccine pipeline: current status and future plans</article-title><source>Clin Infect Dis</source><year>2019</year><volume>68</volume><issue>Supplement_1</issue><fpage>S22</fpage><lpage>S26</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy884</pub-id><pub-id pub-id-type="pmid">30767002</pub-id><pub-id pub-id-type="pmcid">PMC6376107</pub-id></element-citation></ref><ref id="CR207"><mixed-citation publication-type="other">Sanchez TH, Brooks JT, Sullivan PS, Juhasz M, Mintz E, Dworkin MS, Jones JL, Adult/Adolescent Spectrum of HIVDSG (2005) Bacterial diarrhea in persons with HIV infection, United States, 1992&#8211;2002. Clin Infect Dis 41(11): 1621&#8211;1627 10.1086/498027<pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/498027</pub-id><pub-id pub-id-type="pmid">16267735</pub-id></mixed-citation></ref><ref id="CR208"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sastry</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><name name-style="western"><surname>Kong</surname><given-names>WP</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>GY</given-names></name><name name-style="western"><surname>Ko</surname><given-names>K</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Silacci</surname><given-names>C</given-names></name><name name-style="western"><surname>Thom</surname><given-names>M</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>AM</given-names></name><name name-style="western"><surname>Corti</surname><given-names>D</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>G</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></name><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>PD</given-names></name></person-group><article-title>Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus</article-title><source>PLoS ONE</source><year>2017</year><pub-id pub-id-type="doi">10.1371/journal.pone.0186854</pub-id><pub-id pub-id-type="pmcid">PMC5658087</pub-id><pub-id pub-id-type="pmid">29073183</pub-id></element-citation></ref><ref id="CR209"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>CS</given-names></name><name name-style="western"><surname>White</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Filler</surname><given-names>SG</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yeaman</surname><given-names>MR</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Hennessey</surname><given-names>JP</given-names><suffix>Jr</suffix></name></person-group><article-title>NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><issue>52</issue><fpage>7594</fpage><lpage>7600</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.038</pub-id><pub-id pub-id-type="pmid">23099329</pub-id><pub-id pub-id-type="pmcid">PMC3513491</pub-id></element-citation></ref><ref id="CR210"><mixed-citation publication-type="other">Schmoele-Thoma B, Falsey AR, Walsh EE, Swanson K, Zareba A, Cooper D, Gruber W, Jansen KU, Radley D, Scott D, Dormitzer P (2019) Phase 1/2, first-in-human study of the safety, tolerability, and immunogenicity of a RSV prefusion F-based subunit vaccine candidate. IDWeek Washington, DC, pp 2&#8211;6. Oct 2019 PO2755</mixed-citation></ref><ref id="CR211"><mixed-citation publication-type="other">Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A (2002) Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 51(RR-11): 1&#8211;22<pub-id pub-id-type="pmid">12211284</pub-id></mixed-citation></ref><ref id="CR212"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>SK</given-names></name><name name-style="western"><surname>Katoch</surname><given-names>K</given-names></name><name name-style="western"><surname>Sarin</surname><given-names>R</given-names></name><name name-style="western"><surname>Balambal</surname><given-names>R</given-names></name><name name-style="western"><surname>Kumar Jain</surname><given-names>N</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N</given-names></name><name name-style="western"><surname>Murthy</surname><given-names>KJR</given-names></name><name name-style="western"><surname>Singla</surname><given-names>N</given-names></name><name name-style="western"><surname>Saha</surname><given-names>PK</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>A</given-names></name><name name-style="western"><surname>Singh</surname><given-names>U</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Banavaliker</surname><given-names>JN</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>DS</given-names></name><name name-style="western"><surname>Sachan</surname><given-names>S</given-names></name><name name-style="western"><surname>Wasim</surname><given-names>M</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>S</given-names></name><name name-style="western"><surname>Dutt</surname><given-names>N</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>N</given-names></name><name name-style="western"><surname>Penmesta</surname><given-names>SRR</given-names></name><name name-style="western"><surname>Gaddam</surname><given-names>S</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Khamar</surname><given-names>B</given-names></name><name name-style="western"><surname>Dey</surname><given-names>B</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>DK</given-names></name><name name-style="western"><surname>Arora</surname><given-names>SK</given-names></name><name name-style="western"><surname>Bhaskar</surname><given-names>S</given-names></name><name name-style="western"><surname>Rani</surname><given-names>R</given-names></name></person-group><article-title>Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>3354</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-03514-1</pub-id><pub-id pub-id-type="pmid">28611374</pub-id><pub-id pub-id-type="pmcid">PMC5469738</pub-id></element-citation></ref><ref id="CR213"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>AK</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>MT</given-names></name></person-group><article-title>Infectious disease vaccines</article-title><source>Nat Rev Drug Discov</source><year>2019</year><volume>18</volume><issue>3</issue><fpage>169</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/d41573-018-00011-6</pub-id><pub-id pub-id-type="pmid">30824885</pub-id></element-citation></ref><ref id="CR214"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheppard</surname><given-names>DC</given-names></name><name name-style="western"><surname>Yeaman</surname><given-names>MR</given-names></name><name name-style="western"><surname>Welch</surname><given-names>WH</given-names></name><name name-style="western"><surname>Phan</surname><given-names>QT</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Filler</surname><given-names>SG</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Waring</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>Functional and structural diversity in the Als protein family of Candida albicans</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><issue>29</issue><fpage>30480</fpage><lpage>30489</lpage><pub-id pub-id-type="doi">10.1074/jbc.M401929200</pub-id><pub-id pub-id-type="pmid">15128742</pub-id></element-citation></ref><ref id="CR215"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simor</surname><given-names>AE</given-names></name></person-group><article-title>Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review</article-title><source>J Am Geriatr Soc</source><year>2010</year><volume>58</volume><issue>8</issue><fpage>1556</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2010.02958.x</pub-id><pub-id pub-id-type="pmid">20646106</pub-id></element-citation></ref><ref id="CR216"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Woods</surname><given-names>CR</given-names></name></person-group><article-title>On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes</article-title><source>Pediatrics</source><year>2010</year><volume>125</volume><issue>6</issue><fpage>1134</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1542/peds.2009-2489</pub-id><pub-id pub-id-type="pmid">20498176</pub-id></element-citation></ref><ref id="CR217"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinhoff</surname><given-names>M</given-names></name><name name-style="western"><surname>Goldblatt</surname><given-names>D</given-names></name></person-group><article-title>Conjugate Hib vaccines</article-title><source>Lancet</source><year>2003</year><volume>361</volume><issue>9355</issue><fpage>360</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)12441-5</pub-id><pub-id pub-id-type="pmid">12573368</pub-id></element-citation></ref><ref id="CR218"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tagliabue</surname><given-names>A</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name></person-group><article-title>Changing priorities in vaccinology: antibiotic resistance moving to the top</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>1068</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01068</pub-id><pub-id pub-id-type="pmid">29910799</pub-id><pub-id pub-id-type="pmcid">PMC5992407</pub-id></element-citation></ref><ref id="CR219"><mixed-citation publication-type="other">Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H, Team MATS (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381: 9871&#8211;1021 1028 10.1016/S0140-6736(13)60177-4<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)60177-4</pub-id><pub-id pub-id-type="pmcid">PMC5424647</pub-id><pub-id pub-id-type="pmid">23391465</pub-id></mixed-citation></ref><ref id="CR220"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>LE</given-names></name><name name-style="western"><surname>Swerdfeger</surname><given-names>AL</given-names></name><name name-style="western"><surname>Eslick</surname><given-names>GD</given-names></name></person-group><article-title>Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><issue>29</issue><fpage>3623</fpage><lpage>3629</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.085</pub-id><pub-id pub-id-type="pmid">24814559</pub-id></element-citation></ref><ref id="CR221"><mixed-citation publication-type="other">The White House (2014) Executive order&#8212;combating antibiotic-resistant bacteria. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://obamawhitehouse.archives.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria">https://obamawhitehouse.archives.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria</ext-link>. Accessed 16 Sept 2019</mixed-citation></ref><ref id="CR222"><mixed-citation publication-type="other">The White House (2015) National action plan for combating antibiotic-resistant bacteria. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://obamawhitehouse.archives.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteriapdf">https://obamawhitehouse.archives.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteriapdf</ext-link>. Accessed 16 Sept 2019</mixed-citation></ref><ref id="CR223"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thornton</surname><given-names>J</given-names></name></person-group><article-title>Polio returns to the Philippines</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10205</issue><fpage>1217</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)32263-9</pub-id><pub-id pub-id-type="pmid">31591973</pub-id></element-citation></ref><ref id="CR224"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomczyk</surname><given-names>S</given-names></name><name name-style="western"><surname>Lynfield</surname><given-names>R</given-names></name><name name-style="western"><surname>Schaffner</surname><given-names>W</given-names></name><name name-style="western"><surname>Reingold</surname><given-names>A</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L</given-names></name><name name-style="western"><surname>Petit</surname><given-names>S</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>C</given-names></name><name name-style="western"><surname>Zansky</surname><given-names>SM</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Baumbach</surname><given-names>J</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>LH</given-names></name><name name-style="western"><surname>Farley</surname><given-names>MM</given-names></name><name name-style="western"><surname>Beall</surname><given-names>B</given-names></name><name name-style="western"><surname>McGee</surname><given-names>L</given-names></name><name name-style="western"><surname>Gierke</surname><given-names>R</given-names></name><name name-style="western"><surname>Pondo</surname><given-names>T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>L</given-names></name></person-group><article-title>Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine</article-title><source>Clin Infect Dis</source><year>2016</year><volume>62</volume><issue>9</issue><fpage>1119</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw067</pub-id><pub-id pub-id-type="pmid">26908787</pub-id></element-citation></ref><ref id="CR225"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomeny</surname><given-names>TS</given-names></name><name name-style="western"><surname>Vargo</surname><given-names>CJ</given-names></name><name name-style="western"><surname>El-Toukhy</surname><given-names>S</given-names></name></person-group><article-title>Geographic and demographic correlates of autism-related anti-vaccine beliefs on Twitter, 2009&#8211;15</article-title><source>Soc Sci Med</source><year>2017</year><volume>191</volume><fpage>168</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.socscimed.2017.08.041</pub-id><pub-id pub-id-type="pmid">28926775</pub-id><pub-id pub-id-type="pmcid">PMC5623105</pub-id></element-citation></ref><ref id="CR226"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>SY</given-names></name><name name-style="western"><surname>Davis</surname><given-names>JS</given-names></name><name name-style="western"><surname>Eichenberger</surname><given-names>E</given-names></name><name name-style="western"><surname>Holland</surname><given-names>TL</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>VG</given-names><suffix>Jr</suffix></name></person-group><article-title>Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management</article-title><source>Clin Microbiol Rev</source><year>2015</year><volume>28</volume><issue>3</issue><fpage>603</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1128/CMR.00134-14</pub-id><pub-id pub-id-type="pmid">26016486</pub-id><pub-id pub-id-type="pmcid">PMC4451395</pub-id></element-citation></ref><ref id="CR227"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tribble</surname><given-names>D</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>R</given-names></name><name name-style="western"><surname>Cantrell</surname><given-names>J</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M</given-names></name><name name-style="western"><surname>Porter</surname><given-names>C</given-names></name><name name-style="western"><surname>Baqar</surname><given-names>S</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C</given-names></name><name name-style="western"><surname>Arora</surname><given-names>R</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>J</given-names></name><name name-style="western"><surname>Ananthakrishnan</surname><given-names>M</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>J</given-names></name><name name-style="western"><surname>Zaucha</surname><given-names>G</given-names></name><name name-style="western"><surname>Turbyfill</surname><given-names>R</given-names></name><name name-style="western"><surname>Oaks</surname><given-names>E</given-names></name></person-group><article-title>Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><issue>37</issue><fpage>6076</fpage><lpage>6085</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.06.086</pub-id><pub-id pub-id-type="pmid">20619378</pub-id></element-citation></ref><ref id="CR228"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tristram</surname><given-names>S</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>MR</given-names></name><name name-style="western"><surname>Appelbaum</surname><given-names>PC</given-names></name></person-group><article-title>Antimicrobial resistance in Haemophilus influenzae</article-title><source>Clin Microbiol Rev</source><year>2007</year><volume>20</volume><issue>2</issue><fpage>368</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1128/CMR.00040-06</pub-id><pub-id pub-id-type="pmid">17428889</pub-id><pub-id pub-id-type="pmcid">PMC1865592</pub-id></element-citation></ref><ref id="CR229"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trovato</surname><given-names>M</given-names></name><name name-style="western"><surname>D&#8217;Apice</surname><given-names>L</given-names></name><name name-style="western"><surname>Prisco</surname><given-names>A</given-names></name><name name-style="western"><surname>De Berardinis</surname><given-names>P</given-names></name></person-group><article-title>HIV vaccination: a roadmap among advancements and concerns</article-title><source>Int J Mol Sci</source><year>2018</year><pub-id pub-id-type="doi">10.3390/ijms19041241</pub-id><pub-id pub-id-type="pmcid">PMC5979448</pub-id><pub-id pub-id-type="pmid">29671786</pub-id></element-citation></ref><ref id="CR230"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsaban</surname><given-names>G</given-names></name><name name-style="western"><surname>Ben-Shimol</surname><given-names>S</given-names></name></person-group><article-title>Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: a systematic review of the literature</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><issue>22</issue><fpage>2882</fpage><lpage>2891</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.04.032</pub-id><pub-id pub-id-type="pmid">28449971</pub-id></element-citation></ref><ref id="CR231"><mixed-citation publication-type="other">Tufts University (2010) The cost of antibiotic resistance to U.S. families and the health care system. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.tufts.edu/med/apua/consumers/personal_home_5_1451036133pdf">http://www.tufts.edu/med/apua/consumers/personal_home_5_1451036133pdf</ext-link>. Accessed 15 Jun 2019</mixed-citation></ref><ref id="CR232"><mixed-citation publication-type="other">Valneva (2016) Valneva&#180;s pseudomonas aeruginosa candidate (VLA43) did not confirm positive vaccine effect in phase II/III trial. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://valneva.com/wp-content/uploads/2019/06/2016_06_02_Valneva_Pseudomonas_PR_ENpdf">https://valneva.com/wp-content/uploads/2019/06/2016_06_02_Valneva_Pseudomonas_PR_ENpdf</ext-link>. Accessed 23 Aug 2019</mixed-citation></ref><ref id="CR233"><mixed-citation publication-type="other">van den Dobbelsteen G, Fae KC, Serroyen J, van den Nieuwenhof IM, Braun M, Haeuptle MA, Sirena D, Schneider J, Alaimo C, Lipowsky G, Gambillara-Fonck V, Wacker M, Poolman JT (2016) Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models. Vaccine 34(35): 415 2&#8211;4160 10.1016/j.vaccine.2016.06.067<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.06.067</pub-id><pub-id pub-id-type="pmid">27395567</pub-id></mixed-citation></ref><ref id="CR234"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Der Meeren</surname><given-names>O</given-names></name><name name-style="western"><surname>Hatherill</surname><given-names>M</given-names></name><name name-style="western"><surname>Nduba</surname><given-names>V</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Muyoyeta</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Brakel</surname><given-names>E</given-names></name><name name-style="western"><surname>Ayles</surname><given-names>HM</given-names></name><name name-style="western"><surname>Henostroza</surname><given-names>G</given-names></name><name name-style="western"><surname>Thienemann</surname><given-names>F</given-names></name><name name-style="western"><surname>Scriba</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Diacon</surname><given-names>A</given-names></name><name name-style="western"><surname>Blatner</surname><given-names>GL</given-names></name><name name-style="western"><surname>Demoitie</surname><given-names>MA</given-names></name><name name-style="western"><surname>Tameris</surname><given-names>M</given-names></name><name name-style="western"><surname>Malahleha</surname><given-names>M</given-names></name><name name-style="western"><surname>Innes</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hellstrom</surname><given-names>E</given-names></name><name name-style="western"><surname>Martinson</surname><given-names>N</given-names></name><name name-style="western"><surname>Singh</surname><given-names>T</given-names></name><name name-style="western"><surname>Akite</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Khatoon Azam</surname><given-names>A</given-names></name><name name-style="western"><surname>Bollaerts</surname><given-names>A</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>AM</given-names></name><name name-style="western"><surname>Evans</surname><given-names>TG</given-names></name><name name-style="western"><surname>Gillard</surname><given-names>P</given-names></name><name name-style="western"><surname>Tait</surname><given-names>DR</given-names></name></person-group><article-title>Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><issue>17</issue><fpage>1621</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1803484</pub-id><pub-id pub-id-type="pmid">30280651</pub-id><pub-id pub-id-type="pmcid">PMC6151253</pub-id></element-citation></ref><ref id="CR235"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ventola</surname><given-names>CL</given-names></name></person-group><article-title>Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 1: childhood vaccinations</article-title><source>P T</source><year>2016</year><volume>41</volume><issue>7</issue><fpage>426</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">27408519</pub-id><pub-id pub-id-type="pmcid">PMC4927017</pub-id></element-citation></ref><ref id="CR236"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ventola</surname><given-names>CL</given-names></name></person-group><article-title>Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 2: adult vaccinations</article-title><source>P T</source><year>2016</year><volume>41</volume><issue>8</issue><fpage>492</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">27504066</pub-id><pub-id pub-id-type="pmcid">PMC4959618</pub-id></element-citation></ref><ref id="CR237"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vesikari</surname><given-names>T</given-names></name><name name-style="western"><surname>Karvonen</surname><given-names>A</given-names></name><name name-style="western"><surname>Prymula</surname><given-names>R</given-names></name><name name-style="western"><surname>Schuster</surname><given-names>V</given-names></name><name name-style="western"><surname>Tejedor</surname><given-names>JC</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R</given-names></name><name name-style="western"><surname>Meurice</surname><given-names>F</given-names></name><name name-style="western"><surname>Han</surname><given-names>HH</given-names></name><name name-style="western"><surname>Damaso</surname><given-names>S</given-names></name><name name-style="western"><surname>Bouckenooghe</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study</article-title><source>Lancet</source><year>2007</year><volume>370</volume><issue>9601</issue><fpage>1757</fpage><lpage>1763</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61744-9</pub-id><pub-id pub-id-type="pmid">18037080</pub-id></element-citation></ref><ref id="CR238"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidunas</surname><given-names>E</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>A</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>M</given-names></name><name name-style="western"><surname>Cai</surname><given-names>P</given-names></name><name name-style="western"><surname>Koh</surname><given-names>EH</given-names></name><name name-style="western"><surname>Patel-Brown</surname><given-names>S</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Carriere</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JE</given-names></name><name name-style="western"><surname>Lotvin</surname><given-names>J</given-names></name><name name-style="western"><surname>Moran</surname><given-names>J</given-names></name></person-group><article-title>Production and characterization of chemically inactivated genetically engineered clostridium difficile toxoids</article-title><source>J Pharm Sci</source><year>2016</year><volume>105</volume><issue>7</issue><fpage>2032</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2016.04.017</pub-id><pub-id pub-id-type="pmid">27233688</pub-id></element-citation></ref><ref id="CR239"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vignesh</surname><given-names>R</given-names></name><name name-style="western"><surname>Shankar</surname><given-names>EM</given-names></name><name name-style="western"><surname>Murugavel</surname><given-names>KG</given-names></name><name name-style="western"><surname>Kumarasamy</surname><given-names>N</given-names></name><name name-style="western"><surname>Sekar</surname><given-names>R</given-names></name><name name-style="western"><surname>Irene</surname><given-names>P</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>S</given-names></name><name name-style="western"><surname>Balakrishnan</surname><given-names>P</given-names></name></person-group><article-title>Urinary infections due to multi-drug-resistant Escherichia coli among persons with HIV disease at a tertiary AIDS care centre in South India</article-title><source>Nephron Clin Pract</source><year>2008</year><volume>110</volume><issue>1</issue><fpage>c55</fpage><lpage>c57</lpage><pub-id pub-id-type="doi">10.1159/000151533</pub-id><pub-id pub-id-type="pmid">18724067</pub-id></element-citation></ref><ref id="CR240"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Gottberg</surname><given-names>A</given-names></name><name name-style="western"><surname>de Gouveia</surname><given-names>L</given-names></name><name name-style="western"><surname>Tempia</surname><given-names>S</given-names></name><name name-style="western"><surname>Quan</surname><given-names>V</given-names></name><name name-style="western"><surname>Meiring</surname><given-names>S</given-names></name><name name-style="western"><surname>von Mollendorf</surname><given-names>C</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Zell</surname><given-names>ER</given-names></name><name name-style="western"><surname>Verani</surname><given-names>JR</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>KL</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>CG</given-names></name><name name-style="western"><surname>Klugman</surname><given-names>KP</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C</given-names></name><name name-style="western"><surname>Investigators</surname><given-names>G-S</given-names></name></person-group><article-title>Effects of vaccination on invasive pneumococcal disease in South Africa</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>20</issue><fpage>1889</fpage><lpage>1899</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1401914</pub-id><pub-id pub-id-type="pmid">25386897</pub-id></element-citation></ref><ref id="CR241"><mixed-citation publication-type="other">von Gottberg A, de Gouviea L, Tempia S, Quan V, Meiring S, von Mollendorf C, Madhi SA, Klugman KP, Whitney CG, Cohen C (2016) Ongoing pneumococcal disease declines and an indirect effect of vaccination, South Africa, 2005&#8211;2015. In: 10th international symposium on pneumococci and pneumococal disease (ISPPD) Glasgow, Scotland 28 Jul 2016 PO01b 156</mixed-citation></ref><ref id="CR242"><mixed-citation publication-type="other">von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, Matee M, Bakari M, Tvaroha S, Adams LV, Horsburgh CR, Pallangyo K, DarDar Study G (2010) Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24(5): 675&#8211;685 10.1097/QAD.0b013e3283350f1b<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAD.0b013e3283350f1b</pub-id><pub-id pub-id-type="pmcid">PMC10525041</pub-id><pub-id pub-id-type="pmid">20118767</pub-id></mixed-citation></ref><ref id="CR243"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voth</surname><given-names>DE</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>JD</given-names></name></person-group><article-title>Clostridium difficile toxins: mechanism of action and role in disease</article-title><source>Clin Microbiol Rev</source><year>2005</year><volume>18</volume><issue>2</issue><fpage>247</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1128/CMR.18.2.247-263.2005</pub-id><pub-id pub-id-type="pmid">15831824</pub-id><pub-id pub-id-type="pmcid">PMC1082799</pub-id></element-citation></ref><ref id="CR244"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahid</surname><given-names>R</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>KL</given-names></name><name name-style="western"><surname>Levine</surname><given-names>MM</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>MB</given-names></name></person-group><article-title>Cell mediated immune responses elicited in volunteers following immunization with candidate live oral Salmonella enterica serovar Paratyphi A attenuated vaccine strain CVD 1902</article-title><source>Clin Immunol</source><year>2019</year><volume>201</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2019.03.003</pub-id><pub-id pub-id-type="pmid">30849494</pub-id><pub-id pub-id-type="pmcid">PMC6959129</pub-id></element-citation></ref><ref id="CR245"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>C</given-names></name></person-group><article-title>Molecular mechanisms that confer antibacterial drug resistance</article-title><source>Nature</source><year>2000</year><volume>406</volume><issue>6797</issue><fpage>775</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1038/35021219</pub-id><pub-id pub-id-type="pmid">10963607</pub-id></element-citation></ref><ref id="CR246"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>TR</given-names></name><name name-style="western"><surname>Weeks</surname><given-names>J</given-names></name><name name-style="western"><surname>Livermore</surname><given-names>DM</given-names></name><name name-style="western"><surname>Toleman</surname><given-names>MA</given-names></name></person-group><article-title>Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study</article-title><source>Lancet Infect Dis</source><year>2011</year><volume>11</volume><issue>5</issue><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(11)70059-7</pub-id><pub-id pub-id-type="pmid">21478057</pub-id></element-citation></ref><ref id="CR247"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>JI</given-names></name><name name-style="western"><surname>Lum</surname><given-names>MK</given-names></name><name name-style="western"><surname>Hall</surname><given-names>DB</given-names></name><name name-style="western"><surname>Silimperi</surname><given-names>DR</given-names></name><name name-style="western"><surname>Bender</surname><given-names>TR</given-names></name></person-group><article-title>Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial</article-title><source>J Infect Dis</source><year>1986</year><volume>153</volume><issue>1</issue><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1093/infdis/153.1.17</pub-id><pub-id pub-id-type="pmid">3484505</pub-id></element-citation></ref><ref id="CR248"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Were</surname><given-names>T</given-names></name><name name-style="western"><surname>Davenport</surname><given-names>GC</given-names></name><name name-style="western"><surname>Hittner</surname><given-names>JB</given-names></name><name name-style="western"><surname>Ouma</surname><given-names>C</given-names></name><name name-style="western"><surname>Vulule</surname><given-names>JM</given-names></name><name name-style="western"><surname>Ong&#8217;echa</surname><given-names>JM</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>DJ</given-names></name></person-group><article-title>Bacteremia in Kenyan children presenting with malaria</article-title><source>J Clin Microbiol</source><year>2011</year><volume>49</volume><issue>2</issue><fpage>671</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1128/JCM.01864-10</pub-id><pub-id pub-id-type="pmid">21106789</pub-id><pub-id pub-id-type="pmcid">PMC3043473</pub-id></element-citation></ref><ref id="CR249"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilcox</surname><given-names>MH</given-names></name><name name-style="western"><surname>Gerding</surname><given-names>DN</given-names></name><name name-style="western"><surname>Poxton</surname><given-names>IR</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>C</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>R</given-names></name><name name-style="western"><surname>Birch</surname><given-names>T</given-names></name><name name-style="western"><surname>Cornely</surname><given-names>OA</given-names></name><name name-style="western"><surname>Rahav</surname><given-names>G</given-names></name><name name-style="western"><surname>Bouza</surname><given-names>E</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C</given-names></name><name name-style="western"><surname>Jenkin</surname><given-names>G</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>W</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>J</given-names></name><name name-style="western"><surname>Gabryelski</surname><given-names>L</given-names></name><name name-style="western"><surname>Pedley</surname><given-names>A</given-names></name><name name-style="western"><surname>Eves</surname><given-names>K</given-names></name><name name-style="western"><surname>Tipping</surname><given-names>R</given-names></name><name name-style="western"><surname>Guris</surname><given-names>D</given-names></name><name name-style="western"><surname>Kartsonis</surname><given-names>N</given-names></name><name name-style="western"><surname>Dorr</surname><given-names>MB</given-names></name><name name-style="western"><surname>Modify</surname><given-names>I</given-names></name><name name-style="western"><surname>Investigators</surname><given-names>MI</given-names></name></person-group><article-title>Bezlotoxumab for prevention of recurrent clostridium difficile infection</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><issue>4</issue><fpage>305</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1602615</pub-id><pub-id pub-id-type="pmid">28121498</pub-id></element-citation></ref><ref id="CR250"><mixed-citation publication-type="other">World Health Organization (2014a) Global tuberculosis report. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/tb/publications/global_report/gtbr14_executive_summarypdf">http://www.who.int/tb/publications/global_report/gtbr14_executive_summarypdf</ext-link>. Accessed 9 Jul 2019</mixed-citation></ref><ref id="CR251"><mixed-citation publication-type="other">World Health Organization (2014b) Status of vaccine research and development for paratyphoid fever prepared for WHO PD-VAC. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/immunization/research/meetings_workshops/Paratyphoid_VaccineRD_Sept2014pdf?ua=1">https://www.who.int/immunization/research/meetings_workshops/Paratyphoid_VaccineRD_Sept2014pdf?ua=1</ext-link>. Accessed 14 Sept 2019</mixed-citation></ref><ref id="CR252"><mixed-citation publication-type="other">World Health Organization (2015) Global action plan on antimicrobial resistance. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/iris/bitstream/handle/10665/193736/9789241509763_engpdf?sequence=1">https://www.who.int/iris/bitstream/handle/10665/193736/9789241509763_engpdf?sequence=1</ext-link>. Accessed 11 Jul 2019</mixed-citation></ref><ref id="CR253"><mixed-citation publication-type="other">World Health Organization (2017a) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHOpdf">https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHOpdf</ext-link>. Accessed 20 Jun 2019</mixed-citation></ref><ref id="CR254"><mixed-citation publication-type="other">World Health Organization (2018) Global Tuberculosis Report. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/tb/publications/global_report/tb18_ExecSum_web_4Oct18pdf?ua=1">https://www.who.int/tb/publications/global_report/tb18_ExecSum_web_4Oct18pdf?ua=1</ext-link>. Accessed 13 Jul 2019</mixed-citation></ref><ref id="CR255"><mixed-citation publication-type="other">World Health Organization (2019a) Global observatory on health R&amp;D. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/research-observatory/monitoring/processes/health_products/en/">http://www.who.int/research-observatory/monitoring/processes/health_products/en/</ext-link>. Accessed 22 Jun 2019</mixed-citation></ref><ref id="CR256"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yong</surname><given-names>D</given-names></name><name name-style="western"><surname>Toleman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Giske</surname><given-names>CG</given-names></name><name name-style="western"><surname>Cho</surname><given-names>HS</given-names></name><name name-style="western"><surname>Sundman</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>TR</given-names></name></person-group><article-title>Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><issue>12</issue><fpage>5046</fpage><lpage>5054</lpage><pub-id pub-id-type="doi">10.1128/AAC.00774-09</pub-id><pub-id pub-id-type="pmid">19770275</pub-id><pub-id pub-id-type="pmcid">PMC2786356</pub-id></element-citation></ref><ref id="CR257"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Lu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Malley</surname><given-names>R</given-names></name></person-group><article-title>Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><issue>33</issue><fpage>13564</fpage><lpage>13569</lpage><pub-id pub-id-type="doi">10.1073/pnas.1307228110</pub-id><pub-id pub-id-type="pmid">23898212</pub-id><pub-id pub-id-type="pmcid">PMC3746895</pub-id></element-citation></ref><ref id="CR258"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Jing</surname><given-names>H</given-names></name><name name-style="western"><surname>Gou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><issue>8</issue><fpage>1047</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.01.034</pub-id><pub-id pub-id-type="pmid">29406241</pub-id></element-citation></ref><ref id="CR259"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><name name-style="western"><surname>Shefer</surname><given-names>A</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nuorti</surname><given-names>JP</given-names></name></person-group><article-title>Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997&#8211;2004</article-title><source>Pediatrics</source><year>2008</year><volume>121</volume><issue>2</issue><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1542/peds.2007-0619</pub-id><pub-id pub-id-type="pmid">18245415</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>